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Probiotic bacteria and synbiotics are used as therapeutic and prophylactic agents.  
The majority of probiotic and synbiotic applications contain bacterial strains that are 
allochthonous to the human gastrointestinal (GI) tract.  Accordingly, many bacterial strains 
do not survive digestion, or are not capable of persisting and competing the resident gut 
microbiota, and are therefore washed out of the GI tract shortly after the treatment is 
discontinued.  This might reduce the health effects of these treatments.  Therefore, research 
is needed to address the ecological challenges that probiotic strains encounter in the GI 
tract in order to develop probiotic regimens.  Determining which ecological factors are 
limiting the colonization of bacteria remains a challenge.  To gain insight into the complex 
interplay between host and microbe, we chose Lactobacillus reuteri and its rodent host as 
a model to investigate which genes of L. reuteri contribute to tolerance towards host gastric 
acid secretion.  We established the urease cluster as the predominant factor in mediating 
resistance to gastric acid, and a mutation of this cluster resulted in substantially decreased 
population levels of L. reuteri in mice. 
 Secondly, we established a method to select for synergistic synbiotic 
combinations.  Based on in vivo selection (IVS), autochthonous putative probiotic strains 
are enriched in the GI tract of subjects by the continued consumption of a prebiotic.  We 
used IVS to select a strain of Bifidobacterium adolescentis that became enriched in a 
human feeding trail with galactooligosaccharides (GOS).  Here we have shown that the 
synbiotic combination of Bifidobacterium adolescentis IVS-1 and GOS significantly 
enriched for the putative probiotic component in rats.  IVS-1 became the most dominant 
operational taxonomic unit in the GI tract, outcompeting the resident Bifidobacterium 
species.  Similarly, we tested this synbiotic in a human trial with obese adults.  In this 
random, placebo-controlled parallel arm study, the synbiotic combination of IVS-1 and 
GOS led to establishment of IVS-1 in significantly higher numbers in the GI tract than a 
commercial synbiotic.   
Together, the studies presented in this dissertation allowed new insights into the 
colonization factors of a true GI symbiont, which could contribute to the development of 
improved probiotics, and provided novel insight into a rational selection of probiotics and 
synbiotics.  
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PREFACE 
 
This dissertation is comprised of five chapters.  Chapter 1 focuses on the current literature 
on synbiotic applications, with an emphasis on clinical studies.  In particular, the claimed 
health benefits of synbiotic applications and the implications of recent studies on future 
design of synbiotics to promote gastrointestinal health are addressed.  Chapter 2 describes 
our published research on the ecological role of genes that mediate acid resistance in 
Lactobacillus reuteri during colonization of the rodent gastrointestinal tract (Krumbeck et 
al. 2015).  In Chapter 3 our published work on the novel concept of in vivo selection is 
introduced, which can be applied to identify bacterial strains that possess enhanced 
ecological performance in synbiotic applications (Krumbeck et al. 2015).  Chapter 4 
describes the results of a human clinical trial that applied a synbiotic combination that has 
been selected by in vivo selection.  Finally, Chapter 5 provides a conclusion that 
summarizes the findings provided in this thesis.  
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Chapter 1 
 
Recent developments on formulating synbiotics to improve gastrointestinal health. 
 
1.1 Purpose of review 
Research on combining probiotics and prebiotics as synbiotics to enhance human 
and animal health has accelerated in the past ten years.  Included are many clinical trials 
that have assessed a wide variety of synbiotic formulations.  In this review, we summarize 
those recent clinical studies as well as other research and commercial applications of 
synbiotics.  In particular, we address the claimed health benefits of synbiotic applications 
and the implications of recent studies on future design of synbiotics to promote 
gastrointestinal health. 
 
1.2 Introduction 
The impact of the gastrointestinal (GI) microbiota on the health of humans and 
animals is now one of the most studied fields in biology and medicine.  New discoveries 
made during the past 20 years have dramatically changed the way that clinicians and 
researchers associate food and diet with health and disease.  While the microbiota that 
resides in the gut has long been considered as important to health, the methods and 
techniques necessary to gain an appropriate appreciation of this complex microbial 
ecosystem have just been developed within the last decade.  In addition, how this 
microbiota interacts with the host and how the composition and activity of a healthy state 
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microbiota is distinguished from an unhealthy or dysbiotic state had also been 
experimentally difficult questions to address.  While modern techniques now allow the 
recognition of a dysbiotic microbial state, the identification of cause and effect between a 
dysbiotic microbiota and a disease phenotype remains challenge.  
 
1.3 Functional importance of the colonic microbiota 
The human gastrointestinal tract is colonized by approximately 1014 microbial cells, 
with the majority (1011 – 1012 per gram) residing in the colon and less than 102 - 103 per 
gram in the stomach and small intestine (1, 2).  This microbiota serves several critical 
physiological functions.  It protects the host from invasive pathogenic microorganisms by 
competing with them for nutrients and niches, as well as by resistance against infections 
(3–5).  Commensal organisms may also produce a variety of antimicrobial substances, 
including bacteriocins and other antagonistic peptides and small molecules (6, 7).  In 
addition, the microbiota aids in the development of the adaptive and innate immune system, 
produces essential vitamins, amino-acids and other metabolites, and facilitates utilization 
of nutrients, especially polymeric carbohydrates (8).  Finally, the microbiota contributes 
caloric energy to the host.  Assuming a typical European diet is consumed, the gut 
microbiota can potentially yield as much as 140-180 kcal a day via fermentation of the 50- 
60 g of carbohydrates that escaped host metabolism (9).  
The extent and rate of carbohydrate digestion and utilization in humans depends 
primarily on anatomical location.  Initially, complex carbohydrates are hydrolyzed in the 
mouth via amylases, and starch and glycogen are further hydrolyzed and broken down into 
sugars, which are absorbed in the stomach.  In the large intestine, indigestible substrates, 
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including various dietary fibers and carbohydrates that were not absorbed in the small 
intestine, are hydrolyzed and fermented by bacteria.  The proximal part of the large 
intestine is responsible for most of the absorption of the short chain fatty acids (mainly 
acetate, butyrate and propionate) that are produced by the colonic bacteria from fiber 
fermentation at a rate of approximately 0.5- 0.6 mole per day (1, 9, 10), depending on the 
microbiota composition, the nature of the fermentable carbohydrate, and the dietary intake 
(6).   
Short chain fatty acids (SCFA) have several beneficial effects on host health (11, 
12).  As the most important and preferred energy source for colonocytes (13), SCFA 
promote epithelial integrity (11).  Additionally, SCFA affect the thickness of the mucus 
layer, support epithelial cell survival, and regulate expression of tight junction proteins (6, 
14).  Disruption of gut integrity has been attributed to serious intestinal diseases, including 
celiac disease, inflammatory bowel disease, and colorectal cancer (12, 15, 16).  The local 
and systemic immunomodulatory properties of SCFA include the suppression of NF-κB 
activity (17–19) and support of increased infiltration of immune cells into the lamina 
propria.  In addition, SCFA have anti-inflammatory properties by modulating immune cell 
chemotaxis, reactive oxygen species, and cytokine release (11).  SCFA also regulate 
colonic mobility and blood flow and can influence colon pH, which has a direct impact on 
the uptake and absorption of nutrients and electrolytes (20). 
Butyrate formation by the colonic microbiota is of particular interest since this 
compound has been shown to have multiple biological effects.  Butyrate has anti-
inflammatory properties, inhibits IL-12 and up regulates IL-10 in monocytes (19, 21).  In 
addition, butyrate has signaling capacities via G-protein coupled receptors (14, 16, 22, 23) 
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and increases levels of anorectic hormones like PYY and GLP-1, that contribute to energy 
metabolism and appetite control (6).  Butyrate also induces apoptosis of neutrophils (24), 
and has anticancer activity in several human cell lines (25–27).   
The colon offers an especially favorable environment for anaerobic microbes, with 
high quantities of nutrients that escaped host digestion, a thick mucus layer secreted by a 
higher number of Goblet cells, reduced intestinal motility, and a favorable pH (28).  Since 
the majority (approximately 70%) of the gut microbiota reside in the large intestine, these 
organisms may have a profound effect on energy storage, host metabolism, and intestinal 
health (1).  While the microbiota provides many beneficial effects on the host, the 
composition of an individual’s microbiota may also predispose that individual for certain 
intestinal as well as systemic diseases, including obesity and diabetes.  Importantly, the 
microbiota is not only shaped by host genetic factors and endogenous factors (gastric acid 
and bile), but also by dietary components that favor specific taxa or groups of bacteria in 
the colon by promoting their growth or activity.  Therefore, establishment of bacteria that 
are associated with a stable and healthy microbiota may be facilitated by dietary strategies.  
However, short-term dietary strategies have shown that overall the gut microbiota is 
exceptionally stable and resilient, since most of the alterations induced to the gut 
microbiota by dietary treatments are only temporary and the pre-treatment conditions are 
re-established once the treatment is discontinued (29–31).  Still, the dietary approach is 
now one of the most promising methods for correcting bacterial dysbiosis and restoring 
homeostasis.  In particular, foods and supplements containing prebiotics, or combined with 
probiotics as a synbiotic, have considerable potential for promoting gut health.   
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1.4 Addressing intestinal health with pro-, pre- and synbiotics 
Among the first dietary products used as intestinal therapeutic agents were 
probiotics.  Indeed, what we now call “probiotics” have been produced and consumed for 
more than 100 years (32, 33), long before the term was actually defined.  Probiotics are 
currently defined as “live microorganisms that, when administered in adequate amounts, 
confer a health benefit on the host” (FAO/WHO 2001-2014).  There are hundreds of 
probiotic strains and products in the marketplace, and many clinicians recommend 
probiotics to patients for a variety of conditions, including antibiotic-associated diarrhea, 
management of acute gastroenteritis, general gastrointestinal disorders, treatment of mild 
ulcerative colitis, and for improved lactose digestion (34).  While consumers have a general 
understanding of probiotics (35), the definition itself has been controversial among 
researchers and regulators (34).  It has been criticized, for example, as being too broad or 
not being broad enough (34).  Leaving the discussion about the definition itself aside, it is 
interesting to note that in Europe, and the U.S., no health claims for probiotic products have 
been approved by regulators.  In contrast, Canada has accepted a limited number of claims 
about the nature of probiotic microorganisms (36), as has Japan (37).  In Australia and New 
Zealand, products can be labelled as probiotics, but this may change as new legislation was 
passed in 2013 (effective in 2016) that regulates nutrition content and health claims on food 
labels and in advertisements (38).   
Despite the hesitation of regulators to confer health claims for probiotics, clinical 
evidence continues to emerge suggesting that probiotics can be effective for a range of 
conditions, including constipation, irritable bowel syndrome, and lactose intolerance (6, 
39).  Systematic and meta-analyses have shown that probiotics may aid the treatment of 
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antibiotic associated diarrhea (40), the prevention of necrotizing enterocolitis in preterm 
neonates (41), the induction of remission and maintenance of IBD (42), the prevention and 
control of hyperglycemia (43), improve levels of total cholesterol HDL and TNF-α in 
patients of non-alcoholic fatty liver disease (44), and reduce glucose, insulin, and HOMA-
IR in diabetes patients (45).  In addition, the effectiveness of probiotics for preventing or 
reducing severity of infectious and antibiotic-associated diarrhea and respiratory tract 
infections has also been reported (6).  
In contrast to the century-old history of probiotics, the prebiotic concept was more 
recently formally introduced in 1995 by Gibson and Roberfroid.  Defined originally as “a 
nondigestable food ingredient that beneficially affects the host by selectively stimulating 
the growth and/or activity of one or a limited number of bacteria in the colon, and thus 
improves host health” (46), the current criteria for prebiotics is now the subject of 
considerable debate (47, 48).  While the general requirements of a prebiotic have been 
retained in the most recently proposed definition, some key elements of the definition, 
including specificity and selectively, have been questioned (48).  The Canadian Food 
Inspection Agency (CFIA) has now established its own definition for prebiotics, but neither 
the U.S. Food and Drug Administration (FDA) nor Europe’s European Food Safety 
Authority (EFSA) have established a definition.   
Prebiotics are comprised of simpler molecules such as inulin, fructo-
oligosaccharides, galactooligosaccharides, isomaltooligosaccharides, and mannan 
oligosaccharides, or more complex compounds such as pectins, resistant starches, 
arabinoxylan or human milk oligosaccharides (49).  Depending on the nature of the 
prebiotic, these substrates may support the growth of certain members of the gut 
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microbiota, such as bifidobacteria, lactobacilli, or ruminococcus (50).  Prebiotics are 
thought to aid their health benefits through several different mechanisms.  These 
mechanisms include the induction of compositional or metabolic changes to the resident 
microorganisms, by stimulating the activity and/or growth of health-promoting bacteria, 
and by the production of SCFA and other end products that reduce the local pH, induce the 
production of immunomodulatory cytokines, and stimulate mucin production (51).  
Substrates like FOS and GOS may also have fermentation independent health effects, such 
as adherence inhibition of pathogens (52). 
Systematic meta-analyses showed that, in some cases, a prebiotic treatment reduces 
fasting insulin levels (53), can aid the treatment of infectious diseases (54) and diarrhea 
(55), and restore bowel function (56).  There are also reports that prebiotics may contribute 
to abdominal pain, diarrhea, and increased production of gas depending on the doses, 
nature of the prebiotic, and the susceptibility of the host (6). 
 
1.5 Synbiotic concepts 
When Gibson and Roberfroid first articulated the prebiotic concept more than 
twenty years ago, they envisioned that prebiotics and probiotics could be combined as 
synbiotics.  Later, Kolida and Gibson (2011) described the two general ways synbiotics 
could enhance the effects of their parts.  Complementary synbiotics are those that contain 
probiotics and prebiotics chosen independently of one another, with each responsible for a 
particular effect or health benefit.  Accordingly, the best case scenario for such a synbiotic 
would be that each constituent, i.e., the probiotic and prebiotic, would have a beneficial 
effect and that the effects would be additive.  For example, the prebiotic would stimulate 
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resident strains of bifidobacteria (presumably stains that improved intestinal health), while 
the probiotic would be established independently, providing an additional health benefit.  
In this complementary approach, the prebiotic component is not necessarily preferentially 
fermented by the probiotic strain and could theoretically support other members of the 
gastrointestinal microbiota.  The probiotic strain would gain no ecological advantage by 
being combined with the prebiotic, and indeed, may not be capable of fermenting the 
substrate at all. 
When the prebiotic is introduced together with a probiotic that cannot ferment the 
substrate, the outcome may be highly unpredictable and would likely depend on the 
composition of an individual’s gut microbiota.  Already it is apparent from human clinical 
studies that a bifidogenic response or other changes in the microbiota following prebiotic 
supplementation occur in some subjects but not in others.  The nature of the responder/non-
responder phenotype (i.e., what makes a responder a responder) remains the subject of 
considerable interest.   Davis et al. suggested that specific bacterial strains capable of 
fermenting the prebiotic or competing well in the colon might be absent in the non-
responder population (29), but that has not been established yet.  The inability of members 
of the gut microbiota to compete in the highly competitive gastrointestinal environment 
could also affect the responder status of subjects.  Indeed, Davis et al. showed that even a 
high abundance of taxa that would be expected to ferment a given prebiotic substrate was 
not a reliable predictor of whether or not the prebiotic was fermented (29).  Salonen et al. 
have shown that obese male individuals on a resistant starch diet could be divided into 
responders and non-responders based on the shifts in the composition of their gut 
microbiota.  In this case a high microbial diversity correlated with a low dietary 
responsiveness (57).  Similarly Martinez et al. have reported a microbial responder and 
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non-responder phenotype in normal weight human subjects who had consumed resistant 
starches (58).  Kovatcheva et al. divided their study cohort in responder versus non-
responders based on the metabolic response to a dietary fiber treatment (59).  A subsequent 
analysis of the gut microbiota of both groups showed that the Prevotella and Bacteroides 
ratio was significantly higher in the responder group.  Due to this responder and non-
responder phenomenon, a prediction of whether or not a subject will have a health 
beneficial effect by a dietary treatment is difficult to establish.  The response to the 
treatment depends not only on the functional and taxonomic composition of the gut 
microbiota but possibly also on host factors.  These factors include the amount of digestive 
enzymes provided by the host, the food transit time, and other potential environmental 
constraints, which could limit the increase of certain bacterial numbers, even if the growth 
substrate is provided (58).  While these host factors may be limiting the success of dietary 
interventions to a certain degree, synergistic synbiotics may provide the functional and 
taxonomic microorganisms that are not present in non-responders.  In contrast to 
complementary synbiotics, synergistic synbiotics consist of a prebiotic substrate that 
specifically supports the growth of a cognate probiotic strain in the gastrointestinal 
ecosystem (32).  Assuming the target strain reaches the colon, this approach potentially 
addresses the responder/non-responder problem by providing the strain and its growth 
substrate in situ.  The presence of an autochthonous member of the gut microbiota capable 
of fermenting the prebiotic prior to the treatment is not necessary.  However, the synergistic 
synbiotics are not limited to addressing the responder/ non-responder phenomenon.  One 
important limitation of many probiotic and synbiotic applications is the low ecological 
success of the probiotic strain (60).  In order to become established in the GI tract, the 
probiotic must not only secure nutrients and other growth factors, but must also outcompete 
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the resident microbiota for these resources.  By providing the probiotic partner organism 
with a new resource opportunity, in this case a selectively fermentable prebiotic, the 
probiotic strain’s competitive fitness can be significantly increased and its persistence 
enhanced (32).   
A literature search has shown that most of the synbiotic combinations used in 
clinical studies and reported in the literature have not been synergistically supporting the 
probiotic strain.  Indeed, only a few studies have provided evidence that a prebiotic 
supports its probiotic counterpart in vivo (Table 1.1), and only one such study was 
conducted with human subjects.  There are a variety of reasons why it is difficult to achieve 
synergism between a probiotic and a prebiotic in vivo.  Most importantly, the synbiotics 
used in these studies have not been rationally designed, and have instead been formulated 
on rather arbitrary bases, such as shelf life, cost, and industrial performance (60), on the 
basis of availability, cost, or other marketing reasons.  So often probiotic strains do not 
utilize the respective prebiotic.  Even when in vitro or in situ screenings of synbiotic 
combinations are applied, these techniques do not account for the ecological factors that 
will affect the probiotic strain in vivo, nor do they account for how other autochthonous 
members of the gut microbiota may benefit from the prebiotic substrate (29, 61, 62).  It can 
be challenging to identify a prebiotic that will specifically and selectively enhance the 
probiotic strain of interest.  New strategies to develop synergistic synbiotic combinations 
now include in vivo selected synbiotic combinations or Multi-taxon Insertion Sequencing, 
which have been recently discussed (49). 
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Table 1.1. Synergistic synbiotics reported in the literature 
Authors/ 
Year 
Probiotic 
component 
Prebiotic 
component 
Study 
subject
s 
Increase of probiotic 
abundance P value 
Health 
outcome 
Tanaka et 
al., 1983 
(63) 
Bifidobac-
terium breve 
4006 
Transgalac-
tosylated 
oligo-
saccharide 
(TOS) 
Healthy 
adults 
Pro: 9-10.2 log/g feces; 
Syn: 10-10.5 log/g feces§ 0.05 Not measured 
Wang et 
al., 1999 
(64) 
Bifidobac-
terium 
LaftiTM 8B. 
Amylomaize BALB/c mice 
Pro: 4.3% recovery rate; 
Syn: 27.92% recovery 
rate in feces 
0.05 Not measured 
Femia et 
al., 2002 
(65) 
Lactobacillus 
rhamnosus 
LGG + 
Bifidobacteriu
m lactis Bb12 
Oligofruc-
tose 
enriched 
inulin 
Male 
F344 
rats 
LGG: Pro: 4.8 ± 3.4·105; 
Syn: 21.1 ±18·105 CFU/g 
of feces;  
Bb12: Pro: 6.1 ± 8.1·105; 
Syn: 8.4 ± 12·105 CFU/g 
of feces 
Not 
given 
Anti-tumoric 
activity in 
azoxymethane 
induced cancer 
Ogawa et 
al., 2005, 
2006 (66, 
67) 
Lactobacillus 
casei subsp. 
casei JCM 
1134T (Lcc) 
Dextran BALB/c mice 
Pro: 1·104 CFU/mg of 
feces;  
Syn: 1.4·106 CFU/mg of 
feces§ 
0.01 
Significantly 
elevated 
natural killer 
cell activity in 
spleen 
mononuclear 
cells 
Krumbeck 
et al., 2015 
(60) 
Bifidobac-
terium 
adolescentis 
IVS-1 
Galacto-
oligosac-
charide 
(GOS) 
Male 
Sprague
-
Dawley 
rats 
Pro: 7.9 ± 0.1 log10 
cells/ g colon content;  
Syn: 9.47 ± 0.2 log10 
cells/ g colon content 
0.0001 None 
Pro: Probiotic; Syn: Synbiotic  
§: Absolute microbial numbers are not given in the original publication and are estimated by the author by careful 
evaluation of graphs in the original publication 
 
That there are few reports describing the use of synergistic synbiotics in clinical 
trials is somewhat surprising considering the many publications on synbiotics.  Just in 2015 
alone, more than 90 publications on synbiotics were published (Figure 1.1).  Most of these 
studies included lactobacilli and bifidobacteria as the probiotic component, and various 
oligosaccharides, inulin or dietary fibers as the prebiotic component (68). 
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Fig. 1.1. Number of publications on the topic “synbiotic” over the past 15 years.  
 
1.6 Synbiotics and their outcome on human health in clinical studies  
The reported literature on synbiotics includes studies from a wide-range of subject 
cohorts.  Research subjects have included humans of all ages, as well as companion animals 
(mainly dogs and cats), and food production animals, such as chicken, cows, pigs, cattle, 
rabbits and fish (69–77).  Rodent animal models have also been widely used (60, 78–80).  
In this review, we focus on human clinical studies and the health claims made for synbiotic 
combinations to improve human health. 
 It is important to note that despite the many health claims made for synbiotic 
combinations in the literature and in the commercial market (Figure 1.2), no claims have 
actually been approved by regulatory agencies in the U.S. and Europe.   
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Fig. 1.2.  Health claims made for synbiotics in human populations. 
Nonetheless, several meta-analyses and systematic reviews suggest that synbiotic 
treatments may provide beneficial health effects (Table 1.2, and 1.3).   
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Table 1.2. Overview of published meta-analyses on synbiotic treatments (adapted from 
Krumbeck et al., 2016 and updated). 
Author/                     
Year 
Disease 
phenotype 
Studies and 
subjects 
included 
P value Type of synbiotic Study subjects Outcome 
Shukla et al., 
2011 
(68) 
Hepatic 
Encephalopat
hy (HE) 
1 trial (n=55) 
0.004 
Probiotic: PP, LM, 
LPSP, LP2; Prebiotic: 
BG, I, P, RS 
HE patients 
Syn. use reduced 
the risk of no 
improvement of 
Minimal HE. 1 trial (n=60) 
Probiotic: BL; 
Prebiotic: FOS, 
vitamins B1, B2, B6, 
B12 
Ford et al., 
2014 
(81) 
IBS and 
chronic 
idiopathic 
constipation 
2 trials 
(n=198) 0.09 
Probiotic: BL, BB, LR, 
LA, LB,ST , LC; 
Prebiotic: FOS 
IBS patients 
No reduced 
symptoms. 
2 trials 
(n=160) 0.003 
Probiotic: BL2, LP, 
LR, LA; Prebiotic: 
FOS 
Beneficial for 
chronic idiopathic 
constipation 
treatment. 
Kinross et 
al., 2013 
(82) 
Clinical 
outcome after 
elective 
surgery 
8 trials 
(n=361) 0.002 
Probiotic: LC, LP2, 
LP, LM, LA, LB, BL2, 
ST, PP, BB, EF, CB, 
BM, LS, BB2, LL; 
Prebiotic: OAF, OF, 
BG, I, P, RS, GOS 
Patients 
undergoing 
elective 
surgery 
The incidence of 
postoperative 
sepsis was reduced 
by syn.  
4 trials 
(n=135) 0.03 
Probiotic: PP, LM, 
LP2; Prebiotic: BG, I, 
P, RS 
Syn. reduced the 
length of 
postoperative 
antibiotic use. 
2 or 3 trails 
each (n 
between 198 
and 260) 
>0.05 
Probiotic: LC, LP2, 
LP, LM, LA, LB, BL2, 
ST, PP, BB, EF, CB, 
BM, LS, BB2, LL; 
Prebiotic: OAF, OF, 
BG, I, P, RS, GOS 
No significant 
changes observed 
for prevention of 
pneumonia, wound 
infection, urinary 
tract infection, 
mortality and 
length of hospital 
stay. 
Beserra et 
al., 2015 
(53) 
Glycaemia, 
insulin 
concentration
s and lipid 
parameters  
2 trials 
(n=364) 0.04 
Probiotic: BL, LC, LR, 
ST, BB, LA, LB; 
Prebiotic: FOS 
Adults with 
overweight or 
obesity 
Reduced plasma 
fasting insulin 
concentrations. 
3 trials 
(n=260)  <0.05 
Probiotic: LS2, BL, 
LA, BB; Prebiotic: I, 
FOS 
Reduced plasma 
triglyceride 
concentrations. 
2, 3 or 4 trails 
each (n 
between 49 
and 104) 
Not given 
Probiotics: LC, LR, 
ST, BB, LA, BL, LB, 
LS2; Prebiotic: I, FOS 
No significant 
changes were 
observed for total 
cholesterol, LDL-
c, HDL-c and 
fasting glucose. 
15 
Table 1.2 continued      
Mugambi et 
al., 2012 
(77)  
Growth and 
stool 
frequency 
2 trials 
(n=227) 0.29 
Probiotic: BL, LR, LP; 
Prebiotic: GOS, 
ScFOS  
Infants 
Syn. failed to 
improve growth 
rate, but 
significantly 
improved stool 
frequency.  
2 trials 
(n=122) 0.006 
Probiotic: BL; 
Prebiotic: GOS, FOS 
Chang et al., 
2016 
(83) 
Atopic 
dermatitis 
(AD) 
6 trials 
(n=369) 
0.03 
Probiotic: LR,BL2, 
LA, BB, LC, ST, BI, 
LB, LS; Prebiotic: 
FOS, lcFOS, GOS, 
scGOS, starch Children 
Syn. support the 
treatment of atopic 
dermatitis, 
particularly mixed 
strains of bacteria 
are used.  
0.048 
Syn. support the 
treatment of atopic 
dermatitis in 
children older than 
1 year. 
2 trials 
(n=1320) 0.26 
Probiotic: BL, BB, LR, 
PF; Prebiotic: GOS, 
ScFOS  
Syn. do not support 
prevention of AD. 
Sawas et al., 
2015 
(84) 
Prevention of 
infections 
after liver 
transplant 
4 trials 
(n=246) <0.001 
Probiotic: BB, BL2, 
LP2, PP, LPSP, LM, 
LA, LC, LR, LB2; 
Prebiotic: GOS, fiber 
Adult patients 
receiving a 
liver 
transplant 
Syn. reduced 
infection rate of 
urinary tract and 
intra-abdominal 
infections. Syn. 
reduced hospital 
stay and duration 
of antibiotic use. 
Yang et al., 
2016 
(85) 
Prevention of 
infections 
after GI 
surgery 
16 trials 
(n=1,370) 
Not given 
Probiotic: LC, ST, BB, 
LA, BL2, LB, LP2, 
PP, LM, LP, LS2, BM, 
CB; 
Prebiotic: FOS, GOS, 
OAF, OF, BG, I, P, RS 
Patients 
undergoing 
GI surgery 
Subgroup analysis 
of synbiotic trials 
showed no health 
benefits due to 
synbiotics 
Probiotic type: BB= Bifidobacterium breve; BB2= Bifidobacterium bifidum; BI= Bifidobacterium infantis; BL= Bifidobacterium 
longum; BL2= Bifidobacterium lactis; BM= Bacillus mesentericus; CB= Clostridium butyricum; EF= Enterococcus faecium; LA= 
Lactobacillus acidophilus; LA2= Lactobacillus affinolactis; LB= Lactobacillus bulgaricus;LB2= Lactobacillus brevis; LC= 
Lactobacillus casei; LL= Lactococcus lactis; LM= Leuconostoc mesenteroides; LP= Lactobacillus paracasei; LP2= Lactobacillus 
plantarum; LPA= Lactobacillus paracasei; LPSP= Lactobacillus paracasei subsp. paracasei; LR= Lactobacillus rhamnosus; LS= 
Lactobacillus salivarius; LS2= Lactobacillus sporogenes; PF= Propionibacterium freudenreichii; PP= Pediococcus pentosaceus; 
ST= Streptococcus thermophilus  
Prebiotic type: BG= β-glucan; GOS= galacto-oligosaccharides; I= inulin; P= pectin; OF= oligofructose; OAF= oat fiber; RS= 
resistant starch; FOS= fructo-oligosaccharides; Sc= short chain; Syn= Synbiotic 
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Table 1.3.  Overview of systematic reviews on synbiotic treatments. 
Author/                     
Year 
Disease 
phenotype 
Studies and 
subjects 
included 
P 
value Type of synbiotic 
Study 
subjects Outcome 
Ghouri 
et al., 
2014 
and 
Saez-
Lara et 
al., 2015 
(86, 87) 
Ulcerative 
colitis (UC) 
maintenance 
1 trial (n=120) 
& 0.03 
Probiotic: BL; 
Prebiotic: Psyllium 
UC 
patients 
IBDQ score: improved 
quality of life. 
Ulcerative 
colitis 
induction and 
maintenance 
1 trial (n=41)  
& 
0.05 Probiotic: BB; Prebiotic: GOS 
Improvement of endoscopic 
grading compared to standard 
therapy group. 
Ulcerative 
colitis 
induction 
1 trial (n=18) 
*#& 
0.06 
Probiotic: BL; 
Prebiotic: Synergy I 
(I+OF mix) 
Sigmoidoscopy score not 
improved. 
0.05 Inflammatory markers 
improved. 
Management 
of Crohn's 
Disease (CD) 
1 trial (n=35)  
& 
0.02 
Probiotic: BL; 
Prebiotic: Synergy I 
(I+OF mix) 
CD 
patients 
Improved clinical response 
compared to placebo. 
1 trial (n=24)  
* & 
>0.05 
Synbiotic 2000: 
Probiotic: LA2, PP, 
LP2, LPSP; Prebiotic: 
BG, I, P, RS 
No improvement in 
endoscopic, clinical and 
laboratory parameters. 
Saez-
Lara et 
al., 2015 
(87) 
Ulcerative 
colitis (UC) 1 trial (n=10) 
Not 
given 
Synbiotic therapy; 
Probiotic: BB, BL, LC; 
Prebiotic: Psyllium 
Patients 
with 
active 
UC 
Synbiotic was safe and 
effective. 
*: also discussed in Hedin et al., 2007 (88);  #: also discussed in Zigra et al., 2007 (89);  
IBDQ: Inflammatory bowel disease questionnaire 
Probiotic type: BB= Bifidobacterium breve; BL= Bifidobacterium longum; LA2= Lactobacillus affinolactis; LP2= 
Lactobacillus plantarum; LPSP= Lactobacillus paracasei subsp. paracasei; PP= Pediococcus pentosaceus.  
Prebiotic type: BG= β-glucan; GOS= galacto-oligosaccharides; I= inulin; P= pectin; OF= oligofructose; RS= resistant starch. 
 
However, comparisons between different trials is rather difficult, since studies often 
vary between the specific probiotics and prebiotics used, their respective doses, the 
duration of the study, the targeted population, expected and measured effects of treatment.  
Even the funding source has been suggested to influence outcomes (90).  Of particular 
concern for synbiotic trials is when investigators did not determine the treatment effects 
17 
independently.  In such an approach it is not possible to establish that improvement of a 
clinical endpoint in the synbiotic treatment group was indeed more beneficial than just the 
pro- or prebiotic treatments alone.  Therefore the synbiotic concept cannot be validated in 
that case.  The majority of clinical trials have chosen such an approach.  A literature 
research of synbiotic trials published within the last 15 years (see below), showed that out 
of 26 trials presented here, only one provided a prebiotic only, probiotic only, and synbiotic 
only group (91), and only one trial provided an additional placebo control group (92). 
Out of the 26 trials presented here, only one performed a genus specific analysis of 
the microbiota of the subjects (93), and only three of the trials used a species specific 
analysis for the applied probiotic (92, 94, 95).  All other studies did not conduct any 
microbial analyses to confirm the survival or activity of the probiotic component at a strain-
specific level or even at higher taxonomical levels.  Finally, another common limitation of 
these studies is the lack of experimental power, which may result in overstating or 
underestimating the actual health benefits of the applied synbiotic.  This phenomenon of 
disadvantages of synbiotic meta-analyses has been previously recognized and criticized for 
probiotic meta-analyses as well (96).  
In general, most of the meta-analyses have focused on the disease phenotype rather 
than on the exact nature of the treatment.  Consequently, these analyses often do not 
differentiate between prebiotic, probiotic or synbiotic trials, with very few trials 
specifically using synbiotics.  However, systematic meta-analyses specifically analyzing 
synbiotics are often impossible due the limited number of trials.  Other meta-analyses do 
not distinguish between a probiotic or synbiotic treatment and combine those trials into one 
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analysis, which is not appropriate for assessing the potential health benefits of a synbiotic 
treatment (Table 1.4). 
 
Table 1.4.  Overview of Meta-analyses synbiotic treatments that combined pro- 
and synbiotic trials into one analyses.  
Authors/Year Disease phenotype Overall outcome 
Pitsouni et al., 
2009 (97) 
Patients undergoing 
abdominal surgery  
Pro-/ synbiotic treatment may reduce postoperative infections after 
abdominal surgery. 
Rossi et al., 
2012 (98) 
Patients with chronic kidney 
disease 
Limited but supportive evidence for the effectiveness of pre- and probiotics 
on reducing uremic toxins. No conclusion about synbiotics. 
Zhang et al., 
2010 (99) 
Patients with acute 
pancreatitis 
Pre-, pro- or synbiotics treatment shows no statistically significant benefit. 
Safety and efficacy: Use pre- pro- or synbiotics with caution in critically ill 
patients and patients with severe acute pancreatitis. 
Watkinson et 
al., 2007 (101) 
Patients admitted to adult 
intensive units 
There is currently a lack of evidence to support the use of pre- pro- or 
synbiotics. 
He et al., 2013 
(102) 
Patients undergoing colorectal 
resection for cancer 
Pro-/synbiotics administration had a positive effect on the incidence of 
diarrhea (P = 0.001), the incidence of symptomatic intestinal obstructions (P 
=0.008), the incidence of operative total infections (P =0.0010), and 
pneumonia infection (P = 0.04).  
Pro-/synbiotics administration increased numbers of Lactobacillus (P < 
0.00001), and decreased the counts of Enterobacteriaceae. 
Dang et al., 
2013  (103) Prevention of eczema 
Pro- and synbiotic treatment may reduce incidence of infant eczema. 
Prebiotics alone have no effect. 
Lytvyn et al., 
2015 (104) 
Prevention of postoperative 
infections following 
abdominal surgery in adults 
Probiotics/synbiotics reduce the risk of surgical site infections compared to 
placebo or standard of care and potentially benefit for urinary tract infections 
with no increased risk of adverse events, and no occurrence of serious 
adverse events reported as related to study product. 
Petrof et al., 
2012 
(105) 
Critically ill patients, 
including burn, multiple 
trauma, pancreatis, diarrhea 
patients and general intensive 
care unit patients 
Clinical trials suggest that probiotics patients may reduce overall infection 
rates in critically ill patients. 
Arumugam et 
al., 2016 (106) 
Decrease of postoperative 
sepsis GI surgical patients 
Pro-/synbiotics significantly reduced risk of postoperative sepsis by 38%  
(P = <0.0001) 
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Review of selected clinical trials on synbiotic treatments 
 As introduced earlier, the study design is crucial when synbiotic treatments are 
being assessed for their health beneficial effects.  To justify the application of a synbiotic 
treatment instead of a probiotic or prebiotic only treatment, appropriate controls must be 
used to assess if the synbiotic treatment acts synergistically.  Thus, controls must include 
a placebo, the probiotic treatment alone, the prebiotic treatment alone, and the synbiotic 
combination.  Only this study design allows investigators to assess whether or not a 
synbiotic treatment is more effective than the probiotic and prebiotic treatments alone and 
whether or not synergy is given.  In addition, the survival and/or metabolic activity of the 
probiotic component should be quantified in a strain-specific manner to ensure survival 
and establishment of the probiotic.  However, this requires a significantly higher number 
of subjects, and only a small number of trials fulfill these criteria. 
 In the next sections, recent human trials that applied synbiotics to treat specific 
clinical disorders are reviewed.  These include trials on metabolic syndrome, inflammatory 
bowel disease, diarrhea, colon cancer, and inflammatory bowel syndrome 
 
Metabolic syndrome  
Metabolic syndrome refers to a group of metabolic disorders that collectively 
contribute to heart and other health problems.  Risk factors include central obesity, 
impaired glucose tolerance, dyslipidemia and hypertension (107, 108).  This syndrome is 
associated with obesity, type II diabetes, heart disease, and cancer (109).   
20 
Several synbiotic formulations have been used in clinical trials.  Eslamparast et al. 
conducted a prospective, randomized, double-blind, and placebo-controlled study 
analyzing the effect of 250 mg fructooligosaccharide (FOS) and a probiotic cocktail of 
seven different strains (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus 
thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, 
and Lactobacillus bulgaricus) on 38 subjects suffering from metabolic syndrome (110).  
Subjects were instructed to consume the supplement or placebo (maltodextrin) twice daily 
for 28 weeks, and were instructed to follow strict dietary recommendations, lower their 
energy intake, and increase their physical activity.  At the end of the study, individuals in 
the synbiotic treatment had significantly improved levels of insulin resistance, fasting 
blood sugar, triacylglyceride, and serum high-density lipoprotein levels compared to the 
placebo treatment.  No difference was observed in body mass index (BMI), low-density 
lipoprotein levels, anthropometric parameters, and energy intake/expenditure.  The authors 
concluded that the synbiotic treatment can increase the efficacy of a dietary therapy in the 
management of metabolic syndrome and insulin resistance.  While the design and analysis 
of this study were adequate for the study goals, an analysis of the gut microbiota was not 
included.  The authors stated that “because previous studies had shown beneficial effects 
of VLS#3 and Lactobacillus longum and fructooligosaccharide, demonstrating their 
beneficial effects on intestinal microbiota, this synbiotic capsule was chosen for the present 
study as it contained all these strains in addition to others.”  However, the mentioned 
“Lactobacillus longum” is not a strain that has ever been described in the literature before 
and is most likely either a B. longum or a different Lactobacillus strain.  Additionally, the 
authors claim that VLS#3 was chosen for its previously reported health benefits.  But in 
the study conducted here, the applied synbiotic mixture did not contain all the strains 
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present in VLS#3 and left, seemingly randomly, two strains, B. infantis and L. delbrueckii, 
out.  Therefore no comparison to other studies using VLS#3 can be made.  Leaving these 
issues aside, no comparison was made between a pro- and prebiotic treatment alone, thus 
not confirming that the synbiotic treatment was more effective than the probiotic or 
prebiotic treatment alone.  
Lactobacilli, bifidobacteria and FOS were combined as synbiotic treatments for 
gastric bypass patients.  The synbiotic treatment contained Lactobacillus paracasei LPC-
37, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM, and 
Bifidobacterium lactis HN019 (each at 109 CFU) and 6 g of FOS (111).  Patients were 
divided into a placebo, prebiotic, and synbiotic treatment group.  The supplement was taken 
for 15 days after which a significant weight loss was seen in the prebiotic group.  The BMI 
was also lower in the prebiotic and placebo group than in the synbiotic group.  Other blood 
and inflammatory markers were not different among the groups, and the fecal microbiota 
was not addressed.  Effects of SCFA production induced by FOS treatment were only 
indirectly measured by assessing plasma cytokines, and no effect was detected.  Although 
clinical benefits for each of the tested strains are reported by the authors, there was no 
rationale given by the authors for combining them as a synbiotic.  Also, the low number of 
bypass patients (n = 3 per group) makes the interpretation of this data rather difficult and 
further investigation will be needed.  
The effect of a synbiotic consisting of Lactobacillus sporogenes (2.7 × 108 CFU) 
and 1.08 g of inulin was tested in 62 type II diabetic patients in a randomized double-
blinded cross-over controlled clinical trial (112).  The study lasted three weeks, and patients 
were instructed to consume the treatments three times a day.  The synbiotic was compared 
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to a placebo, and results suggested the synbiotic led to significantly decreased serum 
insulin levels (P = 0.03) and serum high-sensitivity C-reactive protein levels (P = 0.01).  
Increases in plasma total glutathione (P < 0.001) and serum uric acid levels (P = 0.04) were 
also reported.  However, no effects on cholesterol levels were observed, and the fecal 
microbiota of the patients were not investigated.  The same research group tested this 
synbiotic in combination with beta-carotene, and a reduced amount of L. sporogenes and 
inulin in 102 diabetic patients (113).  In this case cholesterol levels were affected 
significantly in addition to insulin compared to a control.  Pro- or prebiotic-alone 
treatments were not included, making it impossible to determine if the observed effects 
were due to the synbiotic or the individual synbiotic components.  Inulin has been 
previously shown to have beneficial effects in the treatment of diabetes (114–116).  Finally, 
as noted previously (117), “Lactobacillus sporogenes” is not a validly named species and 
the applied species here is more likely a Bacillus coagulens.  However, without a 
classification analysis, the identity of the strain used in this study cannot be established. 
The same synbiotic combination of Lactobacillus sporogenes (40 × 108 CFU, 
consumed three times a day) and inulin (2.8 g, consumed three times a day) was tested in 
81 diabetic patients (118).  The synbiotic, probiotic, or placebo was delivered in form of 
bread.  After eight weeks of treatment, plasma nitric oxide was increased (P = < 0.0001) 
and malondialdehyde levels were significantly reduced (P = 0.001) compared to both 
placebo and probiotic only treatments.  Since a prebiotic only treatment only was not 
included it remains unclear if this effect could have been achieved by inulin only.  The 
survival of the probiotic strain during the bread making process or storage was not reported, 
nor any analysis of the gut microbiota.  The actual dose of L. sporogenes per day therefore 
remains speculative.  
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A synbiotic cocktail containing Lactobacillus casei, Lactobacillus rhamnosus, 
Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, 
Bifidobacterium longum, Lactobacillus bulgaricus (2 x 108 CFU total), and FOS (unknown 
amount) was tested for its potential to support a weight loss regime (119).  Forty-six 
patients of metabolic syndrome consumed the synbiotic or placebo (maltodextrin) for 12 
weeks twice a day.  All patients experienced significant weight loss, and the synbiotic 
treatment reduced the systolic blood pressure (P < 0.05).  However, 90% of the subjects in 
the synbiotic group used medication to reduce blood pressure compared to 75% in the 
placebo group before and throughout the duration of the study.  While this difference was 
not significant, and could have affected the outcome.  The fecal microbiota was not 
examined and the nature of the study design precludes any conclusions about the efficacy 
of the prebiotic or the probiotic strains applied here.  
A study conducted with patients suffering from type II diabetes claimed a health 
benefit of a synbiotic combination compared to a placebo (120).  However, the value of 
this study is limited by the fact that no further details of the nature of either the synbiotic 
or placebo treatment was given.  
 
Inflammatory bowel disease 
Ulcerative colitis (UC) and Crohn’s disease (CD), the two types of inflammatory 
bowel diseases (IBD), are chronic inflammatory pathologies of the gastrointestinal tract.  
Both conditions occur in individuals who are genetically susceptible and exposed to 
environmental risk factors (121).  Even though the etiology of IBD has been extensively 
studied, the disease pathogenesis is not fully known, nor is there a cure (122).  The 
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characteristics of the inflammation are different, with CD being scattered throughout the 
GIT, typically involving the distal small intestine and colon with transmural inflammation 
and occasionally associated with granulomas, whereas in UC the inflammation is usually 
confined to the mucosa of the colon (123, 124).  Both UC and CD are characterized by a 
relapsing and remitting course leading to a very significant reduction in life quality during 
the disease (125). 
Several synbiotic formulations have been used in clinical studies to treat IBD.  In  
Furrie et al., Synergy 1 (6 g of inulin/oligofructose) and 2 x 1011 CFU Bifidobacterium 
longum were administered to UC patients (93).  One of the strengths of this study was that 
the probiotic strain was isolated from a healthy human subject and had been assessed for 
its aerotolerance, acid tolerance, resistance to bile salt, and adherence to epithelial cells.  
Its ability to use the prebiotic substrate as an energy source was also established in vitro.  
The organism was further shown to alter the cytokine expression in a HT29 epithelial cell 
line and reduce proinflammatory cytokine levels in vitro.  For the clinical study, 18 patients 
were divided into synbiotic and placebo groups, each receiving the respective treatments 
twice daily for four weeks.  The synbiotic treatment led to reduced inflammation and 
regeneration of epithelial tissue compared to the placebo group, reduced mRNA levels of 
human beta defensins, and lowered levels of tumor necrosis factor α and interleukin 1 α.  
Although survival of the probiotic strain was not measured in a strain-specific manner, 
bifidobacteria-specific rRNA levels were increased 42-fold in the synbiotic group 
compared to approximately 5-fold in the placebo group.  Unfortunately, this study did not 
investigate the effects of the probiotic independently. 
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Another B. longum synbiotic clinical trial was performed by Fujimori et al.  In this 
study, a B. longum strain (2 x 109 CFU) was combined with eight grams of psyllium as the 
prebiotic component.  Subjects were UC outpatients (n = 120) (91).  This trial did include 
probiotic and prebiotic only treatment groups in the study design to allow for comparisons.  
While most tested blood markers showed no differences among the three treatments, C-
reactive protein was significantly decreased (P = 0.04) and the total protein level in the 
blood samples increased (P = 0.03) in the synbiotic group.  Hemoglobin and hematocrit 
only increased in the probiotic group (P = 0.04).  Total inflammatory bowel disease 
questionnaire scores showed significant improvement only for the synbiotic group.  The 
investigators concluded that the synbiotic treatment led to a greater life-quality than the 
pre- and probiotic treatments alone.  However, this study did not investigate the 
mechanisms responsible for this improvement nor was the survival of the probiotic 
determined.  Therefore no conclusion about the nature of the synbiotic can be drawn, i.e. 
if the synbiotic acted synergistic or complementary.  
In another clinical study, the effect of a Bifidobacterium breve-GOS synbiotic on 
subjects with mild to moderate UC was assessed (94).  Synbiotics contained B. breve (109 
CFU, Yakult) and 5.5 g of galactooligosaccharide.  Forty-one patients were treated with a 
placebo or the synbiotic for one year.  End-points included endoscopic scores and 
myeloperoxidase levels in lavage solutions; both were significantly lower in the synbiotic 
treated group.  An analysis of the fecal microbiota by plate counting was also performed 
for subjects in the synbiotic group before and after the treatment.  Of all assessed microbes, 
only Bacteroidaceae were significantly decreased after the synbiotic treatment.  The 
abundance of Bifidobacterium remained the same, and B. breve was only detected after the 
treatment but not before (5.75 ± 1.65 log10 CFU/g feces).  Therefore, it can be concluded 
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that B. breve survived the passage through the GI tract.  Whether or not the applied 
prebiotic was supporting the probiotic could not be determined from this study.  
Interestingly, here no bifidogenic effect was observed due to galactooligosaccharide 
treatment.  This is contrary to results previously reported (126). 
A combination of 6 g of Synergy 1 (inulin/oligofructose) and 2 x 1011 CFU 
Bifidobacterium longum showed improvements in Crohn’s disease in patients that 
continued using their conventional CD medication (95).  Compared to a placebo, the 
synbiotic significantly reduced TNF-α gene expression (P = 0.041), disease activity 
indexes (P = 0.02), and histological scores (P = 0.018) after six months of treatment.  The 
microbiota of tissue biopsies was analyzed in both species- and genus-specific manner.  
Interestingly, 8 out of 13 patients had increased numbers of Bifidobacterium longum and 
bifidobacteria at the three month time point compared to the baseline in the synbiotic group, 
increasing to 11 patients after six months.  The nature of this responder/non-responder 
phenomenon was not addressed.  
Chermesh et al. investigated the potential of Synbiotic 2000 to prevent 
postoperative recurrence of CD (127).  This formulation contained 1010 CFU Pediococcus 
pentoseceus, 1010 CFU L. raffinolactis, 1010 CFU L. paracasei subsp. paracasei 19, and 
1010 CFU L. plantarum 2362 and as fermentable fibers 2.5 g of β-glucans, 2.5 g of inulin, 
2.5 g of pectin, and 2.5 g of resistant starch.  The frequency of the treatment was not stated.  
Of 30 enrolled patients, nine patients completed the study, which lasted 24 months.  
Synbiotic 2000 had no effect compared to the placebo on endoscopic or clinical relapse, 
nor the postoperative occurrence of CD.  However, it significantly improved weight 
increase and normalization of hemoglobin levels at the three month follow up time point.  
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No analysis of the gut microbiota was done, nor were reasons given for the selection of the 
synbiotic combination.  Of the prebiotic components none were correlated to any health 
benefits by the authors.  Only fructooligosaccharides were mentioned as beneficial in 
general.  Unfortunately, this study had a small sample size, lacked a pro- or prebiotic 
control arm, and used a seemingly arbitrarily selection process to determine the synbiotic 
combination.   
The plant fiber, psyllium, was combined as a synbiotic with bifidobacteria and 
lactobacilli, and used to treat CD patients (128).  The synbiotic contained 9.9 g of psyllium 
and 3 × 1010 CFU Bifidobacterium breve, 3 × 1010 CFU of Lactobacillus casei, and 1.5 × 
1010 CFU of Bifidobacterium longum.  Ten active CD patients were enrolled in this 13 
month trial.  The trial was not placebo controlled and subjects were allowed to discontinue 
using psyllium during the trial if abdominal bloating occurred.  All subjects were allowed 
to reduce the pro- and/or prebiotic treatment on their own will, thereby individualizing the 
treatments.  Subjects also received aminosalicylates and prednisolone at varying doses.  All 
subjects continued taking the probiotic treatment, but their doses varied between 12 and 73 
× 1010 CFU.  Four subjects discontinued the prebiotic treatment, and for the remaining six 
patients the doses varied between 3.3 and 9.9 g per day.  Based on the clinical outcome, 
the authors divided the subjects into complete responder, partial responder, and non-
responders.  Eight complete responders lowered their Crohn’s Disease activity index scores 
by more than 70 points and six achieved remission.  Patients who discontinued the 
synbiotic treatment and those following it through the whole duration of the study were 
found in the responder as well as the non-responder group.  Therefore, no correlation 
between a synbiotic treatment and a health improvement could be determined.   
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Rossi et al. conducted a observational study applying SynGutTM (Bifidobacterium 
lactis W51, Lactobacillus acidophilus W22, Lactobacillus plantarum W21, Lactococcus 
lactis W19, and inulin) to 96 IBS patients for two months (129).  While this study had no 
control group, no pro- or prebiotic group, and no standardized scoring system, it reported 
an improvement of IBS symptoms in 74% of the participants.   
 
Diarrhea  
Diarrheal diseases are often caused by infectious agents, which lead to lose, or 
liquid, bowel movements with increased frequency, water content, and volume.  
Worldwide, diarrhea is the leading cause of hospitalizations, morbidity, and mortality 
(130). 
 The potential of Lactobacillus acidophilus, Lactobacillus rhamnosus, 
Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (2.5 x 109 CFU 
total), combined with 625 mg of fructooligosaccharide as a synbiotic, was tested in children 
with acute diarrhea (130).  Treatment with oral rehydration salts (ORS) and intravenous 
therapy was also provided.  Compared to a control group (receiving only ORS and/or 
intravenous therapy), the synbiotic combination significantly shortened the duration of 
diarrhea (P < 0.0001) and shortened the hospital stay (P = 0.002).  The gut microbiota of 
these children was not analyzed.  
In a similar study, children with acute rotavirus diarrhea were treated with 
Lactobacillus sp., Streptococcus sp., Bifidobacterium sp. (1 x 109 CFU total) and 990 mg 
of FOS (131).  A standard fluid therapy and nutritional support were provided.  A total of 
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35 children were enrolled in the synbiotic group and were compared to a placebo group.  
The duration of diarrhea was significantly shorter in the synbiotic group (P < 0.0001), and 
for half of the patients receiving a synbiotic treatment, intestinal mucosal healing was 
reported 50 hours after the synbiotic administration.  The gut microbiota was not analyzed.  
No further descriptions were given to explain why half of the group responded to the 
treatment.   
An arabinogalactan and xylooligosaccharide mixture was used to formulate a 
synbiotic that also included Lactobacillus paracasei B21060 (2.5 x 109 CFU).  The 
prebiotics were present at 500 mg and 700 mg, respectively.  Subjects included 55 children 
with acute diarrhea, who also received ORS treatment.  The synbiotic showed a 
significantly higher resolution rate (P = 0.005) than the placebo group after the first 72 
hours (132).  This study allowed for additional treatments (e.g., diosmectite, domperidone 
or racecadotril) given by the parents after the first 72 hours, which may have influenced 
the total duration of diarrhea.  No analysis of the fecal microbiota was performed.  The 
additional treatments may have influenced the efficacy of the synbiotic treatment.  
A combination of Streptococcus thermophilus, Lactobacillus bulgaricus (9.7 x 108 
CFU), Bifidobacterium animalis subspecies lactis (Bb-12) (5 x 109 CFU), and 1g of inulin 
was assessed for its potential to prevent diarrhea, vomiting and other infections in young 
children (133).  One hundred and forty-nine children participated in this placebo controlled 
double-blind study.  After 16 weeks of treatment, synbiotic treated children had 
significantly fewer days of fewer, but significantly more days with watery stools (P < 0.05).  
No analysis of the microbiota was performed and it remains unknown which components 
of the treatment might have caused this effect.  
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To assess the potential to prevent and/or shorten the occurrence of traveler’s 
diarrhea, 196 healthy adults received a synbiotic combination named Agri-King Synbiotic 
(AKSB).  This preparation contained fructooligosaccharide, 4.5 x 109 CFU Enterococcus 
faecium SF68 and 5 x 109 CFU Saccharomyces cerevisiae CNCM I 4444 consumed twice 
daily (134).  This paper does not state the amount of fructooligosaccharide present in the 
AKSB capsules.  A literature research suggests that this preparation contains 115 mg of 
fructooligosaccharide per capsule (135).  A phase I study had shown that AKSB was safe 
and also that both strains were washed out within seven days after the treatment was 
discontinued.  Study subjects traveling to Asia, Africa, South and Central America were 
instructed to consume the synbiotic or placebo treatment one to two times daily, and to 
continue the treatment if diarrhea should occur.  Approximately half of the study cohort 
experienced traveler’s diarrhea, but no benefit of the synbiotic treatment was detected.  To 
justify the combination of E. faecium and S. cerevisiae the authors stated that E. faecium 
was capable of competing with other Gram-negative bacteria.  However, the authors do not 
show evidence for this here and instead refer to another paper that analyzed this 
phenomenon in stored meat samples and not for the gut microbiota (136).  No further 
comments were made regarding S. cerevisiae or fructooligosaccharide.   
 
 Colon cancer  
 Colorectal cancer is the third most common form of cancer and has a very high 
mortality.  In addition to genetic factors, environmental factors including radiation, 
chemical carcinogens, and diet contribute to tumorigenesis in the colon (137).  Current 
treatments are associated with a high risk of complications and a low success rate.  
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Investigators have suggested that by maintaining a healthy weight, diet, and physical 
activity, up to one third of colon cancers may be prevented (138).  Numerous pro-, pre-, 
and synbiotic studies using rodent models suggest that these treatments may have 
preventive and therapeutic properties.  However, human studies are difficult to perform 
and therefore rare. 
Rafter et al. and Roller et al. assessed a combination of Lactobacillus rhamnosus 
GG (1 x 1010 CFU), Bifidobacterium lactis Bb12 (1 x 1010 CFU) and 12 or 10 g of Synergy 
1 on colon cancer and polypectomized patients in two similar phase II anti-cancer studies 
(139, 140).  The synbiotic treatment was compared to a placebo in a 12 week trial.  Fecal 
water obtained from the cancer patients did not improve barrier function in Caco-2 cells, 
but did increase production of interferon γ.  For polypectomized patients, several benefits 
were observed among the synbiotic group, including significant decreased DNA damage 
in colonic mucosa, reduced proliferation, and decreased secretion of IL-2.  The fecal water 
improved barrier function in Caco-2 cells and significantly reduced necrosis in HCT116 
cells.  The investigators also assessed survival of each of the probiotic strains in an 
independent study with healthy human subjects who consumed rifampicin resistant 
mutants of each strain (139).  Rifampicin resistance was used to identify the probiotics in 
a strain specific manner in the fecal samples.  A full recovery of both strains in healthy 
subjects was reported.  For the study patients, a fecal analysis was not performed at the 
strain level, but at the genus level.  The number of Lactobacillus and Bifidobacterium 
consistently increased in the synbiotic group for both cancer and polypectomized patients 
over the 12 week trial, while Clostridium numbers decreased.  Since a probiotic only 
treatment was not applied, a synergy between the probiotic strains and Synergy 1 could not 
be confirmed based on this data.  Roller et al. did not analyze the fecal microbiota, but 
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referred to another study that reported that only 10 % of the consumed amount of LGG and 
Bb12 survived the GI tract in the same synbiotic treatment (141).  Neither study analyzed 
the probiotic and prebiotic components alone.  
 In a four week cross-over trial the effect of the synbiotic combination of 12.5 g of 
resistant starch and 5 x 109 CFU Bifidobacterium lactis was investigated on twenty healthy 
subjects (92).  Even though these patients were healthy, the effect of the dietary treatments 
on markers of early colorectal carcinogenesis was assessed.  A placebo, a prebiotic only, 
and a probiotic only arm were also included.  Full analyses of the fecal microbiota were 
conducted using DGGE and quantitative real-time PCR to assess levels of Bifidobacterium 
lactis.  The DGGE banding patterns showed that the synbiotic treatment introduced 
significantly more changes to the gut microbiota than the placebo or the pro- or prebiotic 
treatments alone.  Interestingly the probiotic treatment led to higher numbers of B. lactis 
than the synbiotic treatment (8.8 x 107 versus 5.4 x 107 B. lactis/g feces).  Therefore a 
synergistic relationship between this strain of B. lactis and the applied resistant starch is 
not likely.  No differences were detected for the SCFA profile, fecal ammonia or pH, serum 
inflammatory markers, or epithelial variables among the treatments.  This study 
demonstrates how even significant changes introduced to the gut microbiota by a dietary 
intervention do not necessarily lead to a change in disease associated phenotypes. 
 
Irritable bowel syndrome  
Irritable bowel syndrome (IBS) is an intestinal disorder characterized by abdominal 
pain, bloating, diarrhea, alternate constipation, distention, or a combination of these 
symptoms.  The cause of this illness has not been established, but visceral hypersensitivity, 
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genetics, the gut microbiota, constant low-grade inflammation, and environment are 
contributing factors (81).  Approximately 11 % of the world’s population may be affected 
by IBS, with higher occurrences among women and younger individuals (142, 143).  
Physiological interventions, dietary manipulations, pharmacologic agents, and modulation 
of the gut microbiota are part of current treatments for IBS (144). 
In one double-blinded, randomized and placebo-controlled study, a synbiotic 
mixture of 5 × 109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus, 
2×109 Lactobacillus gasseri,1×109 Bifidobacterium infantis, 1×109 Bifidobacterium 
longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus, 1×109 
Lactobacillus sporogenes, and 5×109 Streptococcus thermophilus in combination with 2.2 
g Synergy 1 (inulin/oligofructose) was tested for its potential to reduce symptoms of IBS 
(145).  Sixty-four patients were enrolled and treated for four weeks.  No overall satisfactory 
relief was achieved with the synbiotic treatment.  However the synbiotic did improve 
quality of life scores, and the severity of flatulence was significantly decreased.  
Interestingly, the authors provided a rationale for selecting this particular synbiotic 
combination.  Namely, the product is readily available, has a history of safe use, and there 
was only one other study using single-strain synbiotic mixture for the treatment of IBS.  
Nonetheless, effect on the gut microbiota was not studied.   
A recent study examined the effect of Lactobacillus acidophilus (1.8 x 107 CFU/g), 
Bifidobacterium animalis subsp. lactis Bb-12 (2.5 x 107 CFU/g), and Beneo dietary fibers 
(2%) on the quality of life and IBS symptoms of 76 constipation-predominant IBS patients 
(146).  The synbiotic was delivered twice daily in 180 g of fermented milk for four weeks.  
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Several markers of IBS symptoms improved after four weeks, but there was no difference 
between the synbiotic and the placebo (fermented milk).   
Bittner et al. tested the efficacy of the synbiotic Prescript-AssitTM in a two week 
randomized, placebo-controlled study, followed by a two week open label treatment and a 
follow up 60 weeks later (147, 148).  Prescript-AssitTM is a combination of 29 soil-based 
microorganisms, including several Anthrobacter, Bacillus, Brevibacterium, Pseudomonas, 
and Streptomyces strains.  The prebiotic components are not well defined, except that one 
of them is leonardite.  A total of 25 patients completed the first two week study, and 22 
completed the 60 week follow up.  The authors concluded that Prescript-AssitTM was 
capable of reducing short-term and long-term symptoms of IBS in the study cohort.  These 
symptoms included general ill feeling/nausea, indigestion/flatulence, and colitis.  Since the 
synbiotic composition was not clearly defined, an assessment of the synergy of this 
synbiotic cannot be made.  The fecal microbiota of the patients was not analyzed and 
therefore no conclusions regarding the mode of action of this synbiotic can be inferred.  
Interestingly, the applied organisms are mostly found in soil are not considered members 
of the human gut microbiota.  Whether or not these organisms are capable of reaching the 
colon or interacting with the autochthonous microbiota remains unknown.  Unfortunately, 
a rationale for choosing soil organisms in a human trial is not given. 
The efficacy of Flortec, a synbiotic combination containing 5 x 109 CFU 
Lactobacillus paracasei B21060, xylo-oligosaccharides, glutamine, and arabinogalactone, 
was tested in a parallel-arm, double blind study in patients of IBS (149).  Patients were 
instructed to consume the synbiotic or prebiotic treatment twice a day for twelve weeks 
and were asked to report GI symptoms on a daily basis.  No placebo control or probiotic 
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only arm was included.  A total of 167 IBS patients were enrolled in this study, however, 
55 discontinued the treatment prematurely.  The main reason to withdraw was a perceived 
lack of benefit (33 % of the cases).  For the remaining patients, no differences were 
observed between the prebiotic and the probiotic treatment groups.  Compared to the 
baseline, both treatments led to a decrease in IBS scores after one week.  There was, 
however, a significant difference among the number of patients that had at least one bowel 
movement per day with 70 % in the synbiotic group and 35 % in the prebiotic group.  An 
analysis to assess how a responder differed from a non-responder was not conducted.  
Subsequently, 47 patients who had a diarrhea predominance were analyzed as a subgroup.  
The number of bowel movements and IBS score significantly decreased due to the 
synbiotic treatment compared to the baseline and the prebiotic group.  In this study, patients 
were allowed to use a “rescue treatment”.  Approximately 8 % of the study subjects used 
such a treatment, which was not closer defined then “medications effecting gastrointestinal 
motility and/or perception”.  These additional treatments were not taken into account 
during the assessment of the syn- and prebiotic treatments.  Collectively, the absence of 
both a placebo control arm and an analysis of the gut microbiota makes it difficult to 
establish the effectiveness of the synbiotic.   
Dughera et al. conducted an open-label, uncontrolled, and multi-center study in ten 
Italian gastroenterological centers (150).  The applied synbiotic was Zir Fos®, containing 
5 x 109 CFU of Bifidobacterium longum W11 and 2.5 g of Fos-Actilight, a short-chain 
fructooligosaccharide.  A total of 129 patients with constipation-predominant IBS were 
enrolled and received the treatment for three months.  Measured symptoms included 
abdominal pain, bloating, well-being, stool shape, stool frequency, concomitant treatments 
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and comorbidity.  The results showed that the synbiotic treatment significantly reduced 
abdominal pain and bloating, and induced a higher stool frequency (P < 0.0001).   
This same synbiotic (i.e., Bifidobacterium longum W11 and Fos-Actilight) was 
tested on 636 patients with constipation-variant IBS (151).  A clear statement about 
duration of the treatment was not given, only that the treatment lasted for at least 36 days.  
The dose was the same as in the study above (150), and the treatment effects were evaluated 
at the end of the study and at a one month follow up visit.  The results are similar to those 
reported by Dughera et al., in that the treatment resulted in significantly decreased bloating 
and abdominal pain (P < 0.0001) and increased stool frequency significantly.  Most (~84%) 
of the patients reported improved symptoms at the end of the treatment, but at the follow-
up evaluation the number decreased to 63 %. 
In neither trial were the fecal microbiota analyzed nor were control groups with 
probiotic, prebiotic, or placebo treatment included.  Based on these studies no conclusion 
can be drawn about a synergy between the probiotic and prebiotic.  
 
The ideal human trial to assess health benefits of a synbiotic treatment 
The development and selection of successful synbiotic combinations is a very 
complex issue (32).  As noted above and previously recommended by Kolida and Gibson 
(32), synbiotic trials have to be carefully designed and controlled in order to demonstrate 
the additive effect of each component, and to assess the minimum effective dose of each 
component of the synbiotic in order to achieve the desired health benefit, while avoiding 
side effects.  As demonstrated here and previously (32), most studies did not provide the 
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necessary controls to confirm an additive or synergistic effect of the synbiotic.  
Importantly, the rationale for how the synbiotic had been formulated is rarely stated.  In 
contrast, an ideal clinical trial would include synergistic synbiotics that had been shown to 
survive passage through the GI tract and also had an ability to become established in the 
GI environment.  Considering ecological criteria is also important when formulating 
synbiotic combinations, including demonstrating that the probiotic strain is capable of 
metabolizing the given prebiotic under competitive conditions.  Changes introduced to the 
gut microbiota should also be assessed to determine if cross feeding or other ecological 
events had occurred, e.g. niche competition, niche partitioning, or niche exclusion with the 
resident microbiota.  It is also critical to validate that the probiotic had been enriched using 
strain-specific probes or primers in quantitative PCR assays.  The experimental design 
should include treatments consisting of each component of the synbiotic.  Once the 
characteristics of the pro- and prebiotic are established independently as well as in 
combinations and an additive effect of the components has been demonstrated, 
randomized, controlled and double-blinded human trials should be conducted, with 
prebiotic, probiotic, and synbiotic treatments and a placebo control.  Survival of the test 
strains and changes in the composition of the gut microbiota should be assessed, in addition 
to measuring the health or clinical biomarkers of interest.  The study cohort needs to be 
sufficiently large to assure adequate power for the statistical analysis.  Ideally, the synbiotic 
should be compared to another a similar synbiotic containing a different strain.   
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1.7 Commercial synbiotics: recent developments and future prospects 
The functional foods market, that includes gastrointestinal health products, is 
estimated to be worth more than US $ 43 billion.  Currently, the US, Europe, and Japan 
represent 90 % of the global functional food market (152).  Within the US market, probiotic 
products had an estimated revenue of US $ 3.4 billion in 2013, and already in 2014 sales 
of probiotic products were the fasted growing of all supplements with a 22 % increase and 
US $ 10 billion revenue (153).  It is therefore the most popular functional food ingredient 
after minerals and vitamins (154).  The market revenue for prebiotics is estimated at US $ 
334 million, and synbiotics at 69 million.  These numbers are expected to increase with the 
new markets in the Middle East, China, India and New Zealand (35).   
Despite the substantial market opportunities for these products, researchers, 
clinicians, and regulatory agencies continue to emphasize several important issues.  In 
particular, demonstrating that products are safe and effective remains a top priority.  
Manufacturers are especially motivated to develop appropriate health claim strategies 
(155).  This situation is complicated by different health claim regulations that vary from 
one country to another and the degree of evidence required to support a health claim (156).  
Currently, neither EFSA nor the FDA have approved any health claims made for pre-, pro- 
or synbiotic combinations.  Moreover, probiotic and synbiotic products must be 
distinguished between a pharmaceutical product and a food product (157).  The FDA 
guidelines state that if any agent, including probiotics, is ingested for the purpose of curing, 
mitigating, treating, diagnosing or preventing disease, it is classified as a “drug” and must 
undergo the regulatory process similar to any new pharmaceutical.  This can be a 
burdensome process for probiotic/synbiotic foods, especially since the majority of food 
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products are not produced in pharma grade facilities and the FDA may require phase I 
safety studies for new synbiotic products.  In Europe the European Nutrition and Health 
Claims regulations intend to: (i) ensure that claims are “clear, accurate and based on 
scientific evidence”; and (ii) prohibit foods that bear “claims that could mislead 
consumers”.  Ultimately, high-quality human intervention studies are necessary to support 
any health claims of a product (156). 
 Another obstacle for the food industry is the lack of consumer understanding of 
these products.  Although consumers apparently understand probiotics, at least in general, 
they are less familiar with prebiotics (or confuse it with probiotics), and even fewer 
understand synbiotics (35, 47).  Therefore some products are not even marketed as 
synbiotics, but rather as probiotics.  Nonetheless many synbiotic products are on the 
market.  To date, most synbiotic-containing foods claim to improve general gut health or 
the body’s natural defense mechanisms by supporting the immune system or lowering 
blood cholesterol.   
Synbiotic products are most commonly presented to consumers as powders or 
cultured dairy products like yogurts or smoothies.  Prebiotics can be used in most food 
applications, but the environmental sensitivity of probiotics limits their practical use in 
non-refrigerated foods, since the survivability of the probiotic strains dictates which 
synbiotics can be developed (35).  However, new microencapsulation technologies that 
protect the bacteria against otherwise detrimental processing treatments could lead to a 
variety of new synbiotic products, including desserts, candy, juices, cheeses, or chocolate 
(158–162).  Interestingly many pre- and synbiotic products contain rather small amounts 
of the prebiotic component (on a per serving basis), which may be too low to induce a 
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health effect.  Low doses are used, in part, to avoid adverse gastrointestinal complaints 
(163), but perhaps also for cost reasons. 
Interestingly, despite the new products introduced into the marketplace and 
questions concerning safety and efficacy, synbiotic foods have a long history of save 
consumption.  As reviewed by Ashwani et al., many indigenous synbiotic foods can be 
found around the world, including Central America, India, Eastern Europe, China and 
Africa (164).  Most of these synbiotic preparations are fermented beverages, either with 
defined starter cultures, or by “spontaneous fermentation” (165).  However, the uncertainty 
of the actual microbial composition likely results in inconsistent final food products, 
unsuitable for industrial sale.  Nonetheless, these indigenous synbiotic foods have market 
potential if produced on an industrial scale and with appropriate quality standards (164).  
 
1.8 Remaining questions and specific aims 
Disturbances of the microbial composition in the gastrointestinal tract have been 
associated with deterioration of host health and functions.  These developments may either 
be directly induced by the gut microbiota, via an altered metabolite synthesis, or via the 
host immune system (6).  While the microbiota composition in the human gastrointestinal 
tract is remarkably stable, it can be successfully modulated by certain synbiotic treatments.  
These treatments could offer great advantages to human health when selected on a rational 
basis.  However, there are currently many potential limitations that hinder the development 
of synergistic synbiotic formulations.  There is a need to validate the potential health 
benefits of synbiotics in carefully controlled human clinical trials.  Additionally the future 
development of new synbiotic combinations should focus on the development of 
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synergistic synbiotics that prioritize the ecological properties and requirements of the 
probiotic strain.   
The work presented in this thesis aims to answer three important questions, which 
are relevant for our understanding of how the gut microbiota is shaped and how we can 
establish successful concepts for the modulation of the gut microbiota.  
The first objective of this thesis was to gain insight into the complex interplay 
between the host and intestinal microbes.  For this approach we chose Lactobacillus 
reuteri, which is a commonly used probiotic strain.  L. reuteri has been shown to be a true 
symbiont in rodents and densely colonizes the forestomach of mice (166, 167).  The aim 
of this study presented in Chapter 2 was to systematically determine which genes of L. 
reuteri 100-23 contribute to tolerance towards host gastric acid secretion.  A better 
understanding of microbial colonization factors in their host contributes to our 
understanding of ecological requirements for novel probiotic strains.  If these and other 
findings are truly understood and applied to the rational selection of synbiotic strains, the 
next generation of synbiotic combinations may have a greater ecological advantage and 
could be more competitive than current synbiotic combinations on the market.  
The second objective of this thesis was to test if rationally selected synbiotic 
applications have a higher potential to establish probiotic strains in the gastrointestinal 
tract.  To answer this question, Chapter 3 analyses the potential of a novel technique to 
select synergistic synbiotic combinations.  In this study we characterized the potential of 
an in vivo selected combination of Bifidobacterium adolescentis and GOS in a rat model.   
After the ecological advantages of in vivo selected synbiotics had successfully been 
established, the third objective was to test the potential of this synbiotic combination in 
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human subjects in Chapter 4 in comparison to a commercial synbiotic.  The rationally, in 
vivo selected synbiotic was established in the GI tract of the subjects in significantly higher 
numbers then the commercial synbiotic.   
Together, the studies performed for this thesis present a comprehensive 
examination of the role of the stomach and dietary factors, such as probiotics, prebiotics 
and synbiotics, on the establishment of bacteria in the gastrointestinal tract. 
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Chapter 2 
 
Characterization of the ecological role of genes mediating acid resistance in 
Lactobacillus reuteri during colonization of the gastrointestinal tract. 
 
Preface 
This chapter has been previously published: Characterization of the ecological role of 
genes mediating acid resistance in Lactobacillus reuteri during colonization of the 
gastrointestinal tract. Janina A. Krumbeck, Nathan L. Marsteller, Steven A. Frese, Daniel 
A. Peterson, Amanda E. Ramer-Tait, Robert W. Hutkins, and Jens Walter. Environmetal 
Microbiology (2015). doi:10.1111/1462-2920.1310 
 
2.1 Summary 
Rodent-derived strains of Lactobacillus reuteri densely colonize the forestomach 
of mice and possess several genes whose predicted functions constitute adaptations towards 
an acidic environment.  The objective of this study was to systematically determine which 
genes of L. reuteri 100-23 contribute to tolerance towards host gastric acid secretion.  
Genes predicted to be involved in acid resistance were inactivated, and their contribution 
to survival under acidic conditions was confirmed in model gastric juice.  Fitness of five 
mutants that showed impaired in vitro acid resistance were then compared through 
competition experiments in ex-germ-free mice that were either treated with omeprazole, a 
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proton-pump inhibitor that suppresses acid secretion in the stomach, or left untreated.  This 
analysis revealed that the urease cluster was the predominant factor in mediating resistance 
to gastric acid production.  Population levels of the mutant, which were substantially 
decreased in untreated mice, were almost completely restored through omeprazole, 
demonstrating that urease production in L. reuteri is mainly devoted to overcome gastric 
acid.  The findings provide novel information on the mechanisms by which L. reuteri 
colonizes its gastric niche and demonstrate that in silico gene predictions and in vitro tests 
have limitations for predicting the ecological functions of colonization factors in bacterial 
symbionts. 
 
2.2 Introduction 
A complex and diverse collection of microorganisms colonizes the gastrointestinal (GI) 
tract of mammals, affecting the health and immune status of the host.  Among other functions, these 
microbial communities enhance energy absorption from ingested food, contribute to the 
development of their host’s immune system, and provide colonization resistance against pathogens 
(Sekirov et al., 2010).  As a result of co-evolution, the bacteria that reside in the mammalian gut 
have developed a high degree of ecological fitness and specialization (Oh et al., 2010; Frese et al., 
2011; O’Callaghan and O’Toole, 2013).  Given the importance of the gut microbiota to the health 
of its host, there is currently much interest in formulating strategies that modulate its composition.  
However, remodeling this complex ecosystem requires an understanding of the mechanisms by 
which specific gut microbes colonize the GI tract and the factors that distinguish resident 
autochthonous members of the microbiota from allochthonous ones (Walter, 2008). 
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Among the bacteria that are autochthonous to several mammalian species is Lactobacillus 
reuteri (Walter, 2008).  L. reuteri forms high populations in the rodent stomach that are maintained 
throughout the life of the animal.  Colonization is achieved, in part, by the ability of the organism 
to adhere to the surface of the non-secretory epithelium present in the forestomach, resulting in 
formation of a biofilm-like structure (Walter et al., 2007; Frese et al., 2013).  The ability of L. 
reuteri strains to form these biofilms is strictly dependent on their host origin, with only rodent 
isolates being capable of forming biofilms (Frese et al., 2013).  This translates to a higher ecological 
fitness of rodent strains when colonizing the mouse gastrointestinal tract (Frese et al., 2011).  L. 
reuteri is therefore an example of a bacterium that maintains a tight, host-specific relationship with 
its mammalian host (Oh et al., 2010), and hence serves as a model to study ecologically important 
traits that facilitate host-microbe symbiosis in mammals at the molecular level (Frese et al., 2011; 
Tannock et al., 2005). 
A combination of comparative genomic and transcriptomic analyses have been used to 
identify genes that were overexpressed during gut colonization and contributed to host specificity 
and biofilm formation in rodent strains of L. reuteri (Frese et al., 2011, 2013; Schwab et al., 2014; 
Wilson et al., 2014).  Several of these genes (Table 2.1) are predicted to be involved in acid 
resistance, reflecting the acidic pH in the gastric niche, which varies depending on food loading 
and emptying (McConnell et al., 2008) from pH 4 and 5.7 in the lumen (Ward and Coates, 1987), 
and between pH 3.5 and 4 in the forestomach (Ward and Coates, 1987; Gärtner, 2001; Teixeira et 
al., 2014).  In particular, the presence of the urease gene cluster is mostly specific to rodent strains 
and its expression was induced during colonization of the mouse gut, without contributing to 
biofilm formation (Frese et al., 2011, 2013).  Wilson and colleagues confirmed its induction in vivo 
and showed that the cluster contributed to ecological performance in Lactobacillus-free mice 
(Wilson et al., 2014).  In addition, genes encoding glutamate decarboxylase and glutaminase were 
also found to be overexpressed during stomach colonization (Schwab et al., 2014; Wilson et al., 
2014).  The dlt operon, which contributes to acid resistance through the incorporation of D-alanine 
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esters into cell wall-associated teichoic acids, is essential for L. reuteri colonization of the 
gastrointestinal tract (Walter et al., 2007).  Several other acid resistance mechanisms (glutamate 
decarboxylase, glutaminase and arginine deaminase) support growth of L. reuteri during sour 
dough fermentation (Su et al., 2011; Teixeira et al., 2014).   
Although it is established that gastric acid constitutes a potent barrier to bacterial pathogens 
(Tennant et al., 2008), little is known about how lactobacilli autochthonous to the stomach 
overcome this environmental filter.  Of the genes predicted to be involved in acid resistance, only 
the urease cluster and the dlt operon have been studied in colonization experiments in mice (Walter 
et al., 2007; Wilson et al., 2014).  However, the mechanisms by which these factors facilitate 
colonization have not been determined, and other functions, independent of acidity, could explain 
the importance of these factors in vivo.  In addition, it is unknown which of the other acid resistance 
factors present in L. reuteri contribute to acid resistance during stomach colonization.  The goal of 
this study was therefore to determine the ecological significance of acid-resistance genes present 
in L. reuteri 100-23 during gut colonization, and to systematically determine to what degree they 
contribute to tolerance to host gastric acid secretion.  To achieve this, we compared the ecological 
fitness of mutants in ex-germ-free mice treated with omeprazole, a proton-pump inhibitor that 
raises the pH of the stomach from approximately pH 3 to 5 (depending on food loading) to 
approximately 6.8 to 7.0 (Betton et al., 1988), with mice that were left untreated.   
 
2.3 Results 
2.3.1 Selection of genes of L. reuteri 100-23 predicted to be involved in acid resistance 
Genes selected for this study are listed in Table 2.1 and included: (i) the gene 
encoding for the α-subunit of the urease enzyme (ureC).  This gene cluster, which 
hydrolyses urea to ammonia, which increases the pH (Cotter and Hill, 2003), is mainly 
found in rodent strains of L. reuteri but is absent in other isolates and is overexpressed 
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during gut colonization (Frese et al., 2011; 2013; Wilson et al., 2014); (ii) arginine 
deiminase (Adi), which increases acid resistance by intracellular consumption of protons 
and ammonia production (Arena et al., 2002; Cotter and Hill, 2003; Rollan et al., 2003; 
Vrancken et al., 2009; Teixeira et al., 2014); (iii) the glutamate decarboxylase (GadB), 
which is specific to L. reuteri strains isolated from rodents (Frese et al., 2011) and induced 
in vivo (Wilson et al., 2014), and further implicated in acid resistance during growth in 
sourdoughs (Su et al., 2011; Teixeira et al., 2014); (iv) the cystathionine γ-lyase (Cgl), 
which catalyses several reactions transforming compounds such as L-cystine, L-
cystathionine, L-homoserine, or L-cysteine (De Angelis et al., 2002; Wang, 2002).  L-
cysteine is degraded into pyruvate, hydrogen sulfide and ammonia, the latter of which 
could increase the pH (Wang, 2002); (v) the dltA gene, which is involved in D-alanyl 
esterification of teichoic acids associated with cell walls, is an important colonization factor 
of L. reuteri (Walter et al., 2007) associated with in vitro acid resistance in L. reuteri 
(Walter et al., 2007) and other organisms (Boyd et al., 2000; Kristian et al., 2005); and (vi) 
homologues of a two-component regulatory system consisting of a histidine sensor kinase 
(lisK, lr69622) and response regulator (lisR, lr69623), which has been previously shown to 
be involved in acid response regulation in Listeria monocytogenes and Lactobacillus 
acidophilus (Kallipolitis and Ingmer, 2001; Cotter and Hill, 2003; Azcarate-Peril et al., 
2005).  At the protein level, the LisR and LisK homologues have 76 % and 47 % similarity 
to the proteins in L. acidophilus, whereas they show less than 32 % similarity to other two-
component systems (cemAKR, bfrKRT, and lr70529/lr70530) described for L. reuteri 100-
23 (Frese et al., 2011; Su and Gänzle, 2014).  As a negative control, a mutant with an 
inactivated high molecular mass surface protein (lsp mutant) was included in our studies, 
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as this adhesin contributes to ecological performance in vivo but is not predicted to be 
involved in acid resistance (Walter et al., 2005). 
Table 2.1.  Genes selected for functional characterization 
Gene Protein Description Putative 
Function 
Reason for Study 
lr70114 UreC Urease enzyme, α 
subunit 
Acid 
resistance 
Host specific (Frese et al., 2011; Wilson et al., 
2014), upregulated in biofilms (Frese et al., 
2013) and in vivo (Frese et al., 2011; Schwab 
et al., 2014; Wilson et al., 2014), and involved 
in acid resistance and critical for ecological 
success (Kakimoto et al., 1990; Cotter and 
Hill, 2003; Wilson et al., 2014). 
Ir71325 GadB Glutamate 
decarboxylase 
Acid 
resistance 
Upregulated in biofilm in L. reuteri 100-23 
(Wilson et al., 2014) and involved in acid 
resistance (Su et al., 2011; Teixeira et al., 
2014). 
Ir69360 Cgl Cystathionine γ-
lyase 
Reactive 
oxygen 
resistance (Lo 
et al., 2009) 
Upregulated in biofilm in L. reuteri 100-23 
(Frese et al., 2013) and in acid-adapted B. 
longum biotype longum (Sánchez et al., 
2007); pathway produces ammonia (Lo et al., 
2009), which may have buffering capacity. 
Ir71377 Adi Arginine 
deiminase 
Acid 
resistance 
Upregulated in the stomach when compared 
to the cecum in conventional mice (Schwab et 
al., 2014) and involved in acid resistance in L. 
reuteri 100-23 (Teixeira et al., 2014). 
Ir69622 LisK Histidine sensor 
kinase of two-
component 
regulatory system 
Two-
component 
regulatory 
system 
Involved in acid response regulation in 
Listeria monocytogenes (Kallipolitis and 
Ingmer, 2001; Cotter and Hill, 2003) and 
Lactobacillus acidophilus (Azcarate-Peril et 
al., 2005).  
Ir69623 LisR Response 
regulator of two-
component 
regulatory system 
Two-
component 
regulatory 
system 
Involved in acid response regulation in 
Listeria monocytogenes (Kallipolitis and 
Ingmer, 2001; Cotter and Hill, 2003) and 
Lactobacillus acidophilus (Azcarate-Peril et 
al., 2005).   
Ir1649-
Ir1652 
DltA D-alanylation of 
lipoteichoic acids 
Acid 
resistance, 
biofilm 
formation 
Involved in acid resistance in several 
organisms (Boyd et al., 2000; Kristian et al., 
2005; Lebeer et al., 2008) and strongly 
contributes to ecological performance in L. 
reuteri 100-23 during gut colonization 
(Walter et al., 2007). 
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2.3.2 In vitro characterization of putative acid resistance genes 
Isogenic mutants (Table 2.2) of each gene were generated by insertional 
mutagenesis and compared with the wild- type for survival in simulated gastric juice at pH 
1.5 and 2 (Fig. 2.1A–F).  Depending on the gene tested, the gastric fluid was supplemented 
with the substrate necessary for the particular pathway.  The analysis revealed that the 
ureC, adi, cgl, gadB and dlt mutants were all impaired in their ability to tolerate acidic pH.  
For the ureC, Cgl, gadB and dltA mutants, the inhibitory effect of acidic conditions 
appeared to be similar at pH 1.5 and 2.  Exceptions were the adi mutant, which was more 
impaired at pH 2 (Fig. 2.1B), and the dlt mutant, which was considerably more impaired 
in its survival at pH 1.5 than at pH 2 (Fig. 2.1E).  The omission of urea, arginine, glutamic 
acid or cysteine reduced the survival rates of the wild-type to those of the respective 
mutants (grown with the substrates), showing that acid resistance is facilitated by these 
substrates.  The two-component system with similarity to LisRK did not contribute to acid 
resistance (Fig. 2.1F).  As expected, the lsp mutant was not impaired in survival in gastric 
juice (data not shown). 
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Table 2.2.  Strains used in this study 
   
Lactobacillus reuteri 100-23 Isolate of rat gastrointestinal tract Wesney and Tannock 
(1979) 
Lactobacillus reuteri 100-23c Plasmid-cured derivate of strain 100-23 McCOnnell and 
colleagues (1991) 
Lactobacillus reuteri 100-23 ure C mutant Urease α-subunit inactivated Frese and colleagues 
(2013) 
Lactobacillus reuteri 100-23 lsp mutant Large surface protein inactivated Walter and colleagues 
(2005) 
Lactobacillus reuteri 100-23 cgl mutant Cystathionine γ-lyase inactivated Frese and colleagues 
(2013) 
Lactobacillus reuteri 100-23 gadB mutant Glutamate decarboxylase inactivated This study 
Lactobacillus reuteri 100-23c lisR mutant Response regulator of two-component 
regulatory system involved in acid 
resistance in Listeria monocytogenes and 
Lactobacillus acidophilus 
This study 
Lactobacillus reuteri 100-23c lisK mutant Histidine sensor kinase of two-component 
regulatory system involved in acid 
resistance in Listeria monocytogenes and 
Lactobacillus acidophilus 
This study 
Lactobacillus reuteri 100-23c dlt mutant D-alanylation of lipoteichoic acids in the 
bacterial cell wall inactivated 
Walter and colleagues 
(2007) 
Lactobacillus reuteri 100-23c adi mutant Arginine deiminase inactivated This study 
Escherichia coli EC1000 Contains copy of pVW01 repA gene Russell and 
Klaenhammer (2001) 
 
79 
 
Fig. 2.1. Determination of the capacity of genes (Table 2.1) to confer survival under acidic 
conditions.  The viability of strains was determined after incubation in artificial gastric 
fluid at pH 2 and 1.5 for 6 h at 37°C.  Survival of (I) wild-type strains incubated without 
the substrate of the respective enzyme and (II) mutant strains incubated with the respective 
substrate are shown relative (%) to that of the wild-type strain incubated with the respective 
substrate.  (A) ureC; (B) adi; (C) cgl; (D) gadB; (E) dltA; and (F) lisR and lisK.  Because 
there is no added substrate for the dltA, lisR and lisK genes, only the survival of the mutants 
was compared with the wild-type.  Data are shown as means with standard deviations of 
triplicate independent experiments (biological replicates). 
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2.3.3 Importance of acid resistance genes during colonization of the mouse GI tract 
The ecological importance of the five genes found to contribute to acid resistance 
in vitro (see above) was subsequently tested via competition experiments of mutant and 
wild-type strains in germ-free mice that were treated with omeprazole or left untreated.  
Therefore, for genes that contribute to acid resistance in vivo, omeprazole would lead to an 
increase in competitive fitness of the mutants.  Controls received either a sham treatment 
[containing only the dimethylsulphoxide (DMSO), polyethylene glycol and water used to 
dissolve the omeprazole] or no treatment (bacteria only).  A schematic summary of the 
experimental design is depicted in Fig. 2.2A. 
The analysis revealed that the inactivation of ureC had a large impact on the 
tolerance of L. reuteri 100-23c towards host gastric acid secretion (Fig. 2.2B).  Without the 
neutralizing effect of omeprazole, the ureC mutant represented around 0.1% of the L. 
reuteri population in the gut after 8 days of colonization.  Omeprazole treatment restored 
the population of the ureC mutant to 29.8% ± 11 of the total lactobacilli population detected 
in the forestomach and 50.2% ± 15 in the cecum.  The omeprazole solvent, polyethylene 
glycol, has weak buffering capacity, which likely is responsible for the increase of mutant 
abundance in mice on the sham treatment (Fig. 2.2B).  
The adi mutant was only slightly impaired in vivo.  When in direct competition with 
the wild-type strain, the mutant represented 26.9% ± 13 of the total lactobacilli in the 
forestomach and 35.7% ± 17 in the cecum.  No significant differences were observed for 
omeprazole or sham treatment (Fig. 2.2C).  The inactivation of gadB also only led to a 
slight impairment in vivo (Fig. 2.2D), with the mutant comprising 19.5% ± 11 and 13.0% 
± 10 of the total lactobacilli population in forestomach and in the cecum, respectively.  
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Omeprazole treatment had no detectable effect in the forestomach (23.5% ± 14), but 
significantly enhanced survival in the cecum (31.3% ± 25).  
 
 
Fig. 2.2. Mouse competition experiment with mutant and wild-type strains in ex-germ-free 
C57BL/6J mice treated with omeprazole, sham or no treatment.  A. Conceptual summary 
of the experimental design for mouse experiments.  Mice were divided into three groups.  
Group 1 mice were treated daily with omeprazole, whereas group 2 mice were gavaged 
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with the polyethylene glycol, water and DMSO sham.  Group 3 mice served as the control 
animals and received no treatment.  All treatments were administered for 8 days.  On day 
two, all mice received a single gavage with a 1:1 mixture of wild-type and mutant.  The 
proportions of total lactobacilli composed of each mutant in the forestomach and cecum of 
mice co-inoculated with wild-type and mutant strains were shown.  B–G. In vivo 
competition experiment between wild-type and ureC mutant (B); wild-type and adi mutant 
(C); wild-type and gadB mutant (D); wild- type and cgl mutant (E); wild-type and dltA 
mutant (F); wild-type and lsp mutant (G). Data are shown as means with standard errors of 
the mean.  Significance of P ≤ 0.05 is denoted by a single asterisk (*), P ≤ 0.01 as two 
asterisks (**), and P ≤ 0.001 by three asterisks (***).  Circles and triangles represent the 
forestomach and cecum, respectively, of a single mouse. 
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The cgl mutant showed a high degree of impairment when competing with the wild-
type in both the forestomach (4.8% ± 3) and the cecum (7.5% ± 6), demonstrating that this 
gene is ecologically relevant in vivo (Fig. 2.2E).  Similar findings were obtained for the dlt 
mutant, which was highly impaired (Fig. 2.2F), an observation consistent with previous 
findings in Lactobacillus-free mice (Walter et al., 2007).  In both mutants, omeprazole did 
not influence the ecological performance.  Thus, it appears that both cgl and dltA encode 
for ecologically relevant colonization factors that are not involved in providing resistance 
to gastric acid secretion.  
The lsp mutant lacks a putative adhesin that is not involved in acid resistance.  We 
included this mutant to determine unspecific effects of omeprazole on the competiveness 
of mutant strains in general.  As shown previously (Walter et al., 2005), the lsp mutant was 
impaired in vivo, forming around 10% of the population.  However, as expected, no 
difference between the three treatments was observed (Fig. 2.2G).  
Altogether, these experiments demonstrate that the urease gene cluster is the only 
factor that mediates resistance against gastric acid secretion in L. reuteri 100-23 during 
stomach colonization, and that no other acid resistance factor was able to compensate for 
its loss under the given experimental and dietary conditions. 
 
2.3.4 Urease activity is regulated by pH 
The in vivo competition experiments demonstrated the importance of the urease 
gene cluster as an acid-related colonization factor for L. reuteri 100-23 in the rodent 
forestomach.  To characterize the regulation of this cluster, the wild-type strain was grown 
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in mMRS broth supplemented with 1% urea and growth and urease activity was monitored 
for 24 h (Fig. 2.3A).  The addition of urea caused a slightly decreased growth rate, but led 
to a rapid increase in pH after 12 h of incubation.  The final pH after 24 h was 7.4 with urea 
supplementation, compared with pH 3.9 without urea in the media (P < 0.0001).  This 
alkalization of the supernatant was not observed for the ureC mutant (data not shown).  
There was no detectable urease activity in the first 8 h.  However, urease activity became 
detectable after 10 h when the pH approached pH 4 (Fig. 2.3A).  
 
 
Fig. 2.3. A. Bacterial growth (OD 600) of L. reuteri 100-23 (continuous line, empty 
symbols, left ordinate axis) and the pH of the media (dotted line, full symbols, right 
ordinate axis) with (triangle symbol) and without urea (square symbol).  B. Urease activity 
over time in cell lysates of wild-type strain 100-23 grown with and without 1% urea in 
mMRS media, gray and white bars respectively.  C. Urease activity in cell lysates of wild-
type strain 100-23 in induction experiment. mMRS media adjusted to pH 4, 5 or 6 with and 
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without 1% urea supplementation, gray and white bars respectively.  n = 3, means and 
standard deviations are shown.  Treatments with different letters (a, b, c) are significantly 
different from one another (P ≤ 0.05). 
 
Urea supplementation had no significant effect on the urease activity at any time 
point.  These findings suggest that urease activity in L. reuteri was not induced by the 
substrate but by rather acidic conditions.  To confirm that induction of urease activity in L. 
reuteri 100-23 occurs via acidity and not urea, cells were grown for 6 h in mMRS, 
centrifuged and re-suspended in fresh mMRS media adjusted to pH 4, 5 or 6. Cells were 
incubated for another 2 h before urease activity was measured.  Cells after 6 h of growth 
were used for these experiments as L. reuteri did not show any urease activity until 10 h of 
growth (Fig. 2.3A), allowing the determination of conditions that induce urease activity.  
This experiment demonstrated that urease activity was induced at pH 4, unaffected at pH 
5 and not detectable at pH 6 (P < 0.01).  The presence of urea did not enhance urease 
activity.  Transcript analysis revealed that expression of ureC was 124 times higher at pH 
4 compared with pH 6 independently of the presence of urea.  These findings demonstrate 
that the urease activity in L. reuteri is regulated on the transcriptional level.    
Two-component systems are commonly used by lactic acid bacteria for 
environmental sensing and signal transduction and are often involved in the acid stress 
response (Cotter and Hill, 2003). Lactobacillus reuteri 100-23 possess homologues to the 
LisRK system, which has been implicated in mediating acid resistance in L. monocytogenes 
(Cotter et al., 1999) and L. acidophilus (Azcarate-Peril et al., 2005).  To test if the lisRK 
genes are involved in regulating urease activity, we compared culture supernatant pH of 
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the lisK and lisR mutants during growth in the presence of urea.  The lisR mutant was also 
tested in the same pH induction experiment described above.  Neither the lisK nor the lisR 
mutation had an effect on the buffering capacity during growth in the presence of urea, and 
urease activity was still induced by low pH in the lisR mutant in the pH induction 
experiment (data not shown).  Hence, it was concluded that this two-component regulatory 
system is not involved in the regulation of the urease gene cluster, which is consistent with 
the finding that the lisR and lisK mutants were not impaired in simulated gastric juice (Fig. 
2.1K).  Therefore, it is currently unknown how L. reuteri senses acidic pH and induces 
gene expression of the urease cluster. 
 
2.4 Discussion 
The rodent stomach consists of two parts: forestomach and corpus.  The 
forestomach represents about two thirds of the total stomach volume and is lined by a 
squamous stratified epithelium.  The corpus is lined by a glandular and secretory 
epithelium covered by a mucus layer (Gärtner, 2001) and harbours the H+ /K+ proton-
pumps responsible for the low pH in the stomach (Fig. 2.2A).  Lactobacillus reuteri 
colonizes the forestomach epithelium, but it is also found throughout the digestive tract, 
including the cecum, where pH values are closer to neutral.  However, the spatial patterns 
of L. reuteri populations throughout the mouse digestive tract suggest that cells in the 
cecum are likely allochthonous to this site and originated from cells colonizing the stomach 
(Walter, 2008).  This notion was supported by the findings of this study; cecal mutant 
proportions always mirrored those of the forestomach, independently of gene function (Fig. 
2.2B–G).  This agrees with previous findings concerning the dlt (Walter et al., 2007), gtfA, 
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inu, (Walter et al., 2008), lsp, msrB (Walter et al., 2005) and ftf (Sims et al., 2011) mutants.  
The forestomach of mice is therefore the primary habitat of L. reuteri, which makes acid 
resistance a key factor for successful colonization.  
Accordingly, several pathways and factors have been identified and functionally 
characterized to contribute to acid resistance in L. reuteri (Fig. 2.4).  However, our 
experiments in omeprazole-treated mice identified the urease gene cluster as the 
predominant factor necessary for L. reuteri 100-23 to tolerate host gastric acidic secretion 
(Figs 2.2B and 2.4A).  Inactivation of the ureC gene resulted in the lowest levels of 
colonization (around 0.1%) of all mutants tested here.  This finding, consistent with 
observations in Lactobacillus-free mice (Wilson et al., 2014), demonstrated the paramount 
ecological importance of the urease cluster.  Restoration of mutant proportions to around 
30% and to 50% with omeprazole in the forestomach and cecum, respectively, indicated 
that host acid secretion is the main ecological factor decreasing mutant levels, and that 
urease production of L. reuteri is almost completely devoted towards resistance to host 
gastric acid production.  Furthermore, the percentage of mutant strains was significantly 
lower in the forestomach in omeprazole treated mice compared with the cecum.  One could 
speculate that ureC has a residual function in the forestomach that is unrelated to host acid 
production.  Instead, ureC may contribute to resistance against the build-up of acidic 
metabolic end-products in the biofilm generated through bacterial fermentation.  Overall, 
our findings show that host acid secretion exerts a substantial selective pressure on the L. 
reuteri population, even in the non-secretory forestomach, and that urease production 
serves as an adaptive phenotype to overcome this pressure.  
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Fig. 2.4. Overview of metabolic pathways of genes assessed in this study.  A. The urease 
gene converts urea to ammonia and CO2.  Ammonia is exported from the cytoplasm using 
the UreI transporter, thus buffering the cell from its surrounding environment. B. 
Glutamate is imported into the cell by an antiport system and converted to GABA using 
the glutamate decarboxylase pathway while generating a ΔΨ and ΔpH.  H+ consumption 
raises the intracellular pH.  Adapted from Su and colleagues (2011) and Price and 
colleagues (2012).  C. L-arginine is imported using an L-arginine–ornithine antiporter and 
converted into citrulline and ammonia by the arginine deiminase enzyme. Citrulline is 
further catalysed to ornithine and ammonia, while consuming H+. Ammonia is exported 
from the cytoplasm potentially using the UreI transporter.  D. D-Alanine is coupled to a 
DltC carrier protein, exported across the cytoplasmic cell membrane and used for 
esterification of teichoic acids associated with the cell wall.  This esterification results in a 
positive charge of the cell wall.  Adapted and simplified from Peschel and colleagues 
(1999).  E. Cysteine is converted to ammonia, hydrogen sulfide and pyruvate by the 
cystathionine γ-lyase.  Ammonia is exported from the cytoplasm using the potentially via 
the UreI transporter, thus buffering the cell from its surrounding environment.  F. F1 -F0 -
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ATPase-producing ATP using a ΔΨ and ΔpH, which is generated, in part, by the glutamate 
decarboxylase pathway.  Dashed arrows indicate that more than one step is involved in the 
pathway. 
 
Although the other four genes (gadB, cgl, adi and dltA) evaluated here also 
contributed to both survival in the in vitro gastric model and ecological performance in 
mice, our findings indicate that they do not contribute to tolerance of host gastric acid 
secretion during forestomach colonization.  Mutants for two of the genes, gadB and adi, 
were only marginally impaired, comprising >20% of the population in competition 
experiments.  The gadB gene has been identified as the most important mechanism of acid 
resistance in Escherichia coli (Feehily and Karatzas, 2013) and was previously shown to 
contribute to acid resistance (Teixeira et al., 2014) and ecological performance of L. reuteri 
100-23 during growth in sourdough (Su et al., 2011).  In our experiments, omeprazole 
treatment did lead to small but significantly higher levels of the gadB mutant in the cecum, 
suggesting that the gene contributed to acid survival during transit into the cecum but not 
the forestomach.  These findings may be explained by GadB of L. reuteri being active 
primarily at pH 2.5 (Teixeira et al., 2014), a feature that may confer a survival benefit when 
the stomach lumen becomes very acidic.  Expression of gadB is required for the conversion 
of glutamate to CO2 and g-aminobutyric acid (GABA) (Su et al., 2011); this function is 
independent of its role in acid resistance.  When glutamate is exchanged with GABA by 
an antiporter- system, a ΔΨ and ΔpH are generated.  This proton motive force generated 
by GadB provides a mechanism for conserving ATP that would otherwise be required to 
fuel the F1 F0 ATPase (Su et al., 2011) (Fig. 2.4B and F).  The loss of the proton motive 
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force may also explain the impairment of this mutant during transit because less energy 
may be available for the cells to launch a stress response towards the acidic conditions in 
the stomach lumen.  
The arginine deiminase pathway is widely distributed among bacteria (Senouci-
Rezkallah et al., 2011), triggered in L. reuteri CRL 1098 by low pH (Rollan et al., 2003), 
and over-expressed in the Lactobacillus population colonizing the stomach of conventional 
mice when compared with the cecum (Schwab et al., 2014).  This pathway consumes 
intracellular protons and raises the cytoplasmatic pH when converting L-arginine and H2O 
to ammonia and citrulline, which is further catalyzed to ornithine, ammonia and CO2 
(Konings, 2002; Teixeira et al., 2014) (Fig. 2.4C).  In vivo, however, the adi mutant was 
only marginally impaired, and the gene did not confer resistance against host acid secretion.  
In contrast to the gadB and adi mutants, the ecological performance of the dlt and 
cgl mutants was substantially impaired in vivo.  Contrary to the consistent involvement of 
the dltA gene in acid resistance of L. reuteri and other organisms in vitro (Boyd et al., 2000; 
Kristian et al., 2005; Walter et al., 2007; Lebeer et al., 2008), host acid production was not 
the factor that reduced mutant populations in mice.  An alternative function of the dlt 
operon is to increase resistance to cationic antimicrobial peptides by generating a positive 
net charge of the cell surface (Kristian et al., 2005; Walter et al., 2007).  This positive 
charge leads to a decreased binding of positively charged antimicrobial peptides, e.g. 
defensins, which may result in increased cell lysis and impaired ecological performance in 
vivo (Walter et al., 2007) (Fig. 2.4D).  A recent study showed that a reduction of the 
negative cell surface charge through Lipid A dephosphorylation mediates resistance to 
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antimicrobial peptides in the Gram-negative Bacteroides thetaiotaomicron (Cullen et al., 
2015).  The dlt operon could have a similar function in L. reuteri.  
Although bacterial cystathionine γ-lyases have not been associated with acid 
resistance, the cgl mutant of L. reuteri 100-23c was impaired in the in vitro acid resistance 
assays (Fig. 2.1C).  Among other reactions, these enzymes catalyze the transformation of 
L-cysteine and water to hydrogen sulfide, pyruvate and NH4+ (Wang, 2002; Lo et al., 2009) 
(Fig. 2.4E).  Although expression of the cgl gene is upregulated in L. reuteri 100-23 
growing in biofilms in vitro (Frese et al., 2013) and in acid-adapted B. longum subsp. 
longum (Sánchez et al., 2007), our mouse experiments did not support a role for cgl in 
overcoming gastric acid secretion.  In L. reuteri BR11, this pathway was shown to improve 
oxidative stress defense and is required for thiol production (Lo et al., 2009);  it could be 
important during forestomach colonization. This study establishes the cgl gene as an 
important colonization factor of L. reuteri 100-23, but further research is needed to 
elucidate the mechanism by which this gene contributes to gut colonization.  
Together with our previous phylogenetic and comparative genomic studies on L. 
reuteri (Oh et al., 2010; Frese et al., 2011), this work provides novel insight into the 
ecology and evolution of a vertebrate gut symbiont, and the mechanisms by which a host-
specific lifestyle can emerge.  Urease is commonly used by bacteria from different phyla 
to tolerate stomach acidity (e.g. in Helicobacter pylori) and in some pathogens (e.g. 
Clostridium perfringens and Yersinina enterocolitica), urease is considered a virulence 
factor that facilitates survival during gastric transit (Mora and Arioli, 2014).  Lactobacillus 
reuteri has acquired the urease cluster, which is extremely rare in the genus Lactobacillus 
(Zheng et al., 2015), by horizontal gene transfer (Frese et al., 2011).  The cluster has then 
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been stably maintained within rodent lineages of the species (Walter et al., 2011).  The 
findings presented here now provide an explanation for the conservation of this trait among 
rodent strains – it constitutes an essential colonization factor that provides a key adaptation 
to the gastric niche in rodents.  During the evolutionary process, it appears that L. reuteri 
has tailored transcriptional regulation of the cluster towards the environmental conditions 
of the murine stomach.  Transcriptional expression of the urease cluster is strictly regulated 
by pH (Fig. 2.3), allowing the organism to respond to the variation in gastric pH and only 
produce urease when the habitat becomes too acidic.  Urea, in contrast, is always present 
as it enters the stomach by diffusion and through the saliva (Burne and Chen, 2000), and it 
was therefore not required for L. reuteri to evolve a mechanism of substrate induction.  
Substrate availability through the rodent host is also a likely reason why urease formation 
evolved to become more important than GadB and Adi, as the latters’ substrates (glutamate 
and arginine) must be provided in the diet where supply is not reliable.  Urea hydrolysis is 
therefore a key facet of host adaptation (and potentially even co-evolution) in the L. 
reuteri–rodent symbiosis, and the absence of the phenotype in most non-rodent strains 
(Walter et al., 2011) is likely an important reason for their low ecological performance in 
the mouse GI tract (Oh et al., 2010; Frese et al., 2011).  
In conclusion, the findings obtained during this study demonstrated that urease 
production is essential and sufficient for L. reuteri 100-23 to cope with host gastric acid 
secretion.  Other genes, such as adi, clg, dltA and gadB, and genes encoding for glutaminase 
[which were overexpressed in acid resistance tests in vitro (Teixeira et al., 2014) and in the 
forestomach (Wilson et al., 2014) but were not studied here due to the presence of several 
copies in the genome] might contribute to resistance against acidic bacterial metabolic end-
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products, or may become more important in a different dietary context.  However, in the 
experiments conducted here, none of these genes was able to complement the loss of ureC 
in mediating resistance to host gastric acid secretion, which appears to exert a major 
selective pressure.  This study provides a better understanding of the phenotypic 
adaptations of vertebrate gut symbionts that contribute to both a highly successful lifestyle 
and specialization towards a particular host.  Most importantly, it demonstrates that gene 
annotations and in vitro tests have limitations to predict the exact ecological functions of 
colonization factors of bacterial gut symbionts. 
 
2.5 Experimental procedures ethics statement 
All mouse experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Nebraska (Project ID 731). 
 
2.5.1 Bacterial strains and media used in the study 
All strains of L. reuteri and E. coli are listed in Table 2.  Lactobacilli were grown 
anaerobically at 37°C in de Man, Rogosa and Sharpe (MRS) medium medium (Difco™; 
Le point-de-Claix, France) supplemented with 10 g l−1 maltose and 5 g l−1 fructose (referred 
to as mMRS).  For gene inactivation in L. reuteri 100-23c (plasmid-free derivative of strain 
100-23), E. coli EC1000 was used as a cloning vector and grown aerobically in Luria–
Bertani media (Difco™; Sparks, MD, USA) at 37°C. Erythromycin (200 μgml−1 for E. coli, 
5 μgml−1 for lactobacilli), kanamycin (40 μgml−1 for E. coli) and chloramphenicol (7.5 
μgml−1 for lactobacilli) were used for the propagation of recombinant strains.  
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2.5.2 Determination of genes predicted to be involved in acid resistance of L. reuteri 
100-23 
Several different approaches were used to select genes of interest for this study.  
First, we identified genes that were specific to rodent strains of L. reuteri (Frese et al., 
2011) and predicted to be involved in acid resistance.  Second, putative acid resistance 
genes that were upregulated in vivo compared with in vitro cultures were identified (Frese 
et al., 2013; Wilson et al., 2014).  Third, genes coding for metabolic path- ways that 
produce ammonia (Lo et al., 2009) and two- component systems involved in acid resistance 
in other bacteria were also considered (Kallipolitis and Ingmer, 2001; Cotter and Hill, 
2003).  One additional criterion for the selection of genes was that the gene had to be a 
single copy gene to generate the knock-out mutants according to the method described by 
Walter and colleagues (2005). 
 
2.5.3 Derivation of mutants 
Genes of interest were inactivated by insertional mutagenesis by site-specific 
integration of the plasmid pORI28 into the target sites in the L. reuteri 100-23c genome 
(Walter et al., 2005).  Internal regions of the genes of interest were amplified using the 
primers in Table S1 for each mutant.  Each knockout mutation was confirmed by 
polymerase chain reaction (PCR) using primers flanking the target region of each gene.  
Strains were routinely maintained in mMRS medium containing 5 μgml−1 of erythromycin, 
unless the mutant was used for the in vitro acid survival assay.  Growth curves showed no 
growth impairments in any of the mutants (data not shown). 
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2.5.4 In vitro acid survival assay 
To simulate the acidic conditions in the mouse stomach, an artificial gastric fluid 
developed by Cotter and colleagues (2001) was used.  The experiment was performed with 
wild- type L. reuteri 100-23c and all mutants; bacterial survival was monitored over time.  
To evaluate acid resistance, lactobacilli were grown in mMRS (pH 6.5) for 12–16 h, 
harvested by centrifugation and washed in PBS.  Pre-warmed gastric fluid was adjusted to 
pH 1.5 and 2 with HCl, and inoculated with approximately 108 cells ml−1.  Samples were 
incubated at 37°C and quantified by serial plating after 0, 1, 2, 3 and 6 h.  To assess the 
importance of the ureC, adi, gadB and LisK/R genes, assays were performed in gastric fluid 
with and without 1% urea, 20 mM arginine, 20 mM glutamic acid or 20 mM cysteine 
respectively.  The role of lsp and dlt genes was assessed without supplementation of the 
gastric fluid.  To gain an insight on the effect of gene inactivation on survival and to allow 
for a better comparison between experiments, cell numbers of the wild-type strain plus 
supplement was set to 100%.  Based on that value the cell numbers of wild-type without 
the respective substrate and mutant strains with the substrate was expressed as percent of 
those obtained with the wild-type incubated with the substrate.  Experiments were done in 
triplicate of biological replicates. 
 
2.5.5 Determination of genes’ role in in vivo acid resistance  
Germ-free C57BL/6J mice (males and females) were bred and reared in flexible 
film isolators and maintained under gnotobiotic conditions at the University of Nebraska-
Lincoln and were randomly assigned to one of three treatment groups.  Mice in group 1 
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received a daily oral gavage of 400 μmol of omeprazole kg−1 (6-methoxy-2-[(4-methoxy-
3,5- dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; Sigma) for 8 days 
(Tennant et al., 2008).  Omeprazole was dissolved in 50 μl of a DMSO-polyethylene glycol 
solution (90% DMSO, 4.5% polyethylene glycol and 5.5% water) and was filter sterilized 
(Zavros et al., 2002).  Mice in group 2 were orally gavaged daily with the DMSO–
polyethylene glycol vehicle and otherwise treated the same way as group 1 animals.  Mice 
in group 3 did not receive any treatment.  On day two, each mouse was inoculated with 106 
cells in a 1:1 ratio of 100-23c wild-type and a mutant strains in a single oral gavage.  The 
inoculum was also plated on mMRS plates with and without erythromycin (5 μgml−1) to 
confirm equal representation of the two strains.  Mice had access to food and water ad 
libitum.  After 8 days, mice were euthanized and forestomach and cecum contents were 
serially diluted and plated on mMRS with and without erythromycin (5 μgml−1) to 
determine the ratio of the wild-type and mutant strains in the samples.  A total of 6–11 
mice per each group (omeprazole, sham, control) were used per experiment.  The 
experiment was repeated twice with the gadB mutant because the first experiment showed 
a trend towards a higher survival rate due to omeprazole treatment compared with the sham 
in the forestomach.  However, this tendency was not confirmed (Fig. 2.2D).  It should be 
noted that polyethylene glycol possesses weak buffering capacity, which may therefore 
impact acid exposure to the lactobacilli.  Therefore, the amount of solution was kept as low 
as possible (50 μl total).  For all analysed gene clusters, it was assumed that the 
corresponding substrates, i.e. glutamic acid, arginine, urea etc., were present in the 
forestomach as they are supplied by the diet, or in the case of urea, enter the stomach by 
diffusion (Burne and Chen, 2000). 
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2.5.6 Determination of pH regulation of urease activity 
Lactobacillus reuteri 100-23c was grown for 6 h in mMRS at 37°C, centrifuged 
and re-suspended in fresh mMRS media adjusted to pH 4, 5 or 6 with HCl (before sterile 
filtration).  Cells were incubated for another 2 h at 37°C, and subsequently 10 ml of L. 
reuteri 100-23c culture was centrifuged for 5 min at 15 000 × g and stored in 10% glycerol 
at −20°C until determination of urease activity. 
 
2.5.7 Measurement of urease activity 
Cell solutions were thawed on ice, washed twice with citrate buffer (pH 4) and 
disrupted with 0.3 g sterile silica beads (0.5 mm) at maximum speed in a cell mill (Mini-
Beadbeater Biospec product) for three 1 min intervals.  Tubes were cooled on ice for 2 min 
between intervals to prevent overheating.  Samples were centrifuged at 10 000 × g for 2 
min.  Supernatant was collected and stored at −20°C until the assays were performed.  
Urease activity in the supernatant was determined by conversion of urea to ammonia, as 
described previously (Chaney and Marbach, 1962).  Citrate buffer (pH 4) containing 167 
mM urea was mixed in equal volumes with cell supernatant and incubated at 30°C for 30 
min.  Ammonia was quantified by the Berthelot reaction (Chaney and Marbach, 1962).  To 
determine protein, cell pellets were washed twice with 10 mM Tris (pH 8) and disrupted 
as described above. Protein concentration was determined according to Lowry and 
colleagues (1951).  Urease activity is expressed as microgram of ammonia formed per 
microgram of protein. 
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2.5.8 RNA extraction from L. reuteri cell cultures 
Lactobacillus reuteri 100-23 was grown for 6 h in mMRS media at 37°C, and cells 
were collected by centrifugation for 10 min at 3214 × g and re-suspended in fresh mMRS 
media adjusted to pH 4, 5 or 6 with HCl.  Cells were incubated for another 30 min at 37°C, 
and subsequently mixed with RNAprotect bacterial reagent (Qiagen, Valencia, CA, USA) 
at a ratio of 1 to 5.  The solution was incubated for 5 min at room temperature, centrifuged 
and stored at −80°C until used for RNA isolation.  Total RNA was isolated after the cell 
pellet was washed with RNase-free PBS buffer and re-suspended in 100 μl of lysis buffer 
(30 mM Tris–HCl; 1 mM EDTA, pH 8.0; 15 mg ml−1 lysozyme; 10 U ml−1 mutanolysin; 
and 100 μgml−1 Proteinase K).  Samples were treated as previously described 
(Rattanaprasert et al., 2014) and subsequently transferred to an RNeasy Mini spin column 
(Qiagen, Hilden, Germany).  Mixtures were centrifuged for 15 s at 14 000 × g and the 
eluate discarded. 350 μl of Buffer RW1 was added and centrifuged as before.  There was 
80 μl of DNase I incubation mix applied to the RNeasy column and incubated at room 
temperature for 15 min.  And, 350 μl of RW1 buffer was added and centrifuged as 
described above.  The flow-through was discarded, 500 μl of Buffer RPE added and 
centrifuged.  500 μl of Buffer RPE was added again and centrifuged for 2 min at 14 000 × 
g.  RNeasy column was placed in a new 2.0 ml collection tube and centrifuged for 1 min 
at 14 000 × g.  RNeasy column was placed in a new 1.5 ml collection tube and RNA eluted 
with 50 μl of RNase-free water.  Samples were centrifuged for 1 min at 12 000 × g.  
According to the manufacturer’s protocol (Applied Biosystems/Ambion, Austin, TX, 
USA) the purified RNAwas subsequently treated with the TURBO DNA-free kit.  RNA 
was quantified using the Qubit® RNABRAssay kit (Invitrogen, Carlsbad, CA, USA), and 
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RNA integrity was validated on a 1% agarose gel.  The absence of DNA contamination 
was confirmed by real-time PCR. 
 
2.5.9 Determination of gene expression by quantitative reverse transcription PCR 
(qRT-PCR) 
The purified RNA was reverse transcribed using the SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions with minor 
modifications as described by Frese and colleagues (2013).  qRT PCR was performed using 
an Eppendorf Mastercycler Realplex2 machine (Eppendorf AG, Hamburg, Germany) and 
Quanti-Fast SYBR Green PCR kits (Qiagen, Valencia, CA, USA).  The ureC and 
glyceraldehyde 3-phosphate dehydrogenase primers (Table S1) were previously validated 
using serial 10-fold dilutions of pooled cDNA to determine specificity and efficiency 
(Frese et al., 2013).  For each 25 μl qRT-PCR reaction, 12.5 μl of 2x Quantifast SYBR 
Green Mastermix, 1 μl of cDNA and 10 μMol of each primer were used.  The DNA was 
denatured at 95°C for 5 min and followed by 40 two-step cycles of 10 s at 95°C, then 30 s 
at 60°C.  Each PCR product was validated on an agarose gel and by inspection of their 
melting curves.  Gene transcripts of the urease α-subunit were quantified relative to the 
glyceraldehyde-3-phosphate dehydrogenase housekeeping gene, and relative 
quantification was performed using the method by Pfaffl (2001). 
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2.5.10 Statistical analysis 
Data are expressed as means ± standard deviations unless otherwise stated.  
Statistical analyses were carried out using GRAPHPAD PRISM 5 (GraphPad Software, 
California, USA).  If only two groups were compared, Student’s t-tests were per- formed.  
ANOVA and Tukey’s post-tests were used for multiple comparisons.  Significance of P ≤ 
0.05 is denoted by a single asterisk (*), P ≤ 0.01 as two asterisks (**), and P ≤ 0.001 by 
three asterisks (***). 
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Chapter 3 
 
In vivo selection to identify bacterial strains with enhanced ecological performance 
in synbiotic applications. 
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3.1 Abstract 
One strategy for enhancing the establishment of probiotic bacteria in the human 
intestinal tract is via the parallel administration of a prebiotic, which is referred to as a 
synbiotic.  Here we present a novel method that allows a rational selection of putative pro- 
biotic strains to be used in synbiotic applications: in vivo selection (IVS).  This method 
consists of isolating candidate probiotic strains from fecal samples following enrichment 
with the respective prebiotic.  To test the potential of IVS, we isolated bifidobacteria from 
human subjects who consumed increasing doses of galactooligosaccharides (GOS) for 9 
weeks.  A retrospective analysis of the fecal microbiota of one subject revealed an 8-fold 
enrichment in Bifidobacterium adolescentis strain IVS-1 during GOS administration.  The 
functionality of GOS to support the establishment of IVS-1 in the gastrointestinal tract was 
then evaluated in rats administered the bacterial strain alone, the prebiotic alone, or the 
synbiotic combination.  Strain-specific quantitative real-time PCR showed that the addition 
of GOS increased B. adolescentis IVS-1 abundance in the distal intestine by nearly 2 logs 
compared to rats receiving only the probiotic.  Illumina 16S rRNA sequencing not only 
confirmed the increased establishment of IVS-1 in the intestine but also revealed that the 
strain was able to outcompete the resident Bifidobacterium population when provided with 
GOS.  In conclusion, this study demonstrated that IVS can be used to successfully 
formulate a synergistic synbiotic that can substantially enhance the establishment and 
competitiveness of a putative probiotic strain in the gastrointestinal tract. 
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3.2 Introduction 
The mechanistic role of the gastrointestinal (GI) microbiota and its metabolites in 
maintaining human health has been well demonstrated (1–3).  Gut microbes provide several 
important benefits for their host, including provision of nutrients, development and 
maturation of the immune system, and protection against pathogens via colonization 
resistance (4).  However, the gut microbiota may also contribute to obesity, inflammatory 
and autoimmune diseases, and other chronic disease states (5–7).  Such diseases are often 
associated with compositional alterations in the fecal microbiota, a condition referred to as 
“dysbiosis” (8).  Given that the presence of specific types of bacteria and their relative 
abundance within the gut are considered to affect host health, there is much interest in 
devising strategies that modulate gut microbiota composition and potentially redress 
disease related dysbiotic patterns (9).  
Dietary approaches currently available to modulate the gut microbiota include 
prebiotics (10–12), fermentable fibers (13, 14), probiotics (or live biotherapeutics) (15), 
and synbiotics, which are a combination of a probiotic and a prebiotic (11, 16).  According 
to Kolida and Gibson (16), synbiotics can be either complementary or synergistic.  
Complementary synbiotics consist of a probiotic and a prebiotic selected to independently 
confer benefits to the host.  In contrast, synergistic synbiotics are comprised of a prebiotic 
chosen specifically for the selected probiotic to stimulate its growth, activity, and survival 
in the gastrointestinal tract (16). 
Synergistic synbiotics therefore hold the potential to improve the establishment of 
a specific bacterial strain when introduced into the gastrointestinal tract.  Unfortunately, 
successful synergistic synbiotic combinations are not well established in the literature 
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despite a large number of studies.  To our knowledge, only two reports describe a synbiotic 
combination in which the prebiotic significantly enhanced the stability, persistence, or 
metabolic activity of a specific probiotic strain in vivo (17–19).  As noted by Kolida and 
Gibson (16), this low success rate may be explained by the selection of most synbiotic 
combinations on an arbitrary basis, including shelf life, industrial performance, 
availability, and cost.  Indeed, few synbiotic preparations are formulated based on a rational 
selection of both the prebiotic and the probiotic (12, 16), such as via in vitro or in vivo 
screens assessing the ability of the probiotic to utilize the prebiotic (17–21).  Even if 
synbiotic formulations were based on these criteria, synergism between the probiotic strain 
and the prebiotic was rarely observed in human and animal trials (22–24).  These 
observations suggest that the probiotic strains were unable to utilize the selected prebiotic 
to expand their populations under the prevailing ecological conditions in the 
gastrointestinal tract.  We therefore propose that synergistic synbiotics are likely to be more 
successful if selection of the probiotic organism is based on ecological criteria. 
In this report, we introduce the concept of in vivo selection (IVS) to identify 
putative probiotic strains with enhanced ecological performance when used in synbiotic 
applications.  The concept consists of isolating putative probiotic strains from fecal or 
intestinal samples after enriching for them with dietary administration of the prebiotic.  We 
reasoned that such strains would likely be able to successfully utilize the prebiotic in vivo 
within the constraints of the competitive gastrointestinal environment.  To test IVS, we 
isolated bifidobacteria from fecal samples of human individuals who had consumed the 
prebiotic galactooligosaccharide (GOS) during a previous human trial (25).  A combination 
of approaches was used to select a candidate probiotic strain (Bifidobacterium adolescentis 
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strain IVS-1) enriched by GOS in vivo.  We then tested the synergistic potential of this 
strain and GOS when administered as a synbiotic combination in a rat model of high- fat-
diet-induced nonalcoholic fatty liver disease (NAFLD).  A NAFLD model without severe 
inflammatory disease was chosen, as inflammation would potentially confound the 
ecological analysis due to its effects on gut microbiota composition.  Although no direct 
physiological benefits were observed in the rats, the results from the gut microbiota 
analysis demonstrated that IVS can be used to select a synergistic synbiotic combination 
that substantially increases the ecological performance of the bacterial strain in vivo. 
 
3.3 Materials and methods 
3.3.1 Isolation of in vivo-enriched bifidobacteria from humans.  
In a previous study (25), fecal samples were collected from subjects who consumed 
cumulative doses of GOS (0, 2.5, 5, and 10 g per day for 3 weeks each). Throughout the 
study, fresh fecal samples were collected and immediately plated onto Rogosa LS agar to 
enumerate bifidobacteria.  Bacterial counts were used to identify GOS responders (i.e., 
individuals who experienced significant increases in numbers of bifidobacteria), and 
colonies were picked during the period in which 10 g GOS day-1 was consumed.  Colonies 
were purified by successive liquid and plate cultures, and stock cultures were prepared and 
stored at -80°C.  A total of 28 individual colonies (2 to 3 per subject) were propagated.  To 
classify isolates, DNA was extracted by using the phenol-chloroform extraction method 
(26), and the 16S rRNA gene was amplified by using the 8F and 1391R universal primers.  
The amplification product was purified (QIAquick PCR purification kit; Qiagen Inc., MD) 
and sequenced by a commercial provider (Eurofins MWG Operon, Huntsville, AL).  
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Identity was determined by comparing sequences to sequences in the GenBank database; 
species were assigned based on the best match. 
 
3.3.2 In vitro growth on GOS.  
Each isolate was screened for its ability to use GOS as a growth substrate in an 
MRS broth culture.  Growth experiments were performed with basal MRS broth containing 
2% (wt/vol) glucose or GOS (Purimune; GTCNutrition, Golden, CO).  The latter contained 
92% GOS, with residual carbohydrates being mainly lactose.  Control cultures were 
therefore also grown on basal MRS broth supplemented with the same amount of lactose 
as that present in the commercial GOS (giving a final concentration of 0.16% lactose).  
Cultures were incubated anaerobically at 37°C, and growth was determined by optical 
density measurement at 600 nm.  Strains that grew on GOS to cell densities similar to those 
on glucose were considered GOS fermenters.  
 
3.3.3 Strain-specific primer design and validation.  
The genome of B. adolescentis IVS-1 was sequenced to draft status by using a 
standard shotgun library prep kit on a Roche GS FLX sequencer at the former Core for 
Applied Genomics and Ecology (CAGE) (University of Nebraska, Lincoln, NE).  
Sequencing resulted in 65,460 reads that were assembled de novo by using the gsAssembler 
(Newbler) module of the GS-FLX Off- Instrument software suite.  This resulted in draft 
sequences of 148 contigs with ~15-fold coverage.  
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Unique genes in B. adolescentis IVS-1 were identified by comparing the annotated 
genome with other available B. adolescentis genomes in the JGI database (using the 
Phylogenetic Profiler for Single Genes tool in IMG).  From this analysis, the clustered 
regularly interspaced short palindromic repeat (CRISPR)-associated helicase Cas3 was 
selected as the target gene, and a putative primer pair was designed by using Primer 3 
software (27).  Candidate primers were evaluated for hairpin and dimer formation by using 
Netprimer (Premier Biosoft International, Palo Alto, CA).  The selected forward (F) primer 
TTGCTTTTGCTCTGGAACATAC and reverse (R) primer 
GTAATGAGGTAATACTGCGTCC were validated in silico by performing a BLAST 
search against the NCBI database.  These primers were also validated experimentally by 
quantitative real-time PCR (qRT- PCR) using DNA from 10 different Bifidobacterium 
strains related to strain IVS-1 (each having >96% identity at the 16S rRNA gene level).  
These strains included Bifidobacterium adolescentis ATCC 15703, Bifidobacterium 
adolescentis L2-32, Bifidobacterium longum subsp. longum ATCC 15707, 
Bifidobacterium longum DJO10A, Bifidobacterium longum ATCC 15697, 
Bifidobacterium longum subsp. longum F8, Bifidobacterium longum subsp. longum 
JDM301, Bifidobacterium sp. strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and 
Bifidobacterium sp. strain HMLN14.  Furthermore, to test if primers could select against 
fecal bacterial communities in both humans and rats, DNA from 23 human fecal samples 
and 10 Sprague-Dawley rat fecal samples from an independent study were tested.  Human 
fecal materials analyzed included the baseline samples (i.e., before GOS supplementation) 
from 18 subjects from a previous study by Davis et al. (25) as well as five other human 
fecal samples from an independent study. 
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3.3.4 Quantitative real-time PCR.  
qRT-PCR was performed by using a Mastercycler Realplex2 instrument 
(Eppendorf AG, Hamburg, Germany).  Each PCR was performed with 25-μl volumes using 
real-time master mix containing SYBR(5 Prime Inc., Gaithersburg, MD) and either genus-
specific primers for Bifidobacterium, F primer TCGCGTC(C/T)G GTGTGAAAG and R 
primer CACATCCAGC(A/G)TCCAC (25, 26), or the strain-specific primers for B. 
adolescentis IVS-1 (described above), each at a concentration of 0.8 μM.  Annealing 
temperatures of 58°C and 61°C were used for the genus- and strain-specific PCRs, 
respectively.  Standard curves for absolute quantification of bacterial cell numbers were 
prepared by using cultures of B. adolescentis IVS-1 grown overnight (14 h), as described 
previously (25, 26). 
 
3.3.5 Administration of the probiotic, prebiotic, and synbiotic to rats.  
A freeze-dried powder of Bifidobacterium adolescentis IVS-1 was produced by a 
contract manufacturer (Culture Systems, Mishawaka, IN).  The powder contained 5 x 1010 
CFU g-1 and was stable during the entire course of the study.  For delivery to the rats, the 
powder was suspended in drinking water (double-distilled water) to reach a concentration 
of 3 x 107 cells ml-1.  GOS was diluted in water at a concentration of 0.033 g ml-1, and the 
synbiotic was prepared by mixing both IVS-1 and GOS in the abovementioned 
concentrations.  All preparations were prepared fresh daily in drinking water for the 
duration of the experiment.  Cell viability and stability were validated by plating samples 
on MRS medium at different time points.  This analysis revealed that IVS-1 was highly 
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stable in drinking water, with levels dropping <1 log over 24 h.  The addition of GOS did 
not influence the viability of the probiotic in drinking water (data not shown). 
 
3.3.6 Rat study design. 
Synergism of the synbiotic preparation was tested in a rat model of NAFLD (28).  
Four-week-old male Sprague-Dawley rats were obtained from Charles River Laboratories 
(Wilmington, MA) and acclimated for five days prior to study initiation.  All animals were 
housed in pairs in individually vented cages mounted on a rack with positive airflow.  The 
room environment was maintained at 20°C to 21°C with a 12-h light-dark cycle.  Prior to 
the start of the study, all rats received a standard rat chow and autoclaved, double-distilled 
water ad libitum during the five day acclimation period.  All animal procedures were 
approved by University of Nebraska—Lincoln IACUC.  
Rats were randomly assigned to one of five treatments, with three to six rats per 
group.  Groups one through four were fed a high-fat diet (60%kcal from fat) (AIN-58G9 
TestDiet) (see Table 3.S1 in the supplemental material), while group five received a 
standard diet (12% fat) (AIN-58G7 TestDiet) for eight weeks.  After four weeks of feeding, 
groups were assigned to one of the following supplement treatments.  Rats in groups one 
and five received no additional treatment.  Group two rats received drinking water 
supplemented with 3.3% GOS to give ~1 g of GOS day-1 rat-1.  Group three rats were given 
drinking water supplemented with ~1 x 109 CFU of B. adolescentis IVS-1 day-1 rat-1.  
Group four rats received both the GOS and IVS-1 (synbiotic mixture), at the same doses 
as those given to groups two and three.  All treatments were prepared fresh daily and 
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administered for four weeks.  The daily water intake per rat was significantly different 
among groups and was used to calculate the absolute doses of probiotic cells per day (P = 
0.001) (see Table 3.S2 in the supplemental material).  Rats fed the probiotic drank 
significantly more water (41.9 ± 8.6 ml) than did rats fed the synbiotic (35.4 x 4.5 ml), 
resulting in a significantly higher dose of IVS-1 in the probiotic group (1.26 x 109 CFU 
versus 1.06 x 109 CFU; P = 0.0001).  GOS consumption was not significantly different 
between the prebiotic- and synbiotic-fed groups (P = 0.2063) (see Table 3.S2 in the 
supplemental material).   
Body weights were determined weekly throughout the study.  All rats were 
necropsied after eight weeks of study.  Blood, cecum, colon content, liver, and epididymal 
fat pads were collected, and the cecum and colon content were immediately frozen in liquid 
nitrogen and stored at -80°C until further use. 
 
3.3.7 Evaluation of host physiological parameters in rats.  
Liver lipid extraction was performed according to methods described previously by 
Folch and colleagues (29).  Aliquots of lipid extract were saponified to quantify 
triglycerides (TGs) by using the TG diagnostic kit (Thermo dimethyl adipimidate kit; 
Thermo Electron Clinical Chemistry, Louisville, CO). Data are reported as μg TGmg-1 (wet 
weight) liver tissue.  To evaluate liver damage, plasma alanine aminotransferase (ALT) 
and alkaline phosphatase (ALP) enzyme levels were measured, which are indicators of 
hepatocyte damage/leakage and cholangiocyte stress, respectively (30, 31).  Blood was 
collected into heparinized tubes at necropsy, and ALT and ALP levels were quantified by 
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using a Mammalian Liver Profile rotor in a VetScan VS2 analyzer (Abaxis, Union City, 
CA).  Levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein 
1 (MCP-1) were quantified as measures of systemic inflammation by using a Milliplex rat 
magnetic bead multiplex assay (Merck Millipore, Billerica, MA) according to the 
manufacturer’s protocol.  
 
3.3.8 Illumina 16S RNA sequencing and sequence analysis.  
Colonic and cecal contents were flash-frozen in liquid nitrogen at necropsy, and 
DNA was extracted as described previously (26), with one modification: the lysis buffer 
contained 20mM Tris-HCl (pH 8), 2mM EDTA, 1.2% Triton X-100 (pH 8.0), and 20 mg 
ml-1 Lysozyme (MP Biomedicals, Solon, OH).  Amplicon sequencing of colonic contents 
was performed by the University of Minnesota Genomics Center, and all samples were 
sequenced together in the same run.  First, theV5-V6region of the 16SrRNA gene was 
amplified with primer pair 784F (5’-RGGATTAGATACCC-3’) and 1064R (5’-
CGACRRCCATGCANCACCT-3’) in a 25μl PCR mixture containing 5 μl of template 
DNA, 5μl of 2x HotStarTaqPCRmaster mix, a final concentration of primers of 500 nM, 
and 0.025 U μl-1 HotStarTaq polymerase (Qiagen Inc.).  Amplification reactions included 
an initial denaturation step at 95°C for 5 min followed by 20 to 25 cycles of denaturation 
(50 s at 94°C), annealing (30 s at 40°C), and elongation (30 s at 72°C).  Next, samples were 
diluted 1:100 in water for input into library tailing PCR.  The PCR was analogous to the 
one conducted for initial amplification except for a Taq polymerase concentration of 0.25 
U μl-1, and the PCR conditions consisted of an initial denaturation step at 95°C for 5 min 
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followed by 10 to 15 cycles of denaturation (50 s at 94°C), annealing (30 s at 40°C), and 
elongation (1 min at 72°C). 
PCR products were quantified by using the Quant-iT PicoGreen double-stranded 
DNA (dsDNA) assay kit (Life Technologies).  A subset of the amplicon libraries was spot 
checked on a Bioanalyzer High-Sensitivity DNA chip (Agilent Technologies, Santa Clara, 
CA) for correct amplicon size.  Next, samples were normalized to 2 nM and pooled.  The 
total volume of the libraries was reduced by the use of a SpeedVac, and amplicons were 
size selected at 420 bp ± 20% by using the Caliper XT system (PerkinElmer, Waltham, 
MA).  Afterwards, library pools were cleaned with 1.8 x AMPureXP beads (Beckman 
Coulter, Brea, CA) and eluted in water.  The amount of DNA in the final pool was 
quantified with PicoGreen and normalized to 2 nM for input into the Illumina MiSeq 
platform (v3 kit) to produce 300-bp paired-end sequencing products.  Clustering was done 
at 10 pM with a 5% spike of PhiX.  The generated sequences were quality filtered with 
Illumina software at the University of Minnesota Genomics Center.  Twenty-two of 24 
samples met all quality control criteria and were used for the microbial community 
analysis. 
 
3.3.9 Microbial community analysis.  
Reads were trimmed to 240 bp with the FASTX-Toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/), and paired- end reads were merged with the 
merge-illumina-pairs application (https: //github.com/meren/illumina-utils/) (P value of 
0.03, enforced Q30 check, perfect matching to primers, and no ambiguous nucleotides al- 
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lowed).  Files exceeding 30,000 reads were subsampled to this number in Mothur 
v.1.31.162 to standardize the sequencing depth across samples.  Subsequently, USEARCH 
v7.0.100163 was used to generate operational taxonomic units (OTUs) with a 98% 
similarity cutoff. OTU generation included the removal of putative chimeras identified 
against the Gold reference database, in addition to the chimera removal inherent to the 
OTU clustering step in UPARSE.  After quality control and chimera removal, samples 
contained an average of 25,718 ± 941 sequences.  The resulting sequences were also 
taxonomically characterized from phylum to genus levels with Ribosomal Database Project 
(RDP) Classifier with the MultiClassifier v1.1 tool.  All phylotypes were computed as 
percent proportions based on the total number of sequences in each sample. 
 
3.3.10 Statistical analysis.  
Results are expressed as means ± standard deviations (SD) unless otherwise stated. 
To analyze bacterial composition, diversity differences, and host physiological parameters, 
one-way analyses of variance (ANOVA) with repeated measures in combination with 
Tukey’s post hoc tests were applied.  To achieve normality for data that were not normally 
distributed, values were subjected to log10 transformations.  If only two groups were 
compared, Student’s t tests were performed.  Spearman’s correlations were used to assess 
correlations between bacterial groups.  To account for type I errors, the false discovery rate 
was used. A P value of < 0.05 and correlation coefficient (r) values of > 0.60 (in absolute 
values) were considered significant.  Analyses of variance and false discovery rate control 
were performed by using SAS/STAT (SAS Institute Inc., Cary, NC, USA), while 
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correlations were determined by using GraphPad Prism version 5.0 (GraphPad Software, 
La Jolla, CA, USA).  
 
3.3.11 Nucleotide sequence accession number.  
The genome sequence of B. adolescentis IVS-1 has been deposited in the 
DDBJ/EMBL/GenBank data- base under accession number JRNZ01000000. 
 
3.4 Results 
3.4.1 In vivo selection of B. adolescentis IVS-1.  
In a previous study (25, 32), we reported a significant and remarkably specific 
enrichment of Bifidobacterium populations in human subjects during dietary 
supplementation with GOS (as demonstrated by 454 sequencing, genus-specific qRT-PCR, 
and quantitative culture), which is in agreement with data from other GOS feeding studies 
(33–38).  Cultural enumeration of fecal samples during the human trial allowed us to 
identify individuals in which bifidobacteria were enriched by GOS and from whom strains 
likely to utilize GOS in vivo could be selected.  This novel strategy for selection and 
recovery of autochthonous strains enriched by a prebiotic is referred to as in vivo selection 
(IVS) (Fig. 3.1A).  Using the IVS approach, a total of 28 presumptive bifidobacterial 
colonies from 11 subjects were isolated and classified by sequencing of the 16S rRNA 
genes.  Eight isolates were classified as Bifidobacterium adolescentis, eight were classified 
as Bifidobacterium longum, three were classified as Bifidobacterium pseudocatenulatum, 
and one was classified as Bifidobacterium bifidum.  Of the remaining isolates, four 
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belonged to the Coriobacterium genus, one could be classified only to the family level 
(Lachnospiraceae), and three could not be sequenced due to insufficient growth.  All 
strains resulting in pure cultures were also screened for their ability to ferment GOS during 
in vitro growth, and 13 were classified as GOS fermenters, 12 were classified as non-
fermenters, and three could not be propagated to be tested (data not shown).  Out of the 13 
strains able to ferment GOS, five were classified as B. longum, five were classified as B. 
adolescentis, one was classified as B. bifidum, one was classified as B. pseudocatenulatum, 
and another one was classified as Lachnospiraceae.  None of the isolated Coriobacterium 
strains were classified as fermenters. 
Based on the culture data, 454 sequencing (32), and the GOS fermentation tests, we 
selected one strain and designated it IVS-1.  This strain originated from a subject who 
showed a strong bifidogenic response to GOS (Fig. 3.1B).  Based on 16S rRNA 
sequencing, IVS-1 had 98.4% identity (100% query coverage and an E value of zero) with 
the 16S rRNA gene of B. adolescentis ATCC15703T and was therefore allotted to this 
species.  However, the strain belongs to a distinct phylogenetic cluster (Bifidobacterium 
species II cluster) detectable by using the V1-V3 region of the 16S rRNA gene (32).  This 
cluster was significantly enriched by GOS in all subjects, including the individual from 
whom IVS-1 was isolated (Fig. 3.1C).  The ability of B. adolescentis IVS-1 to utilize GOS 
was demonstrated by growth in MRS broth containing 2% GOS (see Fig. 3.S1 in the 
supplemental material).  The established metabolic benefits of the species B. adolescentis 
serve as another rationale for the selection of IVS-1 for future applications (39, 40).  
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Fig. 3.1. In vivo selection to identify putative probiotic strains to be used in synbiotic 
applications.  A. Concept of in vivo selection.  B. Proportion of fecal bifidobacteria in a 
human individual consuming GOS (included in chews) in four increasing doses (0, 2.5, 5, 
and 10 g) during a human feeding trial (25), as determined by 454 pyrosequencing of 16S 
rRNA tags.  C. Proportion of Bifidobacterium lineage species II in the same individual, as 
determined by pyrosequencing.  D. Cell numbers of B. adolescentis IVS-1 in the same 
individual, as quantified by strain-specific qRT-PCR. 
 
To verify that B. adolescentis strain IVS-1 was specifically enriched by GOS in 
vivo, we devised a strain-specific qRT-PCR approach with primers based on the genome 
sequence of IVS-1.  Primer specificity was validated against ten closely related 
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Bifidobacterium strains, fecal DNA from all subjects included in the human feeding trial 
(25) and five additional human individuals, and ten fecal samples from Sprague-Dawley 
rats from an independent experiment.  A detectable PCR product was obtained only with 
DNA from B. adolescentis IVS-1 and the fecal sample from which the strain was isolated.  
This finding indicated that the primers were highly strain specific and that strain IVS-1 was 
present only in the human subject from whom it was isolated.  
The strain-specific qRT-PCR system was then used to quantify the abundance of 
IVS-1 in fecal samples from this subject during the GOS feeding study.  This analysis 
revealed that IVS-1 levels were increased 8-fold during both the 5-g and 10-g GOS dose 
periods compared to the 0-g period (P < 0.001) (Fig. 3.1D), before returning to baseline 
levels immediately after GOS consumption ended.  Collectively, these results 
demonstrated the utility of IVS to select a bacterial strain enriched in the human 
gastrointestinal tract through dietary administration of a prebiotic. 
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Fig. 3.2. Test of a synbiotic combination of B. adolescentis IVS-1 and GOS in a high-fat-
diet rat model.  A. Experimental design of the rat study. Rats were fed either a standard 
diet or a high-fat diet for 8 weeks, supplemented with or without a probiotic (IVS-1), a 
prebiotic (GOS), or a synbiotic (IVS-1 plus GOS) for the last 4 weeks.  B. Quantification 
of absolute cell numbers of bifidobacteria in colonic and cecal contents by genus-specific 
qRT-PCR.  C. Strain-specific qRT-PCR was used to quantify absolute numbers of B. 
adolescentis IVS-1 in colonic and cecal contents. 
 
3.4.2 Test of the synbiotic combination using rats on a high-fat diet. 
We systematically tested synergism between strain IVS-1 and GOS when used as 
a synbiotic in rats fed a high-fat diet (Fig. 3.2A).  Decreases in numbers of bifidobacteria 
are often observed during high-fat-diet feeding (41–43).  To determine if our synbiotic 
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strategy could redress this decrease, we employed a rat model of high-fat-diet-induced 
NAFLD where rats develop steatosis (fatty liver) but do not show an increase in body 
weight, develop liver inflammation, or progress to nonalcoholic steatohepatitis (NASH) 
(28).  In our study, all high-fat-diet-fed rats developed steatosis (i.e., liver triglyceride 
levels of > 50 μg mg-1 of tissue) and had slightly increased plasma ALP levels compared 
to rats fed a standard diet (see Table 3.S2 in the supplemental material).  Dietary 
supplements significantly influenced triglyceride liver contents; however, high-fat-diet-fed 
rats did not develop the histopathological liver inflammation characteristic of NASH (data 
not shown) and did not have increased plasma ALT levels (see Table 3.S2 in the 
supplemental material). Plasma tumor necrosis factor alpha (TNF-α) and monocyte 
chemoattractant protein 1 (MCP-1) levels were not significantly elevated in the high-fat-
fed rats compared to the controls (see Table 3.S2 in the supplemental material), indicating 
a lack of systemic inflammation.  Together, these data indicated that all rats receiving a 
high-fat diet developed NAFLD but not severe inflammatory disease that would confound 
the evaluation of synbiotic synergy and gut microbial ecology. 
 
3.4.3 Experiments in rats demonstrate strong synergism between IVS-1 and GOS.  
To test the functionality of the prebiotic to support the establishment of B. 
adolescentis IVS-1 in the rat intestine, rats fed a high-fat diet were administered either IVS-
1 alone, GOS alone, or the synbiotic combination;  all findings were compared to results 
for the high-fat controls (Fig. 3.2A).  Consistent with data from previous studies (41, 42), 
high-fat feeding decreased the abundance of bifidobacteria in both the colon and cecum of 
the rats, although this reduction did not reach statistical significance (Fig. 3.2B and Table 
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3.1).  Genus-specific qRT-PCR analysis revealed that the prebiotic, but not IVS-1, 
significantly increased the total number of bifidobacteria in the cecum (Fig. 3.2B).  These 
findings indicate that the introduction of IVS-1 alone did not increase Bifidobacterium 
abundance above baseline levels (~108 cells/g), whereas the prebiotic substrate was able to 
support the resident population.  Compared to IVS-1 and GOS alone, the combination of 
the two dramatically increased the total number of bifidobacteria in the cecum (P < 0.01 
between synbiotic and prebiotic treatments; P < 0.001 between synbiotic and probiotic 
treatments) (Fig. 3.2B).  
Strain-specific qRT-PCR analysis of B. adolescentis IVS-1 clearly demonstrated a 
synergistic effect of IVS-1 and GOS in the colon and in the cecum.  Even though rats 
receiving IVS-1 alone consumed significantly more IVS-1 on a daily basis than did rats 
given the synbiotic due to increased drinking water consumption (P < 0.0001) (see Table 
3.S2 in the supplemental material), the synbiotic led to an almost 2-log increase in the level 
of IVS-1 in the colon and cecum (9.47 ± 0.2 log10 cells g-1 and 9.43 ± 0.2 log10 cells g-1, 
respectively) compared with the probiotic treatment (7.9 ± 0.1 and 7.44 ± 0.3 log10 cells g-
1 in the cecum and colon, respectively) (P < 0.0001) (Fig. 3.2C).  No IVS-1 was detected 
in rats fed the standard diet, the high-fat diet, or the prebiotic alone.  
 
3.4.4. 16S rRNA sequencing confirms synergism between IVS-1 and GOS in vivo. 
We analyzed the 16S rRNA tags obtained via Illumina sequencing to gain a 
community-wide perspective on treatment effects on the resident gut microbiota.  The 
ability of probiotic and synbiotic treatments to establish IVS-1 in rats was assessed based 
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on the abundance of an operational taxonomic unit (OTU) representing the species B. 
adolescentis (OTU_2).  This species was undetectable in rats that did not receive the 
probiotic treatment but constituted 3.4% of the microbiota in rats fed IVS-1 (Fig. 3.3A and 
Table 3.1).  This finding indicates that the B. adolescentis population observed in rats was 
due solely to the administration of IVS-1.  This finding was expected, as this species is not 
a member of the normal rat microbiota.  Sequences representing B. adolescentis were 
enriched to 37.0% in rats receiving the synbiotic treatment, indicating a significant 
enhancement of the probiotic (in terms of abundance) due to the addition of the prebiotic 
(P = 0.0159).  Without GOS, IVS-1 was only the eighth most abundant OTU in the rats’ 
colonic microbiota, while it became the most abundant OTU when given together with 
GOS, having an abundance almost four times higher than that of the second most abundant 
OTU (a Blautia species, at 9.7%) (Fig. 3.3A).  This finding demonstrated that IVS-1 could 
be introduced as the dominant member of the rat gut microbiota when GOS was also 
provided. 
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Table 3.1: Proportions of bacterial taxa significantly influenced by dietary treatments 
 Mean % bacterial abundance ± SDc 
Taxonomic group Standard 
diet 
Control 
High-Fat 
Diet (HF) 
Prebiotic 
(HF) 
Probiotic 
(HF) 
Synbiotic 
(HF) 
ANOVA 
P- value 
Phylum        
Firmicutes 87.6±5 A 88.8±9 A 76.9±8 A 87.8±5 A 59.3±7 B <0.0001 
Actinobacteria 8.9±6 AB 3.6±2 A 19.6±8 BC 7.6±4 A 39.1±7 C <0.0001 
       
Family        
Clostridiaceae 3.9±6 0.5±1 0.8±1 5.4±6 A 0.2±0 B 0.0061 
Incertae Sedis XIV 3.7±6 7.5±10 11.0±15 1.1±2 A 17.3±12 B 0.0342 
Streptococcaceae 12.7±5 21.3±5 A 9.3±1 8.9±6 B 6.6±2 B 0.0045 
Erysipelotrichaceae 16.8±11 21.3±17 9.2±1 A 26.5±10 B 8.3±3 A 0.0226 
Bifidobacteriaceae 5.9±7 A 1.3±1 A 17.0±9 4.1±2 A 37.8±7 B 0.0017 
Coriobacteriaceae 0.6±0 0.3±0 1.0±1 1.9±3 A 0.2±0 B 0.0263 
Rikenellaceae 0.9±1 A 0.1±0 0.3±0 0.1±0 0.0±0 B 0.0181 
       
Genus        
Clostridium 3.9±6 0.5±1 A 0.8±1 5.3±6 B 0.2±0 A 0.0122 
Blautia 3.4±6 7.4±10 11.0±15 0.9±1 A 17.2±12 B 0.0431 
Holdemania 0.1±0 1.0±2 A 0.9±0 0.0±0 B 0.0±0 B 0.0117 
Bifidobacterium 5.9±7 A 1.3±1 A 17.0±9 4.1±2 A 37.8±7 B 0.0017 
Lactococcus 12.4±4 21.0±5 A 9.1±1 8.7±6 B 6.3±2 B 0.0045 
Alistipes 0.9±1 A 0.1±0 0.3±0 0.1±0 0.0±0 B 0.0181 
       
OTUs a       
OTU_2 (B. adolescentis, 
99%) 
0.0±0 A 0.0±0 A 0.0±0 A 3.4±2 BC 37.0±7 BD <0.0001 
OTU_1 (L. lactis, 100%) 12.4±4 21.0±5 A 9.1±1 8.6±6 B 6.3±2 B 0.0045 
OTU_626 
(Lachnospiraceaeb) 
0.4±1 A 0.1±0 A 0.0±0 B ND  0.1±0 0.0002 
OTU_7 (Turicibacter 
sanguinis, 97%) 
3.7±3 2.3±3 2.3±2 9.1±7 A 0.5±1 B 0.0279 
OTU_14 (Blautiab) 0.0±0 A 0.1±0 AB 1.5±1 BC 0.0±0 AB 9.7±6 CF 0.0003 
OTU_33 (L. intestinalis, 
99%) 
ND 0.0±0 A ND 1.1±2 B 0.0±0 A 0.0022 
OTU_9 (Clostridium sp.b) 3.8±6 0.5±1 A 0.7±1 5.3±6 B 0.2±0 A 0.0128 
OTU_6 (B. pseudolongum, 
97%) 
5.8±7 0.9±1 16.6±8 A 0.6±1 0.0±0 B 0.0293 
OTU_44 (C. cocleatum, 
99%) 
ND 1.0±1 A ND 0.0±0 B ND 0.0121 
a Percent homologies to the closest type strain in the database are shown in parentheses. If the strain could 
not be assigned to a type strain (<97% homology), RDP Classifier was used to determine the most likely 
genus, and the RDP Classifier value is shown (80% cutoff).  
b OTU without closely related type strain (<97% homology) classified with RDP Classifier. c Values with 
different uppercase letters are significantly different from each other. HF, high fat; ND, not detected. 
 
132 
3.4.5 Community-wide characterization of effects on gut microbiota.  
GOS treatment alone promoted a remarkably specific bifidogenic response, leading 
to an increase in the abundance of only one OTU related to Bifidobacterium pseudolongum 
(OTU_6) (Table 3.1 and Fig. 3.3A).  These findings confirm the highly specific bifidogenic 
response of GOS, which was previously demonstrated in humans (32).  
Although IVS-1 treatment alone did not significantly increase the abundance of the 
genus Bifidobacterium, it induced a significant increase in the abundance of 
Bifidobacterium adolescentis at the species level (Table 3.1).  Of note, several unexpected 
changes were also detected, such as enrichment of the family Clostridiaceae, the genus 
Clostridium, and an OTU within this genus (OTU_9).  Furthermore, the abundance of an 
OTU related to Lactobacillus intestinalis (OTU_33) increased, while that of an OTU 
related to Lactococcus lactis (OTU_1) decreased (Table 3.1). 
Synbiotic treatment significantly increased the proportion of Actinobacteria (P < 
0.0001), the family Bifidobacteriaceae (P < 0.0017), and the genus Bifidobacterium (P < 
0.0017) (Table 3.1).  These shifts were almost completely equivalent to shifts of OTU_2, 
showing that the above-described alterations at higher taxonomic levels were due to the 
enrichment of IVS-1.  The establishment of IVS-1 was associated with an increase in the 
abundances of the genus Blautia and one OTU within this genus (OTU_14).  In addition, 
there was a reduction in the abundances of the phylum Firmicutes (P < 0.0001) and families 
within this phylum, including Clostridiaceae, Streptococcaceae, and Erysipelotrichaceae.  
The abundances of the genera Clostridium and Lactococcus and OTUs within these genera 
were also decreased (Table 3.1).  
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Fig. 3.3. Characterization of the rat colonic microbiota composition by Illumina 
sequencing of 16S rRNA tags.  A. Analysis of colonic microbiota at the OTU level. OTUs 
representing at least 1% of total sequences are shown individually, while OTUs 
representing <1% are grouped. OTUs in colors other than light blue were significantly 
influenced by the dietary treatment.  B. Principal coordinate analysis (Bray-Curtis distance) 
of beta diversity.  C. NMDS plot of beta diversity based on Bray-Curtis distance. SD, 
standard diet. 
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To assess both the alpha and beta diversities of the community in the colon, 
different diversity indexes were calculated from the data.  Specifically, Shannon’s index 
and the number of observed OTUs were used to determine the alpha diversity, and principal 
coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) plots based 
on Bray-Curtis distance were used to visualize the similarity between samples for each 
treatment. 
On average, 135.41 ± 34.4 OTUs per sample were identified.  Alpha diversity based 
on Shannon’s index was not significantly influenced by the treatment;  however, there was 
a tendency for reduced diversity in the synbiotic group. This was caused by a slight 
reduction in community evenness, likely due to the expansion of a single species (B. 
adolescentis) (data not shown).  Two independent approaches were used to analyze the 
beta diversity of the microbiota communities among treatments.  PCoA and NMDS, based 
on Bray-Curtis distances of beta diversity, revealed that communities from rats fed the 
synbiotic clustered separately from the microbiomes of rats fed all the other treatments, 
which clustered together (Fig. 3.3B and C).  This finding demonstrated that only the 
synbiotic treatment caused a global shift in microbiota structure. 
 
3.4.6 Systematic analyses of associations between members of the gut microbiota.  
To identify potential interactions between IVS-1 and members of the gut 
microbiota, and among other bacterial members, we performed correlation analyses on all 
taxon combinations in the data set.  Correlations were performed by using bacterial 
abundance data from all treatments.  Strong negative correlations between the family 
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Bifidobacteriaceae and the family Clostridiaceae (Fig. 3.4A), the genera Bifidobacterium 
and Lactococcus (Fig. 3.4B), and the genera Bifidobacterium and Akkermansia (Fig. 3.4C) 
were observed.  In addition, strain IVS-1 levels (OTU_2) showed a negative correlation 
with Lactococcus lactis (Fig.3.4D) and a very tight negative association with resident B. 
pseudolongum (r = -0.64; P = 0.0004) (Fig. 3.4E).  These negative associations suggest 
direct or indirect competition between these bacterial taxa.  Positive associations between 
both Bifidobacteriaceae and Bifidobacterium and the genus Blautia were detected, 
suggesting a synergistic relationship, which may be supported by the addition of GOS 
(Table 3.1 and Fig. 3.4F). 
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Fig. 3.4. Correlation analysis of colonic taxa present in rats fed a high-fat diet 
supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic (IVS-
1 plus GOS) or a standard diet.  Bacterial quantities are expressed as percent abundances 
of total bacteria as determined by 16S rRNA sequencing.  Spearman’s correlations between 
Bifidobacteriaceae and Clostridiaceae (A), Bifidobacterium and Lactococcus (B), 
Bifidobacterium and Akkermansia (C), Bifidobacterium adolescentis IVS-1 and 
Lactococcus lactis (D), Bifidobacterium adolescentis IVS-1 and Bifidobacterium 
pseudolongum (E), and Bifidobacterium and Blautia (F) were determined. 
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3.5 Discussion 
Synergistic synbiotics are a promising concept to modulate the composition of the 
gut microbiota and promote the establishment of probiotic organisms in the gut (16).  
Despite this potential, however, there are few in vivo human or animal studies providing 
evidence that prebiotics can be used to support specific probiotic strains.  Unfortunately, 
most synbiotic studies, including work in rats (44–49), mice (50–52), pigs (53–57), 
chickens (58, 59), and humans (60), did not employ strain-specific detection methods and 
therefore did not provide information on the potential synergism between pre- and 
probiotics.  Of the in vivo studies that did discriminate the probiotic strain, most still did 
not demonstrate that in vivo performance could be enhanced by a prebiotic.  This accounts 
for experiments using synbiotic formulations in humans (61), rats (62, 63), and other 
animal models (64).  These findings suggest that, with few exceptions (17–19), probiotic 
strains are unable to compete against the resident gut microbiota, which is inherently 
resistant to outside colonizers (65), even when an exogenous growth substrate in the form 
of a prebiotic is provided.  
Several reasons may explain the low success rates of synergistic synbiotics when 
evaluated in vivo, even for combinations in which the probiotic strain is able to utilize the 
prebiotic substrate in vitro.  First, to become established in the gut, the probiotic strain must 
be able to occupy an ecological niche.  This means that strains must not only outcompete 
the resident microbiota for the prebiotic substrate but also secure other nutrients that might 
be growth limiting (such as amino acids, lipids, vitamins, minerals, and nucleotides, etc.).  
In addition, probiotic strains must tolerate the prevailing environmental conditions in the 
digestive tract (including pH, bile acids, IgA, and defensins).  Ultimately, in vitro tests are 
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unable to predict the ability of a probiotic to benefit from a prebiotic substrate within the 
constraints of the competitive gastrointestinal environment.  In contrast, the IVS approach 
described here overcomes many limitations of in vitro tests used to formulate synbiotics 
because it provides a basis for identifying bacterial strains that are able to utilize the 
prebiotic substrate under the same ecological conditions in which they are intended to 
function.  
In this study, we employed IVS and selected a synbiotic combination that was 
tested in a rat model of NAFLD.  Although the synbiotic did not influence host phenotypes, 
it was highly efficient at enhancing population levels of the probiotic strain, making it the 
most dominant OTU in the gut (Fig. 3.3A and Table 3.1).  These findings provide a proof 
of concept for the potential of in vivo selection to identify synbiotic combinations that are, 
in ecological terms, highly synergistic.  In addition to enhancing the abundance of strain 
IVS-1, the synbiotic used here also redressed the high-fat-diet-induced reduction in the 
level of bifidobacteria detected in rats that is often reported in the literature (41–43).  
Therefore, although no metabolic benefits were seen in the rat model used in our study, the 
synbiotic may be beneficial in other scenarios, as bifidobacteria are considered health-
promoting organisms (6, 26, 66–68).  
The community-wide analysis provided evidence that synergism between GOS and 
strain IVS-1 increased the competitive fitness of the strain in the rat intestinal tract. B. 
pseudolongum, which is a natural member of the rat GI tract (69), was detected in relative 
abundances of 5.8 % and 0.9 % in rats fed the standard and high-fat diets, respectively.  
Although the probiotic treatment did not affect levels of B. pseudolongum, the prebiotic 
treatment increased the abundance of this species to 16.6 %, indicating that B. 
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pseudolongum utilized GOS in vivo.  However, the parallel addition of strain IVS-1 with 
GOS completely excluded B. pseudolongum, and a strong negative correlation between 
this species and IVS-1 was observed (r = -0.67; P = 0.0006) (Fig. 3.4E).  These findings 
indicate that IVS-1 not only had a higher affinity for GOS in vivo than the resident 
Bifidobacterium species but also utilized GOS to increase its competitiveness and 
effectively outcompete a closely related resident species.  This finding is consistent with 
the niche exclusion model, which states that the organism most efficient at using limited 
nutrients outcompetes its competitors for the same niche (70).  Strong inverse correlations 
between bifidobacteria and Clostridiaceae, Lactococcus, and Akkermansia (Fig. 3.4A to 
C) were also observed.  It is likely that these associations are also due to niche competition 
and are potentially enhanced by GOS administration.  Bifidobacteria produce short-chain 
fatty acids that are inhibitory to other bacteria either by lowering the pH or via direct 
antimicrobial effects (e.g., acetic acid) (71).  In summary, these findings demonstrate that 
the competitive fitness of strain IVS-1 was increased by GOS, which supports the 
conclusion that IVS can select synbiotic combinations with extremely high synergism.  To 
what degree the increased competitive interactions between IVS-1 and the resident 
microbiota impact host health is difficult to predict and likely context dependent, but they 
clearly should be considered in future studies. 
Correlation analyses revealed only one positive association among members of the 
rat microbiota, between the bifidobacteria (at the family and genus levels) and the genus 
Blautia.  The abundance of OTU_14, an uncultured Blautia strain, was also significantly 
increased by GOS and in the synbiotic treatment (Table 3.1).  The positive correlation 
between Bifidobacterium and Blautia (Fig. 3.4F) indicates a synergistic effect between the 
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two taxa.  The significant increase in the abundance of Blautia in the synbiotic treatments 
further suggests a syntrophic interaction between IVS-1 and Blautia, as GOS is consumed 
mainly by bifidobacteria (72), and the genus Blautia is not reported to utilize GOS.  In 
contrast, the genus Blautia contains bacteria that are hydrogenotrophic acetogens, which 
utilize H2 and CO2 as energy sources (73).  Although bifidobacteria do not produce these 
gases, cross-feeding between bifidobacteria and butyrate-producing colon bacteria can 
result in H2 and CO2 production (74), which might explain the positive correlations 
between Bifidobacterium and Blautia.  However, additional experiments are necessary to 
establish the mechanism by which GOS can enhance the populations of Blautia in the gut 
and the positive associations between this genus and IVS-1.  
In this study, we have shown how IVS can be used to formulate a highly synergistic 
synbiotic that can substantially enhance population levels and the competitiveness of a 
putative probiotic strain in the gastrointestinal tract and establish it as the dominant member 
of the gut microbiota in a conventional animal model.  To our knowledge, this has not yet 
been reported in the probiotic literature.  The process of IVS is broadly applicable and can 
easily be extended to other host species, body sites, prebiotic substrates (or dietary fibers), 
or target organisms.  For example, it may be possible to use IVS to enhance other putative 
health-promoting genera such as Akkermansia, which has been shown to respond to 
prebiotics in vivo (75).  While we selected B. adolescentis IVS-1 during a human trial that 
did not determine the physiological effect of GOS, IVS might be especially powerful when 
combined with a human clinical trial that determines the beneficial effect of a prebiotic on 
the host as the primary selection criterion.  Therefore, to develop synbiotics for specific 
health applications, the IVS concept should be extended to select bacterial strains that not 
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only responded to the prebiotic but whose expansion correlated with beneficial 
physiological effects for the host.  Such an approach would have the potential to identify 
health-promoting strains whose metabolic activity in vivo could be increased through a 
prebiotic.  This might also result in synbiotic applications with greater health effects than 
those of the prebiotic alone, especially in the subset of humans who do not respond to the 
prebiotic (14, 32).  A human study testing the synbiotic combination identified here (and 
comparing it with a synbiotic that includes a Bifidobacterium strain that can ferment GOS 
but was not selected by IVS) is currently in progress.  Clearly, the application of IVS is 
likely to enhance the ecological performance of probiotic strains or live biotherapeutics 
within the habitats in which they are thought to function, and the technology could be 
readily applied in the design of microbiota-modulating therapies. 
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3.6 Supplemental material  
Table 3.S1. Composition of standard and high-fat diets. 
Nutritional profile High-Fat Diet Standard Diet 
Protein [%] 24.2 17.6 
Fat [%] 34.7 5.2 
Fiber (max) [%] 5.5 3.9 
Carbohydrates [%] 27.8 68.3 
   
Energy (kcal/g) Kcal / % Kcal / % 
From Protein 0.969 / 18.6 0.705 / 18.3 
From Fat (ether extract) 3.122 / 59.9 0.464 / 12.1 
From Carbohydrates 1.113 / 21.4 2.733 / 71.0 
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Table 3.S2.  Body weight, relative epididymal fat pad weight, consumed drinking water, 
consumed IVS-1 and GOS, and host physiological markers.   
 Standard 
Diet 
High-Fat 
Diet 
High-Fat 
Diet 
Prebiotic 
High-Fat 
Diet 
Probiotic 
High-Fat 
Diet 
Synbiotic 
P - value 
ANOVA 
Average body 
weight [g rat-1] 
475 ±19 449 ±46 499 ±81 496 ±62 502 ±51 0.5446 
Average relative 
epididymal fat pad 
weight [% rat-1] 
0.84 ±0.2 1.04 
±0.4 
1.12 ±0.3 1.01 ±0.2 1.08 ±0.5 0.8267 
Average water 
consumption [ml 
rat-1 day-1] 
29.3 ±4.1b 35.6 
±4.5a 
36.3 ±4.9a 41.9 ±8.6c 35.4 ±4.5a <0.0001 
Average IVS-1 
consumption [CFU 
rat-1 day-1] 
NA NA NA 1.26 x 109 a 1.06 x 109 b 0.0001# 
Average GOS 
consumption [g rat-1 
day-1] 
NA NA 1.20 NA 1.17 0.2063# 
Triglyceride content 
[µg TG mg-1 tissue] 
* 
17.8 ±4.3a 70.7 
±1.4b 
62.7 ±1.2bc 53.5 ±0.8c 92.4 ±2.4d <0.0001 
Alkanine 
Phosphatase (ALP) 
[units liter-1] 
227 ±83 399 ±55 464 ±127 458 ±167 460 ±120 0.0646 
Alanine Transferase 
(ALT) [units liter-1] 
34 ±13 42 ±11 36 ±5 37±7 41 ±4 0.6418 
TNF-α [pg ml-1] 14.2 ±2.3 14.1 
±2.6 
16.2 ±3.2 16.7 ±7.9 13.8 ±1.4 0.4718 
MCP-1 [pg ml-1] 224 ±25 228 ±37 239 ±21 248 ±63 243 ±36 0.6345 
* as a threshold for steatosis was a liver triglyceride levels greater than 50 µg/mg of tissue 
NA: not applicable 
# Student’s t-test was applied 
Values with different letters are significantly different from each other 
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Figure 3.S1.  Growth of Bifidobacterium adolescentis IVS-1 in basal MRS supplemented 
with GOS, 0.16% lactose (residual sugar present in the commercial GOS), or basal MRS 
without carbohydrates.  
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Chapter 4 
 
Functional characterization of a rationally selected synbiotic application in obese 
adults. 
 
4.1 Abstract 
One strategy for enhancing the establishment of probiotic bacteria in the human 
intestinal tract is via the parallel administration of a prebiotic.  Such combinations are 
referred to as synbiotics.  We have developed a rationally formulated synbiotic 
combination based on in vivo selection (IVS).  This approach employed ecological criteria 
to select a highly synergistic synbiotic combination, specifically, Bifidobacterium 
adolescentis strain IVS-1 and galactooligosaccharides (GOS).  This synbiotic was 
previously shown to be synergistic in a rat model (1), and we have now tested the ability 
of this synbiotic to improve the abundance of bifidobacteria, and specifically of the 
probiotic strain, in obese human subjects.  The study was designed as a randomized, 
placebo controlled, parallel arm clinical trial.  When the rationally selected synbiotic was 
compared to a commercial synbiotic (Bifidobacterium lactis Bb12 and GOS), the 
synergistic synbiotic combination led to significantly higher levels of the probiotic strain 
in the gastrointestinal tract of the subjects than the control.  In conclusion, this study 
demonstrated that IVS can be used to successfully formulate a synbiotic that can enhance 
the establishment and competitiveness of a putative probiotic strain in the human 
gastrointestinal tract. 
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4.2 Introduction 
The contribution of the gut microbiome to human and animal health is now well 
established (2–4).  Indeed, there are substantial efforts aimed at designing dietary strategies 
that modify the composition of the gut microbiota with the goal of preventing disease and 
promoting health (5, 6).  In particular, probiotic bacteria and prebiotic fibers, as well as in 
a combined form as synbiotics, have been tested in clinical trials to treat a range of 
conditions, including IBS (7, 8), IBD (9–12), lactose intolerance (13, 14), and other 
gastrointestinal (GI) diseases and disorders (15–18). 
In addition to GI diseases, the development of several systemic conditions, 
including metabolic endotoxemia and metabolic syndrome, are also associated with a gut 
dysbiosis that could potentially be redressed through dietary modulations.  Evidence from 
human and animal studies suggests that a constant low grade inflammation of the GI lining 
may precede or initiate the development of metabolic disorders (19).  The origin of this 
inflammation may be caused by alterations in the composition of the gut microbiota, which 
is directly involved in controlling the host’s gut barrier function, and increases systemic 
exposure to pro-inflammatory free fatty acids (20, 21).  While the exact process of 
decreased barrier function and increased permeability due to the gut microbiota remains 
unclear, data from animal studies suggest that several mechanisms are included.  For 
example, changes in the abundance of certain members of the gut microbiota lead to 
changes in the production and availability of short chain fatty acids, which are absorbed by 
the gut epithelial cells.  Additionally, the gut microbiota affects the distribution of tight 
junction proteins, such as ZO-1 and Occludin, and influences the endocannabinoid system 
tone, leading to a higher expression of anandamide and cannabinoid receptor 1 (22, 23).  
These factors lead to increased intestinal permeability and subsequently to an increased 
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translocation of microbe-derived lipopolysaccharides (LPS) into the bloodstream.  This 
induces metabolic endotoxemia, which eventually leads to metabolic syndrome (22, 24, 
25). 
Several studies have established that Bifidobacterium spp. have beneficial effects 
in the pathology associated with impaired barrier function by reducing gut permeability 
and improving epithelial cell barrier function (6, 24, 26–29).  Specifically, Bifidobacterium 
adolescentis administration to rats ameliorated insulin sensitivity, white fat accumulation, 
and liver weight (30), and significantly lowered rates of bacterial translocation (27).  This 
species was also shown to attenuate the formation of reactive oxygen species, activate 
nuclear factor κB (NFκB), and reduced markers of inflammation in the rodent liver (31).  
Similarly, administration of Bifidobacterium longum reduced GI inflammation and 
metabolic syndrome, and reduced levels of LPS and interleukin beta in a rat model (32).  
Another species, Bifidobacterium breve reduced triacylglycerol content, decreased serum 
TNF-α levels, and restored serum LPS levels to levels that were observed in control rats 
(33).  It also suppressed accumulation of epididymal fat pad and body weight, improved 
fasting levels of glucose and insulin, and improved total cholesterol values in a mouse 
model (34).  Finally, supplementation of newborn mice with Bifidobacterium infantis and 
Bifidobacterium bifidum significantly lowered intestinal endotoxin levels compared to 
control mice (35), and B. infantis normalized gut permeability and decreased colonic IFN-
γ secretion in IL-10-deficient mice (26). 
Collectively, these reports suggest that dietary strategies that support both the size 
and physiologic activity of Bifidobacterium populations in the human GI tract could be 
effective for a range of metabolic disorders.  Ordinarily, the abundance of these bacteria in 
adults is relatively low (< 3%) (36), and negatively correlates with high-fat and low fiber 
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diets, which are common in Westernized societies (24, 37).  This low abundance of 
bifidobacteria may be addressed by dietary treatments such as probiotics, prebiotics, or 
synbiotics.  The consumption of prebiotic carbohydrates, such as galactooligosaccharide 
(GOS) and other fibers, have been shown to increase autochthonous bifidobacteria in 
infants (38, 39) and adults (40–42).  However, not all subjects respond to prebiotic 
interventions, even at high doses (36, 43, 44), and the subjects may not possess a particular 
Bifidobacterium strain of interest.  One strategy to enrich for bifidobacteria, even in non-
responders, would be to administer the prebiotic together with a Bifidobacterium strain that 
is capable of metabolizing the prebiotic component in vivo.  Such pairings are referred to 
as synergistic synbiotics (45).  
However, the rational selection of these synbiotic strains is critical as the potential 
of the probiotic strains to become established in vivo is significantly limited due to 
colonization resistance conferred by the resident or commensal microbial population, the 
host, and other abiotic factors.  Allochthonous strains may, for example, lack adaptive traits 
necessary to become competitive and physiologically active in the GI environment.  Their 
ability to compete with the autochthonous microbiota in the GI tract is also compromised 
by niche exclusion, colonization resistance, nutrient availability, the host’s immune 
system, and the prevailing environmental conditions in the digestive tract (46).  These 
abiotic and biotic ecological factors have a major influence on the ability of allochthonous 
organisms (including most probiotics) to reach, and then become established in the human 
GI tract, even if only transiently.  Indeed, studies have shown that bacterial strains that are 
allochthonous to the GI tract are washed out shortly after administration is discontinued, 
and pre-treatment conditions are quickly re-established (36, 47–50).  By selecting bacterial 
strains that are autochthonous, adapted to the host GI environment, the colonization 
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resistance towards the strains based on these abiotic and biotic factors may be attenuated.  
Moreover, incorporating strains autochthonous to the adult GI tract, such as B. 
adolescentis, as a synbiotic might also be expected to enhance their probiotic function and 
colonization success. 
We recently described a novel method for the selection of an autochthonous strain 
of B. adolescentis that was enriched in vivo by GOS (1).  When this strain, B. adolescentis 
IVS-1, was fed to rats, its abundance reached 3.4 % of the total bacterial gut microbiota.  
However, when combined with GOS as a synbiotic, abundance of strain IVS-1 increased 
to more than 35 %.  To determine if this rationally selected synbiotic would also show 
enhanced colonization in humans, we tested it in a parallel arm placebo controlled clinical 
trial with obese adults.  Our goal was to assess the potential of this in vivo selected strain, 
combined with GOS as a synbiotic to establish bifidobacteria and redress metabolic 
aberrancies, with gut permeability as the primary endpoint.  We compared establishment 
with a widely used commercial strain, B. animalis subsp. lactis Bb12, which has been used 
in synbiotic applications with GOS (48, 51, 52).  Each strain was provided as individual 
treatments as well as combined with GOS as synbiotics.  We compared the ability of the in 
vivo selected rationally designed synbiotic to the commercial synbiotic to alter the gut 
microbiota in obese individuals, and tested if GOS supported the colonization of the 
probiotic strains.  This report focusses on the impact of the dietary treatments on the gut 
microbiota, while an assessment of the ability of each synbiotic to improve intestinal 
permeability and endotoxemia is currently ongoing.  
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4.3 Methods: 
Subjects.  This study was designed as a randomized, placebo-controlled, parallel-arm 
clinical trial conducted at Rush University Medical Center (RUMC).  Women and men 
between 18 and 60 years with a BMI of 30.0 - 40.0 kg/m2 were recruited.  Subjects were 
permitted to have elevated liver enzymes due to fatty liver and metabolic syndrome, but 
were otherwise considered as healthy.  Exclusion criteria included (1) prior intestinal 
resection, (2) patient history of GI diseases except for hiatal hernia, GERD, hemorrhoids, 
(3) severe renal disease defined by creatinine more than twice normal, (4) markedly 
abnormal liver function defined by ALT/AST over 4 times normal levels or elevated 
bilirubin (5) antibiotic use within the last 12 weeks prior to enrollment, (6) lean or 
overweight (BMI < 30 kg/m2), (7) intolerant to aspirin, (8) regular use of aspirin, (9) 
excessive alcohol intake (>2 drinks for men, 1 drink for women daily), (10) presence of 
chronic metabolic disease (cardiovascular disease, insulin requiring diabetes or 
uncontrolled diabetes, cancer, etc.), (11) a plan to have a major change in dietary habit 
during the following 6 months, (12) consumption of probiotics, prebiotics or synbiotics 
without an appropriate 4 week washout period, (13) lactose intolerance or malabsorption, 
(14) subjects younger than 18 or older than 60, (15) unwillingness to consent to the study. 
 
Study design.  A total of 105 subjects were recruited and randomly assigned to one of six 
treatment groups (Table 4.1).  The randomization was controlled for age and race.  Three 
visits were required for each subject (Figure 4.1).  At Visit 1, potential subjects were 
screened for eligibility and provided with a form for a 3-day diet record, all supplies for 
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stool collection, and instructions for specimen handling and for completing these tasks 
before the next visit. 
 
Table 4.1. Treatment groups 
Treatment group Treatment 
Group A Lactose control 
Group B 1 x 109 CFU B. adolescentis IVS-1  
Group C 1 x 109 CFU B. animalis subsp. lactis Bb12 
Group D 1 x 109 CFU B. adolescentis IVS-1 + GOS 
Group E 1 x 109 CFU B. animalis subsp. lactis Bb12 + GOS 
Group F Galactooligosaccharide (GOS) 
 
Subjects were instructed to store stool samples in Styrofoam coolers with freezer packs 
until delivery to the hospital.  The samples were not allowed to be older than 24 hours if 
stored at -20°C, and not older than 5 hours if stored at room temperature.  At visit 2, study 
subjects provided the completed food record and the baseline stool sample.  Subjects were 
provided with one of the six treatments and consumed their randomly assigned supplement 
daily for three weeks as instructed.  At the end of three weeks, subjects returned to the 
clinic to provide stool, as previously described.  At the visit after 3 weeks of 
supplementation, the subject provided a stool sample, 3-day food records, and completed 
GI symptom questionnaires regarding adverse events.  The latter included a standardized 
survey that rates bowel movement, stool consistency, discomfort, flatulence, abdominal 
pain, and bloating on a scale from 1 (best) to 10 (worst) (44).  Weight, height, waist 
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circumference, and blood pressure were measured, and BMI was calculated at each visit.  
Blood pressure was measured using an automated cuff with the average of three 
assessments used for statistical comparisons.  Four weeks after the last treatment was 
consumed subjects provided a wash-out stool sample.  Subjects gave a written informed 
consent before the study procedure. 
Eleven subjects (two in group A, four in group B, two in group C, one in group D, 
and two in group E) did not follow all protocol requirements and were subsequently 
excluded from the per protocol analysis presented here.  These subjects were included in 
an intend to treat (ITT) analysis, which can be found in the supplements. 
 
 
Fig. 4.1. Time line for synbiotic trial. 
 
Dietary treatments.  The prebiotic, GOS, was obtained from Friesland Foods (sold under 
the trade name, Vivinal®).  This product contained 72.5 % of GOS, 22.8 % lactose, and 
4.7 % mono-sugars (galactose and glucose).  It was previously established that a dose of 5 
g per day of GOS was sufficient to induce a bifidogenic response (40).  Therefore the total 
amount of GOS powder was raised to 6.9 g to achieve a 5 g GOS treatment.  The material 
was packaged in sachets in the Food Processing Product Development Lab (UNL).  An 
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additional 0.1 g of lactose was added to achieve the same weight as the other preparations.  
The sachet material was impermeable to oxygen and moisture.   
The two organisms that were used in this feeding study were Bifidobacterium 
adolescentis IVS-1 and Bifidobacterium animalis subsp. lactis Bb-12.  The latter was 
obtained from Chrs. Hansen as a high cell density powder.  Strain IVS-1 was produced 
from a contract manufacturer (Danwell Technology, Garden Grove, CA).  The probiotic 
powder was stored for up to six month at -18°C and showed stable CFU numbers (data not 
shown).  Probiotic mixtures were portioned into sachets, each contained 0.1 g of cell 
powder (1010 CFU/g).  In addition, 6.9 g of lactose were added as a carrier/control, for a 
total dose of 7.0 g.  Synbiotics contained 6.9 g of Vivinal® and 0.1 g of probiotic (either 
B. adolescentis IVS-1 or B. animalis Bb12), for a total dose of 7.0 g.  Placebo samples 
contained 7.0 g of lactose.  Subjects were provided with enough samples for the entire 
length of the study and were instructed to consume each dose on a daily basis, either mixed 
with food or liquid, but no tab water.  The subjects were instructed to store samples in a 
cold (-18 °C) environment. 
 
Analysis of fecal microbiota.  Fecal samples were aliquoted and stored at -80°C until 
further analysis.  The DNA was extracted as previously described (29).  Amplicon 
sequencing was performed at the University of Minnesota Genomics Center.  All samples 
were amplified and sequenced in a single run.  The V5-V6 region of the 16S rRNA gene 
was amplified as previously described (1).  Quality filtering performed by the University 
of Minnesota Genomics Center showed that more than 96 % of the samples met all quality 
control criteria.  All reads were trimmed to 240 base pairs using the FASTX-Toolkit.  The 
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reads were quality controlled, merged, OTU clustered, and taxonomically assigned, as 
previously described (1).  If a sample exceeded 37,000 reads it was subsampled using 
Mothur v.1.31.162 to standardize the sequencing depth across samples.  After processing 
samples contained an average of 22,012.7 ± 6,623 sequences.  
 
Quantitative real-time PCR (qPCR).  qPCR was performed by using a Mastercycler 
Realplex2 instrument (Eppendorf AG, Hamburg, Germany).  Each PCR was performed 
with 25-μl volumes using real-time master mix containing SYBR (5 Prime Inc., 
Gaithersburg,MD) and either genus-specific primers for Bifidobacterium (40), or the 
strain-specific primers for B. adolescentis IVS-1 (1), as described previously.  For strain 
specific detection of B. animalis subsp. lactis Bb12 the PCR mixture contained 25 μl of 
PCR reaction mix (QuantiFast® Probe PCR Kit, QIAGEN, Hilden, Germany), 0.3 μmol of 
each primer (BAL-23S-F 5’-CAGGTGGTCTGGTAGAGTATACCG-3’ and BAL-23S-R 
5’-ACGGCGACTTGCGTCTTG-3’), 0.25 μmol of probe (BAL-23S-P 5’-FAM-
CGCCCACGACCCGCAAG-TAMRA-3’), and 5 μl DNA as previously described (53).  
The target of these primers and probe is the elongation factor Tu (tuf) gene of Bb12.  The 
specificity of the primers and probe for Bb12 was validated experimentally by qPCR using 
DNA from 11 different Bifidobacterium strains related to strain Bb12.  These strains 
included Bifidobacterium adolescentis IVS-1, Bifidobacterium adolescentis ATCC 15703, 
Bifidobacterium adolescentis L2-32, Bifidobacterium longum subsp. longum ATCC 
15707, Bifidobacterium longum DJO10A, Bifidobacterium longum ATCC 15697, 
Bifidobacterium longum subsp. longum F8, Bifidobacterium longum subsp. longum 
JDM301, Bifidobacterium sp. strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and 
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Bifidobacterium sp. strain HMLN14.  Furthermore, to test if primers could strain 
specifically select against fecal bacterial communities in humans, baseline DNA samples 
from subjects in groups C (Bb12 + lactose) and group E (Bb12 + GOS), and 10 randomly 
selected samples from other subjects, were tested.  
Standard curves for absolute quantification of bacterial cell numbers were prepared 
by using cultures of B. animalis subsp. lactis Bb12 and B. adolescentis IVS-1 grown 
overnight (14 h).   
 
Statistical analysis.  All data present in the main body of the text was analyzed based on 
a per protocol analysis.  Subjects that were recruited but violated the protocol in any way, 
for example took antibiotics, stored the treatments at room temperature, etc., were excluded 
from the analysis.  These subjects were included in an intend to treat (ITT) analysis, which 
can be found in the supplements.  Data is presented as mean ± SEM for variables that can be 
considered normally distributed (or median and range for variables not normally distributed).  
Group means were compared by ANOVA and post-hoc tests except when data was not 
normally distributed, in which case nonparametric analyses of medians was done using the 
Kruskal-Wallis test.  Correlation analysis were done using the Spearman’s correlation test 
for parametric analysis.  Chi-square tests or Fisher’s Exact Tests were used for incidence 
data.  P <0.05 is considered statistical significant.  If only two groups were compared, 
Student’s t tests were performed.  For analysis of the gut microbiota the data was 
normalized by log10 transformation.  To account for type I errors, a false discovery rate was 
used.  A P value of < 0.05 and correlation coefficient (r) values of > 0.50 (in absolute 
values) were considered significant.  Genera above 0.5 % and OTUs above 1 % abundance 
on average were considered for correlations.  Correlation graphs were generated for 
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parameters that showed significant correlations and were visually inspected.  If the removal 
of one single data-point caused the association to become non-significant, the data point 
was considered an outlier and removed.  All analyses used SPSS (Chicago, IL), GraphPad 
Prism version 5.0 (GraphPad Software, La Jolla, CA, USA), R studio (R Core Team, 2014), 
or SAS/STAT (SAS Institute Inc., Cary, NC, USA). 
 
4.4 Results 
4.4.1 Subject demographics and clinical characteristics 
The subject cohort for this study was primarily female (71 %), middle-aged, non-
Hispanic or Latino, and African American (Table 4.2).  All subjects were obese, with 
participants in group D (IVS-1 + GOS) classifying as extreme obese, in group E (Bb12 + 
GOS) and F (GOS) as Class II obese, and in group A (Lactose), B (IVS-1+ lactose), and C 
(Bb12 + lactose) as class I obese.  Subjects in group D had a significantly higher body mass 
index (BMI) than subjects in group B (P = 0.049).  The average waist circumference was 
40 inches.   
 
4.4.2 Test of synergy of GOS in addition to IVS-1 or Bb12. 
 Our first goal was to determine if the ability of two strains of bifidobacteria to 
become established in the GI tract of obese adults would be enhanced by the addition of 
GOS.  The strains included B. adolescentis IVS-1 that had previously been isolated from a 
GOS-enriched subject, and B. animalis subsp. lactis Bb12, a widely used commercial 
probiotic.  Both strains were capable of fermenting GOS in vitro (1, 54).  Treatment groups 
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included subjects who consumed each of the two test strains alone (groups B and C), 
subjects who consumed the synbiotics (i.e., test strains combined with GOS; groups D and 
E), a GOS-only group (F), and a placebo (lactose) group (A).  Strain-specific qPCRs were 
used to quantify bacterial cell levels for those groups that received either one of the test 
strains alone or as synbiotics using the corresponding strain specific primers for IVS-1 and 
Bb12.  Because Bifidobacterium adolescentis is a common species in the adult GI tract, it 
was necessary to establish that the IVS-1 primers were specific for this strain.   
Results confirmed that no signal was detected in any baseline sample in subjects of 
group B (IVS-1 alone) or D (IVS-1 + GOS) (Figure 4.2A), or in the baseline of another 
additional 20 subjects that were randomly selected (data not shown).  Therefore, it was 
concluded that any IVS-1 that was detected by qPCR after the treatment was given to the 
subjects, was indeed the probiotic strain selected for this study. 
A similar approach was used to test the specificity of the Bb12 primers and probe.  
The primers and probe had been previously designed (53) and are the standard used by 
Chr. Hansen to identify their probiotic product.  The strain Bb12 is a commonly used 
probiotic in dairy products.  It was detected in three subjects before the treatment was 
started.  Analysis of food diaries of these subjects, however, did not identify any indication 
of Bb12 product consumption. 
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Table 4.2.  Demographic and metabolic characteristics of study subjects1 
 
Total 
Sample 
(n=94) 
Group A 
Control 
(n=17) 
Group B 
IVS-1 
(n=18) 
Group C 
Bb12 
(n=164) 
Group D 
IVS-
1+GOS 
(n=16) 
Group E 
Bb12+GOS 
(n=17) 
Group F 
GOS 
(n=16) 
Demographic 
Characteristics               
Gender               
      Female,  
      N (%) 71 (75.5) 13 (76.5) 9 (64.3) 12 (75.0) 11 (78.6) 12 (75.0) 12 (75.0) 
Age, years, 
mean ± SD 44.3±11.2  44.3±11.2  44.3±11.2  44.3±11.2  44.3±11.2  44.3±11.2  45.9±9.6 
Race, n (%)        
   Hispanic/ 
   Latino 9 (9.6)  0 (0.0) 2 (14.3) 2 (14.3) 2 (12.5) 2 (11.8) 1 (6.3) 
   Non- 
   Hispanic/ 
   Latino 
85 (90.4)  17 (100.0) 12 (85.7) 12 (85.7) 14 (87.5) 15 (88.2) 15 (93.8) 
Ethnicity, n (%)        
   White 31 (33.0)  5 (29.4) 8 (57.1) 4 (28.6) 3 (18.8) 6 (35.3) 5 (31.3) 
   African  
   American  58 (61.7)  10 (58.8) 6 (42.9) 7 (50.0) 13 (81.3) 11 (64.7) 11 (68.8) 
   Other2 5 (5.3)  2 (11.8) 0 (0.0) 3 (21.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Education, n (%)        
      ≤ 12 years 20 (21.3)  3 (17.6) 1 (7.1) 2 (14.3) 6 (37.5) 2 (11.8) 6 (37.5) 
  > 12 years 74 (78.7)  14 (82.4) 13 (92.9) 12 (85.7) 10 (62.5) 15 (88.2) 10 (62.5) 
Clinical 
Characteristics3               
   Body weight, 
   kg4 100.0 (25.7)  96.8 (17.7)  94.8 (14.6)  98.5 (32.2) 118.0 (36.7) 112.8 (31.8) 102.3 (18.3) 
   BMI, kg/m2,5 36.7 (8.5)  34.0 (4.5) 33.9 (6.2) A 35.5 (10.3) 
41.6 (12.4) 
B 40.5 (7.1) 36.8 (5.6)  
   Waist     
   circum- 
   ference, inches  
45.0 (7.3)  44.0 (11.0) 43.5 (4.4) 43.0 (9.9) 47.8 (12.3) 47.0 (8.7) 45.0 (3.2) 
1Sample based on those that were randomized to treatment and completed the post-treatment visit (Visit 4)  
2White ethnicity includes 2 Hispanic and 1 Middle Eastern participant; Black/African American ethnicity incudes 1 
mixed ethnicity participant 
 
3All clinical characteristics are listed as median (IQR)  
4Significant difference based on Kruskal-Wallis, but no differences based on post-hoc pairwise comparisons after 
adjustment for multiple comparisons. 
5Different letters indicate significant differences between treatment groups 
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The results showed that compared to the baseline and washout in the fecal samples, 
both strains reached significant increases in total numbers (P < 0.001 in group B (IVS-1 + 
lactose), D (IVS-1 + GOS), and E (Bb12 + GOS); P <0.01 in group C (Bb12 + lactose)), 
in the presence as well as absence of GOS (Figure 4.2A).  In group B (IVS-1 alone), an 
average of 6.99 ± 1.2 log10 of IVS-1 cells g-1 was detected and in group D, receiving the 
synbiotic IVS-1 plus GOS, cell levels reached 7.22 ± 1.6 log10 of IVS-1 cells g-1.  Group C 
received the commercial strain Bb12, which was detected at absolute numbers of 5.83 ± 
0.7 log10 of Bb12 cells g-1 and in group E (Bb12 + GOS) Bb12 numbers reached 6.11 ± 0.7 
log10 of Bb12 cells g-1. 
The numbers of the two probiotic strains for each treatment at each time point were 
then compared directly (Figure 4.2B).  IVS-1 colonized the GI tract at a significantly higher 
number than the commercial probiotic Bb12 in the probiotic only treatments (P = 0.0056).  
Although GOS enriched for both strains, Bb12 and IVS-1, relative to the test strains alone, 
in both cases this trend was not significant (P = 0.7382 and P = 0.3034, respectively).  In 
contrast, when comparing the two synbiotics, GOS significantly increased the number of 
IVS-1 by more than one log compared to the commercial Bb12 synbiotic (7.22 ± 1.6 log10 
and 6.11 ± 0.7 log10 respectively, P = 0.0195).  This result demonstrates an ecological 
advantage of IVS-1 over Bb12 and a limited effect of GOS supplementation on either 
strain.  After a four week washout period, Bb12 could not be detected in group C subjects, 
and only in three subjects at a very low number in the synbiotic group (group E).  One of 
these subjects already had Bb12 present in the baseline sample.  In the IVS-1 + GOS 
synbiotic group D, IVS-1 persisted in six subjects during the washout period, and the 
number of IVS-1 was significantly higher than the number of Bb12 in group E (P = 
0.0057).  
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In addition to strain-specific quantification, the absolute numbers of bifidobacteria 
were measured for all six groups at the three time points by genus-specific quantitative real 
time PCR (Figure 4.3A).  Even though both Bifidobacterium strains were significantly 
enriched as determined by strain-specific qPCR, neither IVS-1 nor Bb12 supplementation 
increased the total number of bifidobacteria.  Only groups D (IVS-1 + GOS) and F (GOS) 
showed a significant increase of bifidobacteria due to the treatments (P = 0.0203 and P = 
0.0191, respectively). 
The Bifidobacterium numbers at the baseline varied greatly within each group, 
ranging from the detection limit (log10 4.67 cells g-1 feces) to log10 10.42 cells g-1 feces in 
group F (GOS).  Therefore, the change in cell number was calculated for each subject 
(Figure 4.3B).  The highest increases in Bifidobacterium numbers were for group F (GOS) 
with 1.30 ± 1.7 log10, followed by group B (IVS-1 only) with 1.22 ± 1.4 log10.  Interestingly, 
the lactose group also had an increase in bifidobacteria (0.51 ± 0.9 log10).  However, none 
of these differences reached statistical significance. 
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Fig. 4.2.  A.  Test of in vivo selected synergistic synbiotic application compared to a 
commercial synbiotic.  Quantification of absolute cell numbers of bifidobacteria in fecal 
samples by qPCR using strain-specific primers for strains B. adolescentis IVS-1 and B. 
lactis Bb12.  Shown are probiotic and synbiotic treatment groups at baseline, treatment and 
washout time points.  Significance of P ≤ 0.05 is denoted by a single asterisk (*), P ≤ 0.01 
as two asterisks (**), and P ≤ 0.001 by three asterisks (***).  B.  Direct comparison of 
abundances of B. adolescentis IVS-1 and B. lactis Bb12 at each time point.  Different letters 
indicate significant differences between groups (P ≤ 0.05). 
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Fig. 4.3.  A. Quantification of absolute cell numbers of bifidobacteria in fecal samples by 
genus-specific qPCR.  B. Change in abundance of bifidobacteria for each subject due to 
treatment consumption.     
  
178 
 
4.4.3 Community-wide characterization of effects on gut microbiota confirms 
ecological advantage of GOS and IVS-1 compared to Bb12 and GOS. 
Community-wide changes that were introduced by the dietary treatments to the 
resident gut microbiota were assessed by sequencing 16S rRNA tags.  Interestingly, only 
one phylum was significantly influenced by the dietary treatments as Actinobacteria was 
significantly higher in subjects treated with IVS-1 + lactose (group B, P = 0.0181, Table 
4.2, Figure 4.S1), and the genus Bifidobacterium in groups B (IVS-1 + lactose) and C 
(Bb12 + lactose).  Apart from this, only at the OTU level were significant changes 
introduced to the gut microbiota.  However, the abundance of these OTUs was extremely 
low in most cases, and high variations in the sample populations were also observed.  
Accordingly, the alpha and beta diversity of each group and between groups was not 
significantly different (data not shown). 
The ability of the test strains (alone and as synbiotics) to become established in the 
GI tract was based on the abundance of operational taxonomic units (OTU) representing 
the species B. adolescentis (OTU_1) and B. lactis subsp. animalis (OTU_167) (Table 4.3).  
B. adolescentis is an autochthonous species in the human GI tract and was detected at low 
average abundances in the GI tract of the subjects at baseline (2.27 ± 4.7 %).  In contrast, 
B. animalis subsp. lactis was detected in baseline samples for only seven subjects.  In four 
of these subjects the abundance of OTU_167 was below 0.01 %.  The other three subjects 
are identical to the ones identified in the qPCR analysis (Figure 4.2).   
Based on the sequencing analysis, OTU_1 was significantly enriched by the 
probiotic-alone and synbiotic treatments to 3.7 and 7.3 %, respectively (Table 4.2).  In 
groups D (IVS-1 + GOS), E (Bb12 + GOS), and F (GOS) OTU_1 B. adolescentis became 
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the most abundant OTU, representing an average of 7.3 %, 7.2 %, and 6.7 % of the 
microbiota, respectively, and the second most abundant in group B (3.4 %).  This increase 
was clearly based on the presence of IVS-1 and/or GOS in the treatments, as the abundance 
of OTU_1 B. adolescentis was only 0.01 % in group A (Lactose) and 1.2 % in group C 
(Bb12 + lactose).  A comparison of the abundance of OTU_1 between group B (IVS-1 + 
lactose), C (IVS-1 + GOS), and group F (GOS) showed no significant difference (P > 0.1).  
There was a significant increase in the relative abundance of OTU_167 B. animalis 
between baseline and treatment in group C (Bb12 + lactose) and E (Bb12 + GOS) (0.4 % 
and 0.1 %, respectively).  
 
4.4.4 Systematic analyses of members of the gut microbiota. 
To identify potential interactions between the test strains and other members of the 
gut microbiota, we performed correlation analyses at the treatment time point.  As a cutoff, 
the genus had to have an average abundance of at least 0.5 %, and the OTU an average 
abundance of at least 1 %, with the exception of OTU_167 (B. animalis) which was 
included even though its average abundance was below 1 %.  No significant correlations 
between the genus Bifidobacterium, or any Bifidobacterium OTUs, and other genera or 
OTU could be identified once outliers were removed.  However, several other significant 
correlations between other members of the gut microbiota were observed (Figure 4.S2 and 
4.S3).   
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Table 4.3. Proportions of bacterial taxa significantly influenced by dietary treatments 
  Mean % bacterial abundance ± SD b  
Treatments Taxonomic Group Baseline Treatment Washout P value 
Group A 
Lactose 
control 
OTUs a     
OTU_2050 (Ruminococcus2 sp.) 0.01±0.0 AB 0.01±0.0 A 0.02±0.0 B 0.0139 
Group B 
IVS-1 
Probiotic 
Phylum     
Actinobacteria 9.16±5.5 A 15.44±6.2 B 14.39±5.9 AB 0.0181 
 Genus     
 Bifidobacterium 7.85±7.8 A 14.66±7.2 B 13.43A±6.9 B 0.0378 
 OTUs a     
 OTU_2353 (Dorea sp.)) 0.01±0.0 A 0.02±0.0 AB 0.02±0.0 B 0.0068 
 OTU_1 (B. adolescentis)  1.30±4.4 A 3.69±5.2 B 3.56±4.7 B 0.0010 
Group C 
Bb12 
Probiotic 
Genus     
Bifidobacterium 9.53±5.3 A 10.18±8.3 B 9.96±6.1 AB 0.0378 
 OTUs a     
 OTU_167 (B. animalis subsp. lactis) 0.04±0.1 AB 0.04±0.1 A 0.00±0.0 B 0.0328 
Group D 
IVS-1 GOS 
OTUs a     
OTU_469 (Anaerotruncus sp.) 0.03±0.1 A 0.00±0.0 B 0.01±0.0 AB 0.0188 
 OTU_102: (Lachnospiracea incertae sedis sp.) 0.35±0.5 A 0.01±0.2 B 0.24±0.6 AB 0.0444 
 OTU_1 (B. adolescentis)  2.48±4.5 A 7.34±7.2 B 4.75±5.1 B 0.0343 
Group E 
Bb12 GOS 
OTUs a      
OTU_167 (B. animalis subsp. lactis) 0.00±0.0 A 0.12±0.2 B 0.01±0.0 A 0.0043 
 OTU_1800 (unclass. Lachnospiraceae sp.) 0.00±0.0 AB 0.01±0.0 A 0.00±0.0 B 0.0241 
Group F 
GOS 
OTUs a      
OTU_643 (Bacteroides sp.) 0.02±0.0 A 0.00±0.0 B 0.00±0.0 AB 0.0372 
 OTU_319 (Butyricimonas sp.) 0.00±0.0 AB 0.00±0.0 A 0.05±0.1 B 0.0382 
a If the strain could not be assigned to a type strain (< 97 % homology), RDP Classifier was used to determine the most 
likely genus (80 % cutoff). b Values with different uppercase letters are significantly different from each other. 
 
 
The ratio of Prevotella to Bacteroides has been previously suggested to be strongly 
associated with diet, especially diets rich in animal fat (Bacteroides) versus carbohydrates 
(Prevotella) (55).  Other studies have reported a significant change in the ratio between 
Prevotella and Bacteroides due to dietary treatments (56), but an analysis of the Prevotella 
and Bacteroides ratio in this study showed no significant difference within a treatment 
group, or when groups were compared (Figure 4.S4).  Furthermore, the abundance of 
butyrate producing genera such as Faecalibacterium, Eubacterium, Roseburia, 
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Lachnobacterium, and Ruminococcus was not significantly influenced by any of the 
treatments, nor was their combined abundance changed by any of the treatments (data not 
shown). 
 
4.4.5 Systematic analyses of subjects that showed IVS-1 persistence after treatment 
termination. 
We observed that for nine subjects IVS-1 persisted during the four week washout 
period.  Three subjects were from group B and six were from group D (IVS-1 alone and 
IVS-1 + GOS, respectively).  The microbiota of these nine persisters was compared with 
the microbiota of all the other subjects in groups B and D (referred to as non-persisters).  
The aim of this analysis was to determine if the persister status could be predicted before 
the treatment had begun (i.e., from the baseline samples), based on the composition of the 
gut microbiota.  In order to identify genera and OTUs that affected persistence of IVS-1 in 
the GI tract of these two groups, a Random Forest classification was performed.  This 
analysis shows the importance that the relative abundances of different taxa have in 
predicting persistence.  Output of this analysis is a “value of mean decrease in accuracy”.  
The higher the value of mean decrease in accuracy of the taxa, the stronger the prediction 
of persistence of IVS-1.  All genera and OTUs with a value of mean decrease in accuracy 
of at least one are reported here (Figure 4.4).  The random forest analysis identified Slackia 
as the most important predictor of persistence.  When the abundance of Slackia was 
compared between persisters and non-persisters, Slackia abundance was higher in non-
persisters with a ratio of almost 200.  However, despite the high ratio, the absolute 
abundance of Slackia was only 0.23 % in non-persisters and almost absent in persisters.  
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Other members of the Coriobacteriales order are also predictive for the ability of IVS-1 to 
persist in the subjects, including Asaccharobacter, Collinsella, and Olsenella.  Except for 
Asaccharobacter, all of these Coriobacteriales were present at a higher abundance in non-
persisters than in persisters.  Three members of the Clostridiales order, Ruminococcus, 
Eubacterium and Mogibacterium, one member of the Bacteroides order, Prevotella, and 
one member of the Erysipelotrichales order, Holdemania, also appeared to have the 
greatest impact on IVS-1 persistence.  At the OTU level, eight OTUs had a value of mean 
decrease in accuracy of at least one; six belonged to the order Clostridiales, one to 
Coriobacteriales, and one to Lactobacillales.  The prediction value of the OTUs for 
persistence appears to be strain dependent.  For example, OTU_21 Blautia sp. and OTU_98 
Blautia sp. were present in higher abundance in persisters then in non-persisters, while 
OTU_103 Blautia sp. had a significantly higher abundance in non-persisters (P = 0.0353).  
Three Lachnospiraceae OTUs were also identified.  OTU_61 Lachnospiraceae incertea 
sedis and OTU_2093 Lachnospiraceae incertea sedis share 96 % identity and are both in 
higher abundance in persisters than in non-persisters (P = 0.0365 and P = 0.0805, 
respectively).  OTU_76, an unclassified Lachnospiraceae sp., on the other hand was 
present in significantly higher numbers in non-persisters (P = 0.0177) and shared 91 % and 
90 % identity with OTU_61 and OTU_2093, respectively.  OTU_1 B. adolescentis was 
only present in two of the persister subjects at the baseline and was not detected by the 
Random Forest analysis (< -1.0).   
Even though no Bifidobacterium species had a Random Forest importance value 
above 1, three Bifidobacterium OTUs had values above zero and were further analyzed 
(Figure 4.6A).  Those three OTUs consisted of OTU_2055 B. pseudocatenulatum (99% 
identity, e-value 6 · 10-120, 100% query cover), OTU_2202 B. pseudocatenulatum (98% 
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identity, e-value 2 · 10-119, 100% query cover), and OTU_7 B. ruminantium/adolescentis 
(100 % identity, e-value 4 · 10-126, 100% query cover in each case according to NCBI).  
OTU_7 had a 144-fold higher relative abundance in non-persisters than in persisters on 
average (P = 0.0454), even though it was not present in all non-persisters at the baseline.  
OTU_7 is very closely related to IVS-1 (98 % identity) and possibly the same species 
(Figure 4.6B).  OTU_2055 B. pseudocatenulatum and OTU_2202 B. pseudocatenulatum, 
were higher in persisters by a ratio of 24 and 5.5, respectively, but their abundance was not 
significantly different between the groups.  
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Fig. 4.4.  Prediction analysis of IVS-1 persisters and non-persisters.  Random Forest 
variable importance plots and relative abundance of genera (A) and OTUs (B) with a 
variable importance of at least 1 in mean decrease in accuracy.  The ratio of the given taxa 
between responders and non-responders is shown on the right.  Taxa are color coded by 
order.   
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Fig. 4.5.  A. Prediction analysis of IVS-1 persisters and non-persisters.  Random Forest 
variable importance plots and relative abundance of Bifidobacterium OTUs with a variable 
importance of at least zero in mean decrease in accuracy.  B. The ratio of the given 
Bifidobacterium OTUs between responders and non-responders.   
 
 While different markers for alpha diversity such as Shannon index, Simpson index, 
and the number of observed species was not significantly different among persisters and 
non-persisters in the baseline sample (Figure 4.S5), the beta diversity of the samples tended 
to separate (Figure 4.6).  However, this trend was not significant (P = 0.2637) 
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Fig. 4.6.  NMDS plot of beta diversity analysis based on Bray-Curtis distance of baseline 
samples between IVS-1 persisters and non-persisters. 
 
 
4.4.6. Analysis of anthropometric markers and gastrointestinal symptoms 
 Anthropometric markers were analyzed at the baseline and after three weeks of 
treatment, and the change (as percent) is reported in Table 4.4.  There was no change 
detected in anthropometrics between groups.   
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Table 4.4.  Percent change in anthropometrics in participants compared to the baseline1 
 
Total 
Sample 
(n=94) 
Group A 
Lactose 
(n=17) 
Group B 
IVS-1 
(n=14) 
Group C 
Bb12 
(n=14) 
Group D 
IVS-1 + 
GOS 
(n=16) 
Group E 
Bb12 + 
GOS 
(n=17) 
Group 
F 
GOS 
(n=16) 
Anthropometrics       
   Body  
   weight,  
   kg 
0.4 (2.9) 0.4 (5.0) -0.1 (2.9) 0.6 (2.4) -0.3 (3.4) -0.1 (3.6) 1.3 (3.6) 
   BMI,  
   kg/m2  0.4 (2.9) 0.4 (5.0) -0.1 (2.9) 0.6 (2.4) -0.3 (3.4) -0.1 (3.6) 1.3 (3.6) 
   Waist  
   circum- 
   ference,  
   inches 
0.0 (4.6) -1.3 (3.8) 0.0 (6.9) 0.2 (5.2) 0.0 (5.5) 1.8 (3.0) 0.0 (5.1) 
1Per-protocol sample based on those that were randomized to treatment and were considered compliant 
to the treatment  
2All clinical characteristics are listed as median (IQR)     
 
A structured 34-item questionnaire with a Likert scale from 0 (no symptoms) to 10 
(very severe symptoms) was used to assess gastrointestinal symptoms at baseline and any 
changes in these symptoms with supplementation.  At baseline, subjects reported no 
symptoms to 28 of 34 (82.4 %) GI symptoms included on the questionnaire; this number 
of symptoms increased to 85.3 % (29 of 34 items) at the end of the treatment.  The most 
common symptoms at baseline were bloating, passing gas, hard stools, and watery stools, 
with 60.6 %, 85.1 %, 46.8 %, and 43.6 % overall indicating presence of these symptoms, 
respectively.  The median symptom score for each of these four symptoms both before and 
after treatment are listed in Table 4.5.  Overall, low median scores indicated that most 
subjects either had minimal GI symptoms or low severity of that symptom.  No significant 
differences existed between median symptom score for the six groups at baseline.  At the 
end of treatment, those in the GOS group had significantly more hard stools than the Bb12 
+ GOS group (Kruskal-Wallis; P = 0.024).  Passing gas increased from a median of 2.0 to 
5.0 with lactose supplementation, but this was not significantly different (Mann-Whitney, 
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P = 0.15).  The severity of passing gas significantly reduced from 4.0 to 1.0 in the Bb12 + 
GOS group (P = 0.040), and severity of hard stools increased from 1.0 to 3.5 in the GOS 
group (Wilcoxon Signed Ranks Test, P = 0.030). 
 
Table 4.5. Gastrointestinal symptoms by supplementation group1,2,3  
 
Total 
Sample 
(n=92) 
Group A 
Lactose 
(n=16) 
Group B 
IVS-1 
(n=14) 
Group C 
Bb12 
(n=14) 
Group D 
IVS-1 + 
GOS 
(n=15) 
Group E 
Bb12 + 
GOS 
(n=17) 
Group F 
GOS 
(n=16) 
Baseline 2       
Bloating  2.0 (4.8) 2.0 (4.8) 1.0 (3.3) 2.0 (4.0) 2.0 (5.0) 4.0 (6.0) 2.5 (7.8) 
Passing Gas 3.0 (5.0) 2.5 (4.8) 2.5 (3.5) 2.5 (4.5) 3.0 (5.0) 4.0 (3.5) * 2.5 (5.8) 
Hard Stools 1.0 (2.8) 0.5 (3.0) 1.0 (2.3) 0.0 (2.3) 0.0 (3.0) 1.0 (3.5) 1.0 (3.8) * 
Watery Stools 1.0 (4.8) 1.0 (3.8) 1.0 (3.5) 1.5 (3.5) 2.0 (5.0) 1.0 (4.5) 2.0 (5.8) 
Treatment End 3,4       
Bloating  1.0 (4.0) 0.0 (4.0) 1.5 (4.0) 1.0 (2.0) 1.0 (3.0) 2.0 (4.0) 2.5 (5.0) 
Passing Gas 3.0 (5.0) 5.0 (4.8) 3.0 (2.0) 3.0 (6.3) 2.0 (3.0) 1.0 (5.0) * 3.0 (5.8) 
Hard Stools 1.0 (3.0) 0.0 (3.0) 1.0 (1.3) 1.0 (3.3) 1.0 (3.0) 0.0 (1.0) A 3.5 (4.8) B * 
Watery Stools 1.0 (3.0) 1.0 (2.0) 1.0 (3.3) 0.5 (1.5) 1.0 (4.0) 1.0 (2.5) 2.5 (4.8) 
1Per-protocol sample based on those that were randomized to treatment and were considered compliant to the 
treatment  
2Change in gastrointestinal symptoms are listed as median (IQR).  Only the most common symptoms experienced 
are listed  
4Different letters indicate a significant difference in distribution between groups within symptom; identical symbol 
indicate differences in symptoms before and after treatment within a treatment group 
 
4.5 Discussion 
There is much interest in the health promoting capabilities of bifidobacteria in the 
human GI tract.  Synbiotics have advantages in promoting bifidobacteria as they could 
result in improved establishment of a specific Bifidobacterium strains in the human gut 
when compared to the probiotic alone, and increase bifidobacteria in individuals that do 
not possess them or that do not respond to probiotics alone.  However, if synbiotics are in 
fact more successful than their parts has not adequately been studied in humans.  Here we 
189 
 
systematically assessed the ability of two Bifidobacterium strains, administered alone and 
combined with GOS as synbiotics, to become established in the gastrointestinal tract of 
obese adults.  In addition, community sequencing was used to identify other changes 
introduced to the gastrointestinal microbiota by the dietary treatments.  
The first objective of this study was to test if the prebiotic carbohydrate GOS 
included in the two synbiotic preparations supported the establishment of the test probiotic 
strains in the human gut.  Both strains were significantly enriched during the treatment 
period compared to baseline and washout levels, whether consumed alone or as synbiotics 
according to the qPCR analysis (Figure 4.2).  The absolute numbers of IVS-1 were 
significantly higher than those detected for Bb12, independently of the presence of GOS.  
This suggests that the autochthonous strain IVS-1 has an ecological advantage over the 
allochthonous commercial strain Bb12.  This is an important finding as it emphasizes the 
necessity to consider ecological requirements of the probiotic strains when synbiotic 
combinations are formulated.  Bb12 and IVS-1 are both capable of utilizing GOS in vitro 
(1, 54), however enhanced Bb12 colonization of the human GI tract is not supported by 
GOS as demonstrated here, and as also previously reported (48–50).  There was a tendency 
of IVS-1 being specifically enriched by GOS.  However, this synergistic effect between 
IVS-1 and GOS did not reach significance in this study cohort.  Interestingly, the synbiotic 
of IVS-1 and GOS led to significantly higher numbers of IVS-1 than the commercial 
synbiotic of Bb12 and GOS.  This indicates that IVS can be used to formulate a synergistic 
synbiotic that can enhance population levels and the competitiveness of a putative probiotic 
strain in the gastrointestinal tract compared to a commercial synbiotic.  Indeed, this is only 
the second report of a prebiotic specifically enriching for a putative probiotic strain in 
humans (57).  
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Secondly, we compared the ability of the two strains and their respective synbiotic 
combinations to alter the composition of the gut microbiota in obese individuals.  Our 
analyses showed that the probiotic, prebiotic, and synbiotic treatments altered the gut 
microbiota of the study subjects to a very limited extent (Table 4.3).  Only in treatment 
group B (IVS-1 + lactose) the phylum Actinobacteria was significantly higher in the 
treatment sample than at the baseline, and the genus Bifidobacterium was significantly 
higher in groups B (IVS-1 + lactose) and C (Bb12 + lactose) compared to the baseline 
based on 16S rRNA sequencing.  One limitation of this sequencing approach is that it 
returns the relative abundance of taxa, instead of the absolute numbers present in the GI 
tract.  Therefore a qPCR approach was done, which is more quantitative.  This analysis 
showed that the absolute number of bifidobacteria was significantly increased by the IVS-
1 + GOS synbiotic (group D) and GOS alone (group F) (Figure 4.3).  This increase in 
numbers and abundance of bifidobacteria due to GOS feeding has been previously shown 
(1, 36).  Interestingly, however, the treatment of Bb12 and GOS did not significantly enrich 
for bifidobacteria.  This may be caused by a large variance in the subject cohort’s 
microbiota, as there was no other member of the gut microbiota identified that was enriched 
by this treatment and could have outcompeted the bifidobacteria for GOS.  While both 
strains, IVS-1 and Bb12, were significantly enriched by the probiotic dietary treatments in 
group B (IVS-1 + lactose) and C (Bb12 + lactose) (Figure 4.2), but the absolute number of 
bifidobacteria was not increased in these groups (Figure 4.3).   
According to the 16S rRNA sequencing analysis, in all other cases only OTUs were 
significantly influenced in their abundances by the treatments (Table 4.2).  This overall 
resilience of the gut microbiota to the treatments was characterized by a great variability 
between the subjects.  For example, the bifidogenic response to GOS treatment varied 
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between an increase of almost 5 logs in one subject and a decrease of 0.6 logs in a different 
individual.  This responder and non-responder phenomenon was previously described for 
GOS treatment in healthy adult subjects (40), and was also observed in this study, despite 
the presence of the added probiotic strain.  The stability of the gut microbiota was also 
confirmed by the lack of change in the alpha and beta diversities, no change in the 
abundance of butyrate producers, and a consistency of the Prevotella and Bacteroides ratio.  
Few significant correlations were found between members of the gut microbiota, and none 
between bifidobacteria and any other taxa.  
Overall these analyses showed that a strain of a core species of the human gut 
microbiota, B. adolescentis, can be established in almost all of the subjects by probiotic 
and synbiotic consumption, and at significantly higher numbers than an allochthonous 
strain.  However, this establishment had little effect on the resident community in the GI 
tract. 
 Strain-specific qPCR analysis at the four week washout time point showed that 
IVS-1 did not only reach higher colonization levels compared to Bb12, but IVS-1 was also 
significantly more persistent than Bb12 (Figure 4.2 B).  This finding supports the concept 
of in vivo selection to select for ecologically more competitive probiotic strains.  The 
autochthonous strain IVS-1 had a significant advantage to become established in the GI 
tract and avoid niche exclusion from the resident microbiota compared to the allochthonous 
strain Bb12.   
Interestingly, IVS-1 persisted in twice as many subjects when consumed as a 
synbiotic with GOS compared to IVS consumption alone.  It has to be taken into 
consideration, however, that the number of subjects that showed persistence was very low, 
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only three in group B (IVS-1 + lactose) and six in group D (IVS-1 + GOS), and the washout 
sample was taken four weeks after the last consumption of the treatment.  This study was 
not designed to specifically test persistence and a strain detection at only four weeks after 
the end of the treatment does not allow any conclusion about long-term persistence of IVS-
1.  In this study the addition of GOS did not significantly support the persistence of IVS-
1, but because of the small sample size a final conclusion about the synergistic effect of 
GOS and IVS-1 in regard to persistence cannot be drawn.  A future study may consider to 
extend the consumption of GOS after IVS-1 consumption has been terminated in order to 
establish if GOS specifically supports IVS-1 colonization and competitive fitness. 
In order to get insight into the ecological niche that IVS-1 may be occupying in the 
GI tract of persisters, the composition of the gut microbiota was compared between 
persisters and non-persisters in order to determine if a persistence of IVS-1 could be 
predicted before the beginning of the treatment.  By Random Forest analysis, mostly 
members of the Coriobacteriaceae family were identified (Figure 4.4).  Coriobacteriaceae 
are frequently found in patients suffering from overweight (58) or inflammatory bowel 
diseases, but there is no corresponding quantitative or functional data available yet (59).  
Slackia was identified as the most important genus predictor of persistence (Figure 4.4).  
The genus Slackia is part of the family Coriobacteriaceae and contains five species (60–
63).  In vitro analyses suggest that none of these species are capable of utilizing GOS (62, 
63).  Additionally, Slackia has been characterized as asaccharolytic (as well as 
Eubacterium and Mogibacterium) (64).  Therefore it is unlikely that Slackia would have 
been competing with IVS-1 for GOS.  This genus is known as a commensal of the 
mammalian microbiota (59) and two of its members, S. isoflavoniconvertens and S. 
equolifaciens. are known equol producers (63).  Whether or not the Slackia detected here 
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produces equol remains unknown.  Overall Slackia is present at very low abundance in 
non-persisters (0.2 %) but almost absent in persisters. 
Other members of the Coriobacteriaceae family, Asaccharobacter, Collinsella, 
and Olsenella, were also predictors of persistence.  OTU_3 Collinsella aerofaciens and the 
genus Collinsella were both present at approximately 3 % abundance in persisters.  
Therefore the genus Collinsella mostly likely consists only of OTU_3 Collinsella 
aerofaciens in this case.  This species is considered to be a member of the core human gut 
microbiome (65).  Interestingly, the identification of Collinsella, C. aerofaciens, and 
Coriobacteriaceae has been consistent in comparison to another study (Maldonado-Gomez 
et al., unpublished).  In that case, these taxa were predictive of long-term persistence for B. 
longum in healthy human subjects.  In this study no significant correlation between IVS-1 
or bifidobacteria and any of these taxa could be identified that could explain this 
phenomenon.  For now it remains speculative which effect the presence of 
Coriobacteriaceae has on the persistence of IVS-1.  
Three Blautia OTUs were identified by Random Forest.  Two of the three Blautia 
OTUs were in higher abundance in persisters than in non-persisters.  Blautia has not been 
reported to utilize GOS, but a strong positive correlation and potentially cross-feeding 
between Blautia and Bifidobacterium was previously reported (1).  On the other side, 
OTU_23, a Streptococcus sp., was also identified to be predictive of IVS-1 persistence.  It 
has been previously shown that this species is capable of utilizing complex carbohydrates 
like GOS (66), so this species could have been competing with IVS-1.  However, this OTU 
was in significantly higher abundance in persisters than in non-persisters (P = 0.0266).  
Again, the number of persister subjects was very low for this analysis and, unfortunately, 
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for now it cannot be explained how the taxa identified by Random Forest shape the GI 
niche that can be occupied by IVS-1.   
Interestingly, three Bifidobacterium OTUs were identified as predictors of IVS-1 
colonization (Figure 4.5).  While the mean decrease in accuracy values were quite low and 
therefore these results have to be considered with caution, two OTUs that potentially 
contributed to IVS-1 colonization were identified (both B. pseudocatenulatum), and one 
that was possibly preventing it (OTU_7).  While the identity of OTU_7 could not be clearly 
established, OTU_7 was a very closely related strain to IVS-1 with 98 % identity.  
Therefore, these two strains may have very similar ecological niche preferences and 
requirements.  Based on niche exclusion theory (67) it could be possible that OTU_7 was 
occupying a niche in the GI tract that could have been occupied by IVS-1 as well, but not 
by both strains at the same time.  IVS-1 was not capable of outcompeting the closely related 
resident strain in this case.   
 
4.6 Conclusion 
This study has provided novel insights into the complex interactions between the 
gut microbiota and dietary regimens consisting of prebiotics, probiotics, and synbiotics.  
The potential of synbiotic applications on human health has been previously established 
(45).  However, many synbiotic formulas lack synergistic activity in that the probiotic is 
not enriched by the prebiotic.  Thus, the probiotic strain is established in the GI tract not 
more effectively had it been introduced by itself.  While this lack of success may be due to 
the arbitrary selection of the synbiotic components, we have previously shown that in vivo 
selection can overcome the ecological limitations imposed on the probiotic strains in the 
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GI tract (1).  By specifically enriching a B. adolescentis strain, IVS-1, with its cognate 
prebiotic substrate, we have previously validated this synergistic synbiotic concept in rats 
(1).  We have now demonstrated the potential of in vivo selected probiotics and synbiotics 
in a human trial as well.  IVS-1 was successfully established in the GI tract of human 
subjects in significantly higher numbers than a commercial probiotic, B. animalis subsp. 
lactis Bb12, and also when the two synbiotic combinations were compared.  IVS-1, as a 
strain of a core species of the human gut microbiota, was established in all but one subject, 
and OTU_1 B. adolescentis became the dominant member of the gut microbiota.  This 
study has clearly established that in vivo selection can identify autochthonous probiotic 
strains that are highly competitive in the GI environment when introduced as probiotics or 
synbiotics.  While there was a trend for GOS specifically and synergistically enriching for 
IVS-1 in this study, this trend did not reach significance.   
This study provided important proof of concept that a rational selection of synbiotic 
combinations based on the ecological requirements of the probiotic strain can significantly 
enhance the colonization, and persistence of probiotic strains.  
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4.8 Supplements 
Fig. 4.S1.  Average 
abundances of taxa 
in fecal samples of 
subjects consum-
ing dietary treat-
ments.   
Bacterial quantities 
are expressed as 
percent abundan-
ces of total bacteria 
as determined by 
16S rRNA sequen-
cing.  Significance 
of P ≤ 0.05 is 
denoted by a single 
asterisk (*). 
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Fig. 4.S2.  Correlation analysis of fecal genera present with at least 0.5% abundance in 
subjects consuming dietary treatments.  Bacterial quantities are expressed as percent 
abundances of total bacteria as determined by 16S rRNA sequencing. 
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Fig. 4.S3. Correlation analysis of fecal OTUs present with at least 1% abundance in 
subjects consuming dietary treatments.  Bacterial quantities are expressed as percent 
abundances of total bacteria as determined by 16S rRNA sequencing.   
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Fig. 4.S4.  Ratio of Bacteroides and Prevetolla taxa present in fecal samples of subjects 
consuming dietary treatments.   
 
211 
 
Baseline
Sh
an
no
n 
In
de
x
Persisters Non-persister
3
4
5
6
7
8
P = 0.8960
Baseline
Si
m
ps
on
 In
de
x
Persisters Non-persister
0.85
0.90
0.95
1.00
1.05
P = 0.8964
Baseline
O
bs
er
ve
d 
S
pe
ci
es
Persisters Non-persister
0
200
400
600
P = 0.8699
Alpha diversity
 
Fig. 4.S5.  Alpha diversity comparison between persisters and non-persisters.    
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ITT analysis  
Table 4.S1.  Proportions of bacterial taxa significantly influenced by dietary treatments 
based on intend to treat analysis. 
  Mean % bacterial abundance ± SD b  
Treatment  Baseline Treatment Washout P value 
 Taxonomic group     
Group A 
Lactose 
control  
OTUs a     
   OTU_2047 (Blautia sp.) 0.01±0.0 A 0.01±0.0 B 0.02±0.0 AB 0.0270 
    OTU_2511 (Blautia sp.) 0.89±1.2 A 1.06±1.6 B 0.91±1.1 AB 0.0278 
Group B 
IVS-1 
Probiotic 
OTUs a     
   OTU_1 (B. adolescentis) 1.32±3.9 A 3.66±4.9 B 3.25±4.2 B 0.0130 
    OTU_2353 (Dorea sp.) 0.01±0.0 A 0.02±0.0 B 0.01±0.0 AB 0.0243 
Group C 
Bb12 
Probiotic 
OTUs a     
   OTU_2003 (unclass. Lachnospiraceae) 0.00±0.0 A 0.08±0.2 AB 0.04±0.1 B 0.0375 
Group D 
IVS-1 GOS 
Family     
   Bifidobacteriaceae 4.67± 4.1 A 11.70±6.6 B 9.02±8.7 AB 0.0260 
 OTUs a     
    OTU_1 (B. adolescentis) 2.31±4.4 A 6.92±7.0 B 4.43±5.0 AB 0.0106 
    OTU_469 (Anaerotruncus sp.) 0.03±0.1 A 0.00±0.0 B 0.01±0.0 AB 0.0391 
Group E 
Bb12 GOS 
OTUs a     
   OTU_156 (Clostridium XI sp.) 0.24±0.3 A 0.07±0.2 B 0.20±0.5 AB 0.0214 
Group F 
GOS 
OTUs a     
   OTU_643 (Bacteroides sp.) 0.02±0.0 A 0.00±0.0 B 0.00±0.0 AB 0.0372 
    OTU_319 (Butyricimonas sp.) 0.00±0.0 AB 0.00±0.0 A 0.05±0.1 B 0.0382 
a If the strain could not be assigned to a type strain (<97% homology), RDP Classifier was used to determine the most 
likely genus, and the RDP Classifier value is shown (80% cutoff). 
b Values with different uppercase letters are significantly different from each other. 
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Fig. 4.S6.  Average 
abundances of taxa in fecal 
samples of subjects 
consuming dietary treatments 
based on intend to treat 
analysis.  Bacterial quantities 
are expressed as percent 
abundances of total bacteria 
as determined by 16S rRNA 
sequencing. 
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Fig. 4.S7.  Ratio of Bacteroides and Prevetolla taxa present in fecal samples of subjects 
consuming dietary treatments based on intend to treat analysis.   
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Fig. 4.S8.  Alpha diversity comparison between persisters and non persisters based on 
intend to treat analysis.    
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Chapter 5 
 
Conclusions and future direction. 
 
5.1 Conclusions 
The importance of gut microbiota on human health has been well demonstrated 
over the past two decades.  New analytical methods, as well as bioinformatics tools have 
led to many new insights into this complex ecosystem.  Food and diet have been shown to 
strongly associate with health and disease, and it has become increasingly recognized that 
human and animal health is profoundly affected by the specific types and proportions of 
microorganisms that inhabit the intestinal tract.  There is now much interest in formulating 
dietary strategies to support a health associated gut microbiota.  However, there is a 
considerable knowledge gap on how diet shapes the bacterial populations, which bacteria 
should be preferably enriched for to support host health, how to formulate dietary 
treatments in order to be most effective, and which ecological requirements have to be met 
in order to introduce new members into the gut microbiota. 
One strategy to establish microbial members that confer health benefits to the host 
in the gut microbiota is with the application of probiotics, prebiotics, and synbiotics.  As 
reviewed in Chapter 1, there is much clinical and commercial interest in the development 
of novel synbiotics.  While the health claims made for synbiotic applications are currently 
outpacing the research, there is little known about the mechanisms by which probiotics and 
synbiotics become established in the GI tract.  The development of novel synbiotics based 
219 
 
on ecological requirements of the probiotic strains to survive and colonize the GI tract may 
enhance the beneficial health effects already observed for some of the synbiotic 
applications.  However, a better understanding of the gastrointestinal niche, with its very 
specific biotic and abiotic factors, and the interaction of the resident microbiota is 
fundamental in order to develop novel probiotics and synbiotics. 
The studies presented here first address ecological colonization factors that enable 
a truly symbiotic model organism, L. reuteri, to densely colonize its rodent host in Chapter 
2, and secondly introduce and establish a novel method to select for putative probiotic 
strains and synbiotic combinations in vivo in Chapters 3 and 4. 
Chapter 2 provided a better understanding of the phenotypic adaptations of a 
vertebrate gut symbiont, L. reuteri, that contribute to both specialization towards a 
particular host and a highly successful lifestyle.  The analysis of this probiotic model 
organism provided new insights into the ecological requirements and challenges that 
probiotic strains face in the GI environment, specifically in the stomach.  This study’s 
objective was to systematically determine which genes of L. reuteri 100-23 contribute to 
tolerance towards host gastric acid secretion.  There were three main findings of this study: 
(i) the urease cluster was the predominant factor in mediating resistance to gastric acid 
production; (ii) gene annotations and in vitro tests have limitations to predict the exact 
ecological functions of colonization factors of bacterial gut symbionts; and (iii) novel 
information was revealed on the mechanisms by which L. reuteri colonizes its gastric 
niche.  Ultimately, the basic molecular research described in this chapter broadens our 
understanding of GI niches and the ecological challenges probiotic strains have to tolerate.   
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Chapters 3 and 4 focus on the effect of probiotic, prebiotic, and synbiotic 
applications on the microbial community in the GI tract.  Relatively little is known about 
the effects of synbiotic treatments on the gut microbiota.  In order to address this knowledge 
gap, a functional analysis of specific microbes to colonize the GI tract was done.  In Chapter 
3, we introduced in vivo selection (IVS) as a technique to select synergistic synbiotic 
combinations.  In this approach putative probiotic strains are enriched in subjects by 
extended consumption of a prebiotic substrate, in this case GOS.  A rat study was then 
conducted to assess the impact of the selected synergistic synbiotic in comparison to 
prebiotic and probiotic feeding alone.  The main finding in this rat model of non-alcoholic 
fatty liver disease (NAFLD) was that even though the synbiotic did not influence host 
phenotypes, it was highly efficient at enhancing population levels of the probiotic strain, 
and making it the most dominant operational taxonomic unit in the GI tract of the rats.  
This was a novel finding that has not been reported in the probiotic literature.  Our findings 
indicated that B. adolescentis IVS-1 not only had a higher affinity for GOS in vivo than the 
resident Bifidobacterium species but also utilized GOS to increase its competitiveness and 
effectively outcompete a closely related resident species.  This study showed that IVS-1 
and GOS were acting as a truly synergistic synbiotic in rats.  
To test the potential of IVS-1 as a probiotic and as a synbiotic application (i.e., IVS-
1 and GOS specifically) in human subjects, we conducted a clinical trial assessing the 
impact of the probiotic, prebiotic, and synbiotic treatments on the microbial community in 
the GI tract of human subjects suffering from obesity.  As described in Chapter 4, we 
compared the rationally selected synbiotic to a commercial synbiotic that applied an 
allochthonous probiotic component (B. animalis subsp. lactis Bb12).  This study aimed to 
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answer two important ecological questions: (i) does the in vivo selected autochthonous 
bacterial strain IVS-1 have an ecological advantage compared to the allochthonous 
bacterial strain Bb12 in the GI tract of human subjects; and (ii) does the supplementation 
of each strain with the prebiotic GOS support the colonization of the respective strain in 
vivo.  Even though both strains were bifidobacteria, there was a significant difference in 
the colonization rate.  IVS-1 colonized the GI tract in significantly higher numbers than 
Bb12 and even became most dominant operational taxonomic unit in the subjects.  This 
suggested that the autochthonous strain IVS-1 had an ecological advantage over the 
allochthonous commercial strain Bb12.  This finding supported our hypothesis that IVS 
can be used to select a bacterial strain that can substantially enhance population levels and 
the competitiveness of a putative probiotic strain in the gastrointestinal tract compared to 
a commercial probiotic.  This was an important finding as it underlined the necessity to 
consider ecological requirements of the probiotic strains when synbiotic combinations are 
formulated.  A clear synergistic effect between IVS-1 and GOS was previously established 
in rats in Chapter 3.  However, in the human study the synergistic effect between IVS-1 
and GOS did not reach significance.   
In summary, the findings in Chapters 3 and 4 demonstrated that the competitive fitness 
of strain IVS-1 was increased by GOS, which supported the conclusion that in vivo 
selection can be a valuable technique to screen for synbiotic combinations with high 
synergism in vivo.   
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5.2 Future direction  
 Our group is currently working on the metabolic data of the human trial described 
in Chapter 4.  This additional data will allow us to correlate health symptoms and 
improvements with the gut microbiota of the study subjects.  This analysis will give us 
important insight into to the health impacts of the prebiotic, probiotic and synbiotic 
treatment in comparison to a commercial synbiotic application.  
 The results presented in this thesis have clearly demonstrated that the application 
of IVS is likely to enhance the ecological performance of probiotic strains or live 
biotherapeutics within the habitats in which they are thought to function.  The technology 
could be readily applied in the design of microbiota-modulating therapies, including novel 
and rational synbiotics. 
 
